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ABSTRACT
Serine hydroxymethyltransferase (SHMT) is a major enzyme for serine, glycine and one 
carbon group metabolism and aberrant SHMT activity has been implicated in some diseases 
such as cancer and schizophrenia.
cDNAs encoding the cytosolic isozyme of human and rabbit SHMT (cSHMT) were 
expressed in E.coli using the pET vector system which produces SHMT proteins fused to an 
amino terminal motif of six histidine residues. This allows rapid purification of cSHMT 
protein by metal ion chromatography. Enzymatically active SHMT was purified.
Mutant SHMT proteins were produced by site directed mutagenesis of the cDNA coding 
for human cSHMT The amino acids mutated had been implicated in SHMT activity by 
chemical modification. Mutant proteins were expressed in E.coli, purified as above and were 
assayed for enzyme activity. Whereas chemical modification had in all cases completely 
inactivated enzyme activity, none of the mutants created completely inactivated the protein 
suggesting that chemical modification of proteins only has a limited role in determining 
residues important in SHMT activity.
Two bacteriophage lambda clones containing human genomic DNA hybridising to 
cSHMT cDNA were characterised. Sequence data was obtained showing although the 
sequence had 90% homology to cSHMT cDNA there were many point mutations, deletions 
and insertions into the genomic DNA including a mutated translation initiation codon. No 
introns were present in the genomic sequence and a 16 base pair direct repeat was found 
either side of the cSHMT homologous sequence. It was concluded that the clones contained 
DNA encoding a processed pseudogene of cSHMT.
PCR amplification of human genomic DNA was performed and sequences from the 
cSHMT gene were identified. Five introns were identified when compared to the known 
cDNA sequence and a further intron may be present.
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CHAPTER 1 
INTRODUCTION
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1.1 Structure and function of Serine Hydroxymethyltransferase
SHMT is a pyridoxal 5’ phosphate dependent enzyme responsible for the reversible
conversion of L-serine to L-glycine and formaldehyde which is complexed with 
tetrahydrofolate (THF) to produce N5,N10-methylenetetrahydrofolate (methyleneTHF). 
SHMT activity was first demonstrated in vivo by Shemin, (1946) and has been extensively 
studied since that date. SHMT is ubiquitous, found in all prokaryotes and eukaryotes, and in 
many different organs within mammals e.g. liver, kidney, spleen, intestine, heart, and lung 
(Snell 1984).
The SHMT enzyme is a homotetramer in eukaryotes (Martinez-Carrion et al., 1972). 
SHMT protein is assumed to be tetrameric in prokaryotes as it is in eukaryotes. However, 
SHMT has been demonstrated to be a homodimer in E.coli (Schirch et al., 1985) and it 
follows that other prokaryotes may share this structure. A SHMT subunit has a molecular 
weight of 53KD in eukaryotes and 46KD in prokaryotes. Purified enzyme is yellow with an 
absorption maximum at 428nm due to bound pyridoxal 5’-phosphate (PLP) bound as a Schiff 
base to the 6-amino group of a lysine residue, forming the holoenzyme. The colourless “apo” 
form can be generated by removing the PLP molecule from SHMT by incubation with L- 
cysteine (Schirch and Mason, 1962).
E.coli SHMT (eSHMT) contains 3 tryptophan residues. Site directed mutagenesis of 
eSHMT has been performed to produce 3 enzymes, each with only 1 tryptophan residue (Cai 
and Schirch, 1996a; 1996b). The folding of eSHMT was followed by using fluorescence 
quenching using these mutant proteins. It was found that 2 domains fold rapidly between 
residues 55-224 and 276-417 as fluorescence from tryptophan residues 183 and 385 was 
quenched in seconds. Tryptophan residue 16 does not form part of any ordered structure 
during the first stages of folding and only reaches the native state when the enzyme is in a
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catalytically active form. The segment between the two rapidly folding domains contains the 
PLP binding lysine and remains in an unordered state even after dimerisation. Following 
dimerisation there is a slow rate determining conformational change during which the 
interdomain region containing the PLP binding lysine becomes ordered. PLP does not bind 
until folding is complete. Recent analysis of the cytosolic isozyme of sheep SHMT suggests 
that the subunits form tetramers before PLP binds to form the holoenzyme. The holoenzyme 
dissociates into its individual subunits with increasing pH of buffer suggesting that the 
subunits are associated electrostatically (Brahatheeswaran et al., 1996).
1.1.1 SHMT isozymes
In most eukaryotic organisms there are two isozymes of SHMT, namely the cytosolic
(cSHMT) and mitochondrial (mSHMT) enzymes. There is evidence of a chloroplast isozyme 
in plants (Besson et al., 1995) and in Euglena gracilis (Sakomoto et al., 1993). SHMT 
isozymes have different primary structures and are encoded by separate genes. For example, 
the genes coding for human cytosolic (glyC) and mitochondrial (glyM) SHMT proteins are 
located on 17pl 1.2 and 12ql3.2 respectively (Garrow et al., 1993). Prokaryotes have a single 
gene (glyA) encoding a single SHMT enzyme. The two SHMT isozymes most extensively 
studied are those isolated from rabbit liver. With the exception that rabbit liver mSHMT has 
a four fold greater affinity for glycine than its cytosolic counterpart (Schirch and Peterson, 
1980), the SHMT isozymes have similar substrate specificity’s and kinetic constants (Akhtar 
et al., 1975; Schirch and Peterson, 1980). mSHMT protein is located in the mitochondrial 
matrix (Cybulski and Fisher, 1976).
Distribution of the SHMT isozymes varies according to the organism and the tissue. For 
example, 75-80% of the SHMT activity in rabbit or monkey liver is predominantly from the 
cytosolic isozyme (Schirch and Peterson, 1980; Snell, 1984) whereas in rat mSHMT and
16
cSHMT contribute equally to the total liver SHMT activity (Snell, 1984). In Chinese 
hamster ovary cells (Chasin et al., 1974), Saccharomyces cerevisiae (Zelikson et al., 1977), 
the central nervous system (Daly and Aprison, 1974) and plant leaves (Bourguignon et al., 
1988) the total SHMT activity is attributed mainly to the mitochondrial isozyme.
1.1.2 Conservation of SHMT primary structure across species
29 amino acid sequences of SHMT protein have been either directly determined or
translated from nucleic acid data. This data shows that the primary structure of SHMT 
protein is highly conserved across all species. For instance, human cSHMT protein has 92% 
identity to rabbit cSHMT and 63% identity to E.coli SHMT. Alignments of the sequences 
with the PILEUP and PRETTY programs (Genetics Computer Group) (appendix 2) indicates 
there are 43 amino acids conserved in all SHMT protein sequences. Divergences between 
SHMT sequences primarily occur at the amino and carboxyl termini of the proteins. In 
addition the eukaryotic SHMT’s are larger than the prokaryotic forms with 4 conserved 
insertions compared to the prokaryotic sequence.
1.1.3 Reactions catalyse by SHMT
In vitro, SHMT has a broad substrate specificity catalysing the aldol cleavage of a number
of 3-hydroxyamino acids to form L-glycine and the corresponding aldehyde. Only those 
reactions producing formaldehyde require THF as a cofactor. SHMT also catalyses 
decarboxylation, transamination and racemisation (for reviews see Schirch, 1982; 1984). 
SHMT also acts as a threonine aldolase (L-threonine acetaldehyde lyase, EC 4.1.2.5) (Schirch 
and Gross, 1968; Akhtar and El Obeid, 1972). This activity is mainly limited to the cytosolic 
isozyme in rat liver (Snell, 1984).
SHMT is in equilibrium between an “open” form where substrates enter and leave the 
active site, and a “closed” conformation where catalysis occurs (Schirch et a/., 1991).
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Racemisation and transamination occur only in the open form suggesting that one reason the 
closed structure is formed is in order to confer reaction specificity.
1.2 Proposed reaction mechanism for serine and glycine interconversion
Addition of saturating levels of L-glycine to SHMT gives a spectrum with 3 distinct peaks
appearing in the order 343nm, 425nm and 495nm. Incubation of SHMT with excess L-serine 
leads to additional spectrum maxima at 343, 427 and 495nm (Schirch, 1984). One reaction 
mechanism which has been derived from the absorption maxima evidence and homology to 
other PLP dependent enzymes involves the formation of a quinoid intermediate either from 
glycine (by loss of a  proton) or from serine (by cleavage of the 2-3 carbon-carbon bond). 
Figure 1.1 illustrates the mechanism proposed by Schirch, (1984). The key steps of this 
mechanism are:
1. The enzyme-PLP undergoes nucleophilic attack from the NH2  group of glycine at c-4’ to 
form the geminal diamine (structure II).
2. A second nucleophilic attack by unpaired electrons on the unprotonated glycine amine to 
form a Schiff base (external aldimine, structure El). This reaction displaces the 6-amino 
group of the enzyme lysine.
3. A base on the enzyme removes a proton from the a  carbon of the bound glycine to form a 
resonance stabilised quinoid intermediate (structure IV).
4. In the presence of formaldehyde the a  carbon of glycine attacks the formaldehyde to form 
the Schiff base of serine (structure V).
5. The transamination procedure is reversed to complete the reaction.
18
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Figure 1.1 Proposed mechanism for SHMT catalysis (Schirch, 1984)
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Other reaction mechanisms have been proposed (Matthews and Dmmmond, 1990). One 
possibility is the conversion of the serine external aldimine (structure V, figure 1.1) to a 
quinoid intermediate and a thiohemiacetal. This mechanism requires a thiol group on the 
enzyme. A further possible mechanism is the direct nucleophilic attack on N5 of THF by the 
P carbon of serine aldimine with the loss of H2O. Both of these mechanisms would yield 
methyleneTHF with the correct stereospecificity but there is no direct evidence to support 
either mechanism.
An insight into the physiological reaction would be gained by determining the X-ray 
crystal structure of SHMT bound to various substrates.
1.2.1 Role of Tetrahydrofolate in SHMT activity
The reaction mechanism proposed above (Schirch, 1984) does not indicate how THF is
involved in the reaction. It was proposed by Jordan and Akhtar, (1970) that the complexing 
of formaldehyde with THF follows the same path as for the non-enzymatic reaction of these 
two compounds described by Kallen and Jencks, (1966). This pathway would lead to the 
racemisation of methyleneTHF but the high stereospecificity of the methyleneTHF produced 
by SHMT rules out this possibility.
The primary role of THF in the reaction is, therefore, to remove formaldehyde from the 
active site as in the absence of THF, serine is broken down to glycine and formaldehyde by 
SHMT but the reaction then stops as formaldehyde is slow to leave the active site. (Schirch, 
1984). The one carbon group is transferred to glycine to form serine via an enzyme- 
formaldehyde complex (Chen and Schirch, 1973a). It was suggested that formaldehyde is 
bound as an imine at the active site and THF appeared to catalyse the formation or breakdown 
of this intermediate (Chen and Schirch, 1973b). However, the SHMT catalysed reaction is 
highly stereospecific and the formation of an enzyme-formaldehyde complex has several
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steps where the stereospecificity could be lost. Matthews and Drummond, (1990) state that 
there is no evidence for the formation of the imine.
In the absence of THF the reaction is ordered with formaldehyde released before glycine.
In the presence of THF, however, the reaction becomes a sequential random mechanism with 
either of the substrates binding first and either product being released first (Schirch, 1984).
The presence of THF also increases the rate of exchange of the a  proton of glycine with 
solvent by more than 2 orders of magnitude (Schirch and Jenkins, 1964). It is thought that 
THF slows down the reverse step of protonation of the quinoid intermediate i.e. the rate of 
which the quinoid is protonated to form structure III (figure 1.1) (Schirch, 1984).
The reaction mechanism and role of THF in SHMT activity will only be elucidated by the 
determination of the tertiary and quaternary structures of SHMT complexed with various 
substrates.
1.2.2 Important amino acids for SHMT activity
In the absence of a determined SHMT tertiary and quaternary structure, residues important
for SHMT activity have been identified by chemical modification and site directed 
mutagenesis. SHMT isolated from several organisms have been studied. As the protein is of a different 
I length in each organism, the amino acids mentioned below refer to the equivalent amino acid 
position in human cSHMT (appendix 1) as identified from the alignments presented in 
appendix 2.
By homology to other PLP dependent enzymes, a lysine residue in E.coli SHMT was 
identified as being the amino acid to which PLP binds to form the internal aldimine (section
1.2). This was confirmed by site directed mutagenesis as being the PLP binding site (Schirch 
et al., 1993) and is equivalent to lysine 257 (K257) in human cSHMT. Therefore, this lysine
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is critical for SHMT activity. Unlike other PLP dependent enzymes this lysine residue does 
not also remove the a  proton (see section 1.2) (Schirch et a l, 1993).
A cysteine residue was implicated as being necessary for catalysis following modification 
with D-fluoroalanine, which resulted in inactivation of lamb cSHMT and loss of a cysteine 
residue (Wang et al., 1981). This residue was found to be equivalent to C335 in rabbit and 
human cSHMT (Gavilanes et al., 1982) but further studies suggested that C335 was not 
necessary for enzyme activity in rabbit cSHMT (Gavilanes et al., 1982).
Extensive work with agents which modify cysteine amino acids, namely 5,5’-dithiobis(2- 
nitrobenzoic acid) (DTNB), iodoacetate and methyl methanethiosulphonate (MMTS), has 
shown that there are at least 2 cysteine residues at the active site of rabbit cSHMT (Gavilanes 
et al., 1982). In rabbit mSHMT there is 1 cysteine residue at the active site but this residue is 
not necessary for enzyme activity (Gavilanes et al., 1983). None of the cysteine residues in 
either isozyme form disulphide bonds.
In sheep cSHMT, cysteine residues equivalent to human cSHMT C68 and C204 are 
protected by PLP when treated with iodoacetate. This study inferred that cysteines equivalent 
to C248 and C262 are buried in the protein (Usha et al., 1994). In rabbit cSHMT cysteine 
204 was also modified by iodoacetate. PLP does not bind to rabbit cSHMT post modification 
ue to steric hindrance so the activity of modified enzyme could not be determined and implies that 
C204 is located at the PLP binding site (Schirch et al., 1980).
Whereas human cSHMT has 10 cysteine residues (Garrow et al., 1993), E.coli SHMT has 
only 3 cysteine residues (Schirch et al., 1985) one of which when modified by DTNB and 
MMTS inhibits the enzyme. This residue is protected from modification by the presence of 
serine. Cysteine 410 in eSHMT was modified by site directed mutagenesis and found to play 
a role in the structure of the enzyme but not catalytic activity (Joshi-Tope and Schirch, 1990).
22
A histidine in eSHMT equivalent to H256 in human cSHMT is totally conserved in all 
SHMT sequences and has been modified by site directed mutagenesis. This residue was 
found not to be essential for catalytic activity (Hopkins and Schirch, 1986). However, there 
was no change from the open to closed conformation on substrate binding. H256 plays a 
critical role in determining substrate specificity by controlling the size of the one carbon 
binding pocket and the orientation of the hydroxymethyl group of serine with respect to the 
PLP ring. This residue is not the base which catalyses the removal of the a  proton (section
1.2) (Stover et al., 1992).
Modification of sheep cSHMT with diethylpyrocarbonate (DEPC) suggests that a 
histidine residue is essential for catalytic activity and that inactivation is protected by serine 
(B.Venkatesha, personal communication). The modified histidine was found to be equivalent 
to H I35 in human cSHMT. However, the modified histidine is not conserved in other SHMT 
proteins (appendix 2). Histidine residues have been modified with DEPC in human and sheep 
cSHMT leading to enzyme inactivation but the specific residues modified have not been 
identified. Inactivation by DEPC was prevented by serine and THF (Vijayalaksmi and Rao, 
1989; Manohar and Rao, 1984).
Arginine residues in eSHMT equivalent to R402 and R411 in human cSHMT have been 
modified by site directed mutagenesis. R402 plays a role in binding the substrate carboxyl 
group and has a role in conversion of SHMT from an open to a closed conformation (Delle 
Fratte et al., 1994). R411 is totally conserved in SHMT sequences (appendix 2) but does not 
appear to play a critical role in catalysis (Delle Fratte et al., 1994).
Usha et al., (1992) determined that THF prevented the chemical modification of arginine 
residues in sheep cSHMT equivalent to R270 and Q462 in human cSHMT by phenylglyoxal 
implying that these residues are at the THF binding site. However, amino acid 462 in human
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cSHMT is not an arginine residue so the arginine residues modified in sheep cSHMT may not 
play a role in THF binding but steric hindrance produced by modifying agents prevents THF 
binding to the correct residues. Phenylglyoxal modification of arginine residues was also 
prevented by serine and THF in human cSHMT (Vijayalaksmi and Rao, 1989).
Human cSHMT has been chemically modified with N-bromosuccinimide (NBS). The 
loss of 1 unidentified tryptophan is correlated to the loss of enzyme activity. This inhibition 
is prevented by the presence of either serine or THF (Vijayalaksmi and Rao, 1989).
An aspartic acid residue in eSHMT equivalent to D228 in human cSHMT has been 
compared to an equivalent residue in aspartate aminotransferase (AAT) in which this residue 
hydrogen bonds to N1 of PLP (Pascarella and Bossa, 1993). To date no work has been 
published to determine whether this is the case in SHMT.
There is a highly conserved motif in all SHMT protein sequences between amino acids 
252-258 around the invariant lysine which binds PLP. This sequence is 4 serine or threonine 
residues followed by histidine, lysine and another serine or threonine with eSHMT and 
human cSHMT only using threonine and not serine. All of these threonines have been 
modified in eSHMT by site directed mutagenesis (Angelaccio et al., 1992). The threonine 
residues equivalent to T252, T253, T255 and T258 in human cSHMT do not appear to play a 
critical role in the mechanism of the enzyme and none of the threonine residues play an 
important role in PLP binding. T253 and T254 are important in defining the orientation of 
the external aldimine with respect to the base which removes the a  carbon. The hydroxyl 
group of T254 plays an important role in the conversion of the geminal diamine to the 
external aldimine (Angelaccio et al., 1992).
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1.3 Use of serine, glycine and one carbon units in the cell
The substrates and products of SHMT are used in a variety of biosynthetic reactions.
1.3.1 Biosynthesis of serine
Serine is synthesized from the glycolytic intermediate 3-phosphoglycerate (figure 1.2).
The rate limiting step in the pathway is the last irreversible step of serine synthesis and is 
catalysed by phosphoserine phosphatase which is regulated by feedback inhibition. The rate 
of serine synthesis is not influenced by the rate of glycolysis (Snell, 1980; Snell and Fell, 
1990). A second proposed pathway of serine biosynthesis by the reverse of the serine 
catabolism pathway by serine aminotransferase has been shown not to be physiologically used 
(Snell, 1986).
1.3.2 Serine catabolism
Serine is utilised in the cell for biosynthesis of the amino acids glycine and cysteine.
Glycine is formed by the action of SHMT and cysteine is formed from serine and methionine 
in a mutienzyme pathway. Serine is also used in the metabolic pathways of several lipids by 
donating a hydroxyl group in the biosynthesis of phosphatidyl serine which in turn is used to 
produce phosphatidyl ethanolamine and phosphatidyl choline. Sphingosine and ceramide, 
lipids found particularly in the nervous system are also utilise serine in their biosynthesis.
Apart from SHMT two other enzymes of serine utilisation are present in the cell, namely, 
serine dehydratase and serine aminotransferase (figure 1.3). Serine dehydratase is a cytosolic 
enzyme present only in the liver in rat and catalyses the conversion of serine to pyruvate for 
lipogenesis and gluconeogenesis (Snell, 1984). Serine aminotransferase is localised to the 
mitochondria in rat liver, kidney and heart and converts serine to hydroxypyruvate for 
gluconeogenesis (Snell, 1984). The enzymes of serine utilisation vary in activity during 
various stages of development in rats (Snell, 1984).
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Figure 1.4 Diagram o f the purine ring indicating the contributions o f glycine (red) 
and 10-formylTHF (blue) to the structure, 10-formylTHF is derived from 
methyleneTHF generated by SHMT
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1.3.3 Glycine catabolism
Glycine acts as an inhibitory and excitatory neurotransmitter and is also used in many
biosynthetic reactions. For example, glycine is a precursor in the production of threonine, 
bile acids, porphyrin rings, purine rings (figure 1.4), collagen and (3 keratin. Along with 
arginine, glycine is a precursor for the formation of creatine used to store phosphate bond 
energy. Glycine is also used in the biosynthesis of glutathione. Glutathione is present at a 
concentration of 5mM in cells and helps keep the cysteine residues of the cell in a reduced 
state, and is essential for maintaining the normal structure of red blood cells. Glutathione 
also acts as an amino acid transporter and helps to detoxify the cell by reacting with H2 O2 . 
Glycine is catabolised in mitochondria to form ammonia and carbon dioxide by the glycine 
cleavage system (GCS). During this reaction a molecule of THF is converted to 
methyleneTHF (Stryer, 1988).
1.3.4 Utilisation of one carbon units
The one carbon units produced by the conversion of serine to glycine by SHMT are also
used in a variety of reactions such as the biosynthesis of lipids, hormones and methionine. 
These one carbon units are complexed with THF in a variety of ways (figure 1.5) and are 
utilised by many different enzymes (figure 1.6). One carbon units are essential in DNA 
biosynthesis as they are required for the biosynthesis of the purine ring (figure 1.4) and for 
converting deoxyuridine monophosphate to deoxythymidine monophosphate.
1.4 Control of SHMT activity
SHMT activity is controlled at different levels in different organisms.
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1.4.1 Escherichia coli and Salmonelia typhimurium
The rate of synthesis of eSHMT is repressed by its end products. Activity is decreased by
growth in media containing high glycine concentrations and moderate concentrations of one 
carbon metabolites particularly adenine and guanine (Miller and Newman, 1974).
In E.coli and S.typhimurium, SHMT activity is controlled at the level of transcription. 
MetR protein (the product of the metR gene) is required for the activation of the glyA  gene 
(Plamann and Stauffer, 1989; Lorenz and Stauffer, 1995). There are two binding sites for 
MetR in the glyA  control region in E.coli and both sites are required for the normal activation 
of expression. DNA footprinting analysis of the glyA  control region suggests that RNA 
polymerase and MetR proteins interact in some way to increase the affinity of RNA 
polymerase for the glyA  promoter (Lorenz and Stauffer, 1996) Homocysteine (a precursor of 
methionine) increases MetR binding. S-adenosylmethionine inhibits metR transcription and 
hence glyA  transcription (Urbanowski et al., 1987).
The purine repressor protein, the gene product of purR also binds to the glyA  control 
region and is a negative regulator of glyA transcription (Steiert et al.9 1990). PurR protein 
prevents RNA polymerase from binding to the glyA  promoter. Hypoxanthine acts as a co­
repressor with PurR and increases the ability of PurR to prevent RNA polymerase binding 
(Lorenz and Stauffer, 1996).
Sequences downstream of the glyA  gene have been shown to be important in the stability 
of glyA  mRNA. A glyA  mutant with phage DNA inserted between the end of the coding 
sequence of the glyA  gene and the proposed transcription termination site had only 30% 
SHMT activity of wild-type (Plamann and Stauffer, 1985). Therefore, sequences distal to the 
glyA  structural gene play an important role in SHMT expression. In E.coli the glyA  gene is 
followed by two REP sequences and a rho dependent transcription terminator. If all three
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sequences are removed, there is a 7 fold reduction in SHMT expression (Plamann and 
Stauffer, 1990). These three sequences are necessary for mRNA stability. It has been 
demonstrated that two unidentified trans acting factors regulate SHMT expression in E.coli 
(Lorenz etal., 1996).
1.4.2 Control of SHMT activity in Neurospora crassa
The for  locus of N. crassa codes for cSHMT. There are several different mRNA start and
stop sites giving 4 different mRNA lengths of 2600, 2300, 2450 and 2050 nt. Glycine 
supplementation of growth medium produces an increase in cSHMT mRNA. There are 5 
potential binding sites for the transcriptional activator CPC-1 upstream of the transcriptional 
start site and one sequence which matches the consensus sequence exactly in the first intron 
of the cSHMT gene (McClung et al., 1992). The CPC-1 protein is involved in the cross 
pathway control (CPC) system in N.crassa similar to a system of amino acid biosynthesis 
control in yeast. It is not yet been demonstrated whether CPC-1 binds for  DNA. However, 
supplementation with formate at ImM and lOmM gives a two fold increase in fo r  mRNA 
levels and supplementation with lOmM glycine gives a 2.8 fold increase in for  mRNA 
abundance but only in the presence of a functional CPC-1 protein (McClung et al., 1992).
1.4.3 Control of rabbit cSHMT activity
Rabbit cSHMT has been shown to be regulated at the level of translation in when
expressed in COS-1 cells (Byrne et al., 1995). The cDNA for rabbit cSHMT has an upstream 
open reading frame and overlapping coding sequence (Byrne et al., 1992). Removing the 
upstream AUG stops translational repression approximately 100 fold demonstrated by an 
increase in expressed cSHMT protein but not in cSHMT mRNA levels.
There is also evidence for a pathway for rabbit cSHMT protein degradation. Two 
asparagine residues equivalent to 6 and 221 in human cSHMT are deamidated to isoaspartyl
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residues (Artigues et al., 1990; 1995). It has been proposed that the deamidation of 
asparagine residues targets proteins for degradation (Robinson and Rudd, 1974). Purified 
rabbit liver cSHMT is degraded in 24 hours when injected into Xenopus laevis oocytes. 
Removing the first 14 amino acids of cSHMT protein reduced the extent and rate of cSHMT 
degradation implying deamidation of N6 may be a signal for cSHMT degradation. The 
sequence asparagine-glycine (the signal for deamidation of asparagine) is present at 
equivalent positions in human and sheep cSHMT but is absent in the protein sequences of 
their mitochondrial counterparts and all other SHMT proteins (Artigues et al., 1995).
1.4.4 Control of mouse SHMT activity
Recently Nakshatri et al., (1996) have demonstrated using subtractive hybridisation to
isolate genes regulated by retinoic acid, that mouse cSHMT gene in the cell line P19 down 
regulated by retinoic acid. Retinoic acid is involved in the control of cell growth arrest and 
differentiation. These authors suggest that inhibition of SHMT expression by retinoic acid is 
an important step in growth arrest.
1.5 Compartmentation of folate and one carbon metabolism
There is evidence that one carbon group metabolism is compartmetalised with most
enzymes involved in folate metabolism having cytosolic and mitochondrial isozymes to
enable the conversion of folates to the state required in the intracellular compartments of each
organism. The reason for this duplication of enzymes in the cytosol and mitochondria is that
many folates do not cross the mitochondrial membrane. Cybulski and Fisher, (1976) first
determined that serine and glycine are rapidly taken up by mitochondria. The same authors
showed that only oxidised folates are taken up by rat liver mitochondria (e.g. folate,
dihydrofolate (DHF), methotrexate). Reduced folates such as THF, 5-methylTHF and
methyleneTHF penetrate only as far as the inter membrane space. DHF is taken up by
mitochondria by a carrier mediated mechanism (Cybulski and Fisher, 1981). However, the
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study was not done under physiological conditions. It has since been demonstrated using 
physiological conditions that 5-formylTHF is taken up by a carrier mediated mechanism by 
mitochondria and that this uptake is inhibited by 5-methylTHF suggesting there is a system 
for the uptake of reduced folate monoglutamates (Home et al., 1992).
As mentioned in section 1.3.3, glycine is catabolised in the mitochondria by the glycine 
cleavage system (GCS) yielding CO2  and ammonia, and converting of NAD+ to NADH and 
THF to methyleneTHF. The GCS is a multiprotein complex comprising of multiple copies of
H, P, L and T proteins (for review of the GCS see Oliver and Raman, 1995). mSHMT is 
coupled to the GCS to recycle THF by converting glycine and methyleneTHF to serine and 
THF.
Another important complex is Cl-THF synthase, made up of 5,10-methyleneTHF 
dehydrogenase, 5,10-methyleneTHF cyclohydrase and 10-formylTHF synthetase (figure 1.6). 
In human cells the three activities are located on a single peptide but in other organisms the 
three activities are located on either two or three peptides (Pelletier and Mackenzie, 1995). 
The Cl-THF synthase complex coupled to SHMT converts serine to 10-formylTHF for 
purine biosynthesis. In the reverse direction the multifuctional enzyme generates THF and 
formate (figure 1.6).
Work has been performed on several organisms and the roles played by folate dependent 
enzymes has found to be different in each organism studied.
I.5.1 One carbon group metabolism in yeast
The yeast S. cerevisiae has been extensively studied as mutants lacking individual folate
metabolism enzymes are relatively easy to obtain and grow. In yeast mitochondria it has been 
shown that Cl-THF synthase converts formate to methyleneTHF (Mckenzie and Jones, 
1977).
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Several research groups have used 13C NMR to follow serine production in S.cerevisiae. 
Pasternak et al., (1994) demonstrated that 25% of one carbon units utilised in cytoplasmic 
purine synthesis are derived from formate in the mitochondria. McNeil et al., (1996) 
determined that the remaining 75% of one carbon units in the cytoplasm were derived from 
serine generated in the mitochondria by the activities of the GCS and mSHMT.
1.5.2 Chinese hamster ovary cell metabolism
Chinese hamster ovary cells (CHO) have also been used to study folate metabolism,
particularly the roles of SHMT isozymes. The results of the studies below infer that in CHO 
cells mSHMT converts serine to glycine and cSHMT converts glycine to serine.
In wild type CHO cells the specific activity of mSHMT is approximately 20 times higher 
than cSHMT. A glycine requiring mutant cell line named 51-11 was produced by 
mutagenesis with ethylmethane sulphonate (EMS). 51-11 cells have lost all mSHMT activity 
and half of the cSHMT activity leaving only 10% of overall wild-type SHMT activity (Kao 
and Puck, 1968). A 51-11 revertant was also produced by EMS mutagenesis to obtain the 
cell line R13 which has 50% of wild type mSHMT activity and normal cSHMT activity 
(Chasin etal., 1974).
Pfender and Pizer, (1980) used K-l (wild-type), 51-11 and R13 cells to measure serine 
and glycine levels. They found a correlation between the amount of mSHMT and the 
intracellular glycine concentration and the extent to which extracellular serine can be utilised 
to increase the glycine pool. K-l and 51-11 have comparable activities for serine biosynthesis. 
However, it was found that for glycine synthesis K-l had an appreciably higher glycine 
concentration than the other two cell lines. 51-11 was unable to expand the glycine pool 
when serine was added to the media.
36
Narkewicz et al., (1996) measured the serine and glycine utilisation and production in 
wild-type (K-l) and 51-11 cells. They found that the rate of glycine production was lower in 
51-11 cells but the rate of glycine utilisation was similar in both cell lines. The rate of serine 
production was similar in both cell lines but the rate of serine utilisation was lower in 51-11. 
Increasing the serine concentration of the growth media lead to an increase in glycine 
production in K-l but not in 51-11. The activity of the GCS was low in both cell lines.
Over expression of human cSHMT in GlyA CHO cells lacking mSHMT activity did not 
eliminate the requirement of glycine in these cells. Therefore, the glycine requirement of 
GlyA CHO cells was not due to the reduced levels of cSHMT limiting the rate of glycine 
synthesis (Choi and Shane, 1996).
The lack of other folate utilising enzymes can lead to glycine auxotrophy in CHO cells. 
Cells with the mutation GLYB have a 10 fold lower rate for serine to glycine conversion but 
have wild-type levels of mSHMT and cSHMT. GLYB auxotrophy was found to be due to 
these cells containing 1/5 of the parental level of folylpolyglutamates which may be due to the 
impaired transport between the mitochondria and the cytosol or impaired recycling of folates 
(Taylor and Hanna, 1982).
It was found that CHO cell line AUXB1 lacks folylpolyglutamyl synthase (FPGS) activity 
and is, therefore, unable to retain folates within the cell. FPGS is the enzyme which adds 
glutamate residues to the THF molecule (figure 1.5). The AUXB1 cell line is auxotrophic for 
methionine, glycine, purines and thymidine. By transfecting cells with the E.coli or human 
FPGS gene it was found that folates could by polyglutamylated by up to 3 residues (Osborne 
et al., 1993). Purine and pyrimidines could be synthesised by the transfected cells but they 
remained auxotrophic for glycine. These cells lacked mitochondrial folates but had normal 
cytosolic folate pools (Lowe et al., 1993). When a mitochondrial target sequence was added
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to the E.coli FPGS gene and was transfected into AUXB1 mitochondrial folates began to 
accumulate and the cells were no longer auxotrophic for glycine (Lin and Shane, 1993). This 
evidence suggests that mitochondrial folates supply one carbon metabolism in the cytosol and 
that this supply might be via formate.
1.5.3 Plant metabolism
In C3 metabolism plants the GCS plays an important role in photorespiration. Rebeille et
al., (1994) showed that the GCS activity in pea leaf mitochondria is greater than that of 
mSHMT. As a result high levels of methyleneTHF are maintained directing mSHMT to 
synthesise serine and recycle the THF for GCS use. Mitochondrial and chloroplast isozymes 
of pea leaf SHMT have been purified (Besson et al., 1995). mSHMT accounts for 50% of 
total SHMT activity in pea leaves with cytosolic and chloroplast isozymes accounting for 20- 
25% each. Total SHMT activity determined from potato tubers is 5-10 times lower 
suggesting a correlation between SHMT and the presence of the photorespiratory system in 
leaf tissue. Chloroplasts are the major site of amino acid biosynthesis (Shah and Cossins, 
1970). Therefore, chloroplast SHMT may have a role in serine or glycine synthesis 
(Somerville and Ogren, 1981). Somerville and Ogren, (1981) also showed that in C3 plants 
glycine decarboxylation via the GCS was the only source of CO2 release. In wild type 
Arabidopsis thaliana plants mSHMT was required for this process and was not required for 
any other function.
A large complex has been isolated from the pea leaf mitochondrial matrix which catalyses 
the rapid transformation of glycine to serine (Neuberger et al., 1986). This complex was 
characterised and found to contain mSHMT and the four proteins of the GCS (Bourguignon 
etal., 1988).
38
Rebeille et al., (1994) deduced that there was no channeling of THF between the T protein 
of the GCS with mSHMT in vitro but the protein concentrations used in this experiment were 
400 times lower than those present in plant leaf mitochondria. Prabhu et al., (1996) used 13C 
NMR to study serine production in Arabidopsis thaliana. The results suggested that 
methyleneTHF is not released from the T protein of the GCS but channeled to mSHMT. A 
second pathway for serine production was found to be from formate by the action of Cl-THF 
synthase and SHMT. As one carbon groups produced by the GCS are used solely for 
photorespiration, it is proposed that this second pathway supplies one carbon groups for all 
the other metabolic requirements of the plant cell.
The mitochondrial folate pool of pea leaf contains folate with 4-5 glutamate residues 
bound and the glutamate chain length of THF has been studied with respect to affinity 
constants for THF and maximal velocities of SHMT and the GCS in pea leaf mitochondria 
(Besson et al., 1993). THF containing chains of 3 or more glutamate residues binds 10 fold 
more tightly to the GCS and mSHMT than THF with a smaller glutamate chain length but the 
maximum velocities remained the same.
In animal cells folate is provided by the exogenous medium but plant cells synthesise 
folate de novo. By measuring pea leaf mitochondrial folate pools, and folate biosynthesis 
enzymes, Neuberger et al., (1996) concluded that mitochondria are the major site for folate 
and thymidylate synthesis in plants. The mitochondrial folate pool represented approximately 
half of the total folate pool in pea leaves and contained all the enzymes necessary for THF 
polyglutamate synthesis whereas folate biosynthesis enzymes were absent from the cytosol. 
Potato tuber mitochondria also contained significant amounts of folate suggesting that this 
was a general feature of plant mitochondria rather than related solely to photorespiration.
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In conclusion the role of SHMT isozymes depends on the organism and its individual 
pathways of one carbon metabolism. The role of the SHMT isozymes in human cells varies 
according to tissue type and the precise roles within each tissue type are still to be elucidated.
1.6 Effects of aberrant SHMT activity in humans
In humans altered SHMT activity has been implicated in several disorders.
1.6.1 Role of SHMT in cell proliferation and cancer
SHMT has been shown to play an important role in the biosynthesis DNA precursors. As
mentioned previously MethyleneTHF is metabolised by the cell to form 10-formylTHF, 2 
molecules of which are also required for purine ring synthesis (see figure 1.4). 
MethyleneTHF is also used by thymidylate synthase to add a methyl group to deoxyuridine 
monophosphate to form deoxythymidine monophosphate (figure 1.6). A molecule of glycine 
is used in the synthesis of purine rings.
The following evidence suggests that SHMT activity and uptake of serine from exogenous 
media play a significant role in proliferating cells. Addition of radiolabelled serine to 
medium in which peripheral blood lymphocytes are growing and stimulating these cells to 
divide with the mitogenic agent phytohaemagglutinin (PHA) leads to the incorporation of 
radiolabel into DNA and the elevation of SHMT activity. Thorndike et al., (1979) and 
Eichler et al., (1981) have shown that SHMT activity is elevated 4-9 fold in PHA stimulated 
peripheral blood lymphocytes compared with non stimulated cells. SHMT activity increases 
and incorporation of radiolabel occurs before an increase in cell number. Inhibitors of DNA 
synthesis block incorporation of radiolabel into DNA. SHMT activity in the uterus or 
prostate has been shown to be increased after stimulation with oestrogen or testosterone 
suggesting that cells undergoing rapid proliferation require an increased supply of one carbon 
units (Schirch, 1982). Snell, (1984) has also shown that there is an increased capacity for
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serine biosynthesis from glycolytic intermediates in the fetal-perinatal period in the rat. 
During this time there is a rapid phase of liver growth and it is thought that serine is needed 
for incorporation into proteins and DNA or RNA precursors during this phase. Serine is 
classified as a non-essential amino acid, as it can be synthesised by cells. However, Eagle, 
(1959) demonstrated that serine is required in the culture media if cells are undergoing rapid 
proliferation. 3-phosphoglycerate dehydrogenase catalyses the first committed step of serine 
biosynthesis and the activity of this enzyme is higher in cells of high renewal capacity e.g. 
kidney, thymus, testis, spleen and in neonatal or regenerating liver (Snell and Weber, 1986) 
with serine dehydratase and serine aminotransferase activities almost absent, meaning all 
serine synthesised can be channeled into utilisation by SHMT.
As a link between increased SHMT activity and cell proliferation has been demonstrated 
it follows that in cancers, where cell proliferation is amplified, there should also be an 
increase in SHMT activity. Studies have been performed on the enzymes of serine 
biosynthesis and utilisation in a variety of solid tumours and tumour cell lines. Snell et al., 
(1988) studied the enzymes 3-phosphoglycerate dehydrogenase, SHMT, serine 
aminotransferase and serine dehydratase. Serine aminotransferase and serine dehydratase 
activities were essentially absent from normal skeletal muscle and normal colon. This pattern 
was repeated in human colon carcinomas and transplantable rat sarcomas. However, the 
activity of 3-phosphoserine dehydrogenase was elevated 30 fold and 10 fold and SHMT 
activity was elevated 6 fold and 5 fold in rat sarcomas and human colon carcinomas 
respectively when compared to normal tissue. In another study (Snell and Weber, 1986) 
hepatomas 20 and 3294A were studied (slow growing and fast growing hepatomas 
respectively). In normal liver serine dehydratase and serine aminotransferase activities are 
present. However, in the hepatomas the activity of these two enzymes were absent. 3-
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phosphoglycerate activity was elevated approximately 10 fold and 60 fold and SHMT activity 
was retained, although at a lower level than in control liver. In a more malignant hepatoma 
(5123tc) SHMT activity was increased 3 fold over control liver SHMT activity. Again in 
1985, Snell found that in rat tumours there were appreciable SHMT and phosphoserine 
aminotransferase activities, but no serine aminotransferase or serine dehydratase activities. It 
has also been demonstrated (Snell et al., 1987) that 3-phosphoglycerate dehydrogenase and 
SHMT activities are increased markedly during the transition of hepatoma 3924A cells in 
culture from a resting non-proliferating phase into a proliferating, growth phase. This 
increase in activity was concomitant with incorporation of radiolabel from exogenous serine 
into nucleic acid. The activities of the two enzymes dropped when cells reached confluency 
and entered the plateau phase.
These studies indicate a pattern of enzyme activities in tumours. If serine 
aminotransferase and serine dehydratase are absent in the normal cell then its corresponding 
tumour will show an increase in enzymes of serine biosynthesis and SHMT. If the activities 
of serine aminotransferase and serine dehydratase are normally present, then these activities 
are removed with the retention of SHMT activity and an increase in serine biosynthesis 
pathway enzymes. In either case there is an increase in serine biosynthesis and a channeling 
of this serine into nucleotide biosynthesis by the action of SHMT.
1.6.2 Schizophrenia and Psychosis
There is considerable debate as to whether SHMT activity contributes to psychotic
disorders including schizophrenia. Evidence is conflicting as to whether SHMT activities and 
serine or glycine concentrations are higher or lower in brains and plasma of schizophrenic 
patients. Some of the evidence is cited below.
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Studies by Carl et al., (1978) found significant decreases in levels of SHMT and 
methionine adenosyltransferase in blood cells from normal patients and those diagnosed with 
schizophrenia. Waziri et al., (1984) demonstrated plasma serine levels were significantly 
higher in patients with psychoses than in control patients and SHMT activities were 
significantly lower in psychotic patients. It was proposed that altered plasma serine 
concentrations could, therefore, be an indicator of susceptibility to psychosis.
SHMT activities and serine and glycine concentrations were measured in medial and 
lateral temporal lobes of frozen autopsied brains of schizophrenics and control brains. It was 
found that the Km of SHMT and concentrations of serine and glycine were higher in the 
medial temporal lobe in schizophrenic patients (Waziri et al., 1990).
Devor and Waziri, (1993) identified a single major gene locus regulating plasma serine 
and glycine concentrations and it is proposed that this locus is SHMT.
Contrary to this evidence a paper by Lucca et al., (1993) demonstrated no difference between 
schizophrenics and a control group when given oral serine and conversion to glycine 
measured. Therefore, SHMT activity could not be deficient.
It is conceivable that an SHMT imbalance could lead to high glycine concentrations. 
There is no active transport of glycine across the blood/brain barrier (Smith et al., 1987) and 
the main source of glycine in the CNS has been demonstrated to be from serine by SHMT 
action (Shank and Aprison, 1970). Glycine is an absolute requirement for activation of the 
NMDA receptor producing an excitatory response in neurones (Kemp and Leeson, 1993). A 
high glycine concentration could potentially have a toxic effect at the NMDA site (Waziri et 
al., 1990). which would in turn have a degenerative effect on neurones leading to abnormal 
brain functions.
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1.6.3 Smith Magensis Syndrome
Smith Magensis syndrome is a mental retardation disorder exhibiting a complex
phenotype. Indicators include developmental and growth delay, facial abnormalities and 
unusual behaviours. The syndrome may be due to a haploinsufficiency of several contiguous 
genes localised to chromosome 17p (Elsea et al., 1995). cSHMT has been shown to be 
localised to 17pll.2 (Garrow et al., 1993). In a study of 26 patients with Smith Magensis 
syndrome, all had one copy of the cSHMT gene deleted and SHMT activity in patient 
lymphoblasts was only 50% of unaffected parents. Loss of cSHMT activity may account for 
some of the traits exhibited by these patients (Elsea et al., 1995).
1.7 Inhibitors of SHMT activity
As the increased activity of SHMT has been demonstrated in cancer cells, the enzyme is a
potential target for drugs to combat some forms of this disease. Along with dihydrofolate 
reductase (DHFR) and thymidylate synthase (TS), SHMT is part of the thymidylate synthase 
cycle, (figure 1.6). Both TS and DHFR have inhibitors in therapeutic use in cancer 
chemotherapy. However, the potential for inhibitors of SHMT activity to be used in the same 
way has often been overlooked. Inhibitors of SHMT activity studied to date fall into two 
classes; natural inhibitors present in a cell and those designed to specifically inhibit SHMT.
The first class includes the compounds 5-methylTHF (Matthews et al., 1982) and 5- 
formylTHF (Stover and Schirch, 1990; 1991) which are competitive inhibitors of SHMT. 
These 2 compound bind the enzyme-glycine complex with similar affinities but the 
triglutamate form of 5-formylTHF is released much more slowly from the enzyme-glycine 
complex than the triglutamate form of 5-methylTHF. Inhibition is increased with increasing 
addition of glutamate residues. Recently Lin et al., (1996) have shown that the plant amino 
acid mimosine inhibits SHMT in CHO cells although the mechanism of inhibition in this case 
is not clear.
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Several different approaches have been used to chemically inhibit SHMT activity. These 
involve either a 3-hydroxy amino acid analogue to mimic serine, antifolates to mimic THF, or 
PLP analogues.
Wang et al., (1981) investigated the activity of D-fluoroalanine and related amino acids 
on lamb and rabbit liver cSHMT. The SHMT catalysed reaction lead to the elimination of 
hydrogen fluoride with the concomitant formation of aminoacrylate, an enzyme-PLP 
intermediate. The reaction inhibited the enzyme with the loss of one cysteine residue. The 
Km for D-fluoroalanine was 50mM suggesting this compound would form an effective drug 
treatment.
The compound 4-chloro-L-threonine was tested by Webb and Matthews, (1995). SHMT 
cleaves this compound to form glycine and chloracetaldehyde, the latter of which is 
responsible for inhibiting the enzyme. SHMT was protected from inhibition by serine and 
glycine.
Other compounds tested include analogues of serine (Tendler et al., 1987). a-vinylserine, 
a-allylserine, a-prop-2-ynylserine and N-(dichloroacetyl)serine were designed as irreversible 
inhibitors and tested for activity. All compounds had little inhibitory effect at 0.25-4mM. At 
2.5-10mM a-vinylserine was found to be a competitive reversible inhibitor. It could be that 
these compounds were too bulky to act as inhibitors or that removal of the (3 proton necessary 
for irreversible inhibition does not occur. So far no amino acid analogue has been found 
which inhibits SHMT at a level required for potential drug use.
The properties of NSC127753, a triazine antifolate, were investigated by Snell and 
Riches, (1989). This compound already has an established anti-tumour activity (Corbett et 
al., 1982) associated with impaired thymidylate synthase activity and decreased cell viability. 
The compound was found to inhibit SHMT in mouse myeloma X63 cells in culture with an
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IC50  of 5x1 O'8 M. Incorporation of [6-3H] deoxyuridine incorporation was also inhibited 
although this result could be due to impaired TS activity.
The effects of antimetabolites of PLP were investigated in vivo by Bukin et al., (1979) on 
mouse spleen SHMT. Compounds were administered to live animals via interperitoneal 
injections. D-cycloserine was found to inhibit SHMT and when pyridoxal azine was 
administered at 75mg/kg body weight injected 1 hour before the injection of D-cycloserine 
there was a slight increase in the effect of D-cycloserine inhibition. Pyridoxal azine also 
exhibited moderate inhibition when administered alone. 4-vinylpyridoxal administered at 
0.5-1.0mg/kg did not reduce SHMT activity alone but increased the effect of D-cycloserine 
and its dimer 2-2.5 fold, leading to more extensive and prolonged inhibition of SHMT.
Trakatellis et al., (1995) used SHMT activity in mitogen stimulated cells to test 
antiproliferative and immunosuppressive compounds, namely D-actinomycin, cytarabine, L- 
asparaginase and cyclosporin. It was found that increasing concentrations of these enzymes 
increased inhibition of SHMT activity and by combining these agents with 4-deoxypyridoxine 
(dB6) the inhibitory effect of dB6 on SHMT was increased. Therefore, by combining these 
drugs with dB6, smaller doses could be used to achieve the same effect.
An alternative strategy for drug design would be to tailor an inhibitor to the structure of 
SHMT. This process is known as rational drug design. However, in order to undertake 
rational design the tertiary and quaternary structure of SHMT is required, which to date has 
not been determined.
1.8 Crystallography of SHMT protein
Unsuccessful attempts have been made to determine the tertiary and quaternary structure
of SHMT by X-ray crystallography. SHMT isolated from both prokaryotic and eukaryotic
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organisms has been crystallised but crystals were either not of a high enough quality or 
disintegrated when subjected to X-radiation.
Miyazaki et al., (1986) crystallised Hyphomicrobium methylovorum SHMT using 
ammonium sulphate. Rhomboid crystals of the apo form of SHMT were produced within 15 
days at 5°C. It is not clear whether any attempts were made to determine the X-ray crystal 
structure of SHMT from these crystals.
E.coli SHMT has also been crystallised in order to perform X-ray crystallography. Two 
crystal forms were obtained, orthorhombic and monoclinic. Both crystal forms diffracted to
2.8 angstroms. (Stover et al., 1993). However, no results have been published and recent 
work published by the authors suggests that they do not have access to an X-ray structure.
Rabbit mitochondrial and cytosolic isozymes of SHMT protein have been crystallised 
(Schirch et al., 1984). mSHMT crystals were tetragonal bipyramids, diffracted to no more 
than 12 angstroms resolution and were sensitive to X-radiation (Stover et al., 1993). The 
cytosolic isozyme crystallised as fine microneedles but no crystals which diffracted could be 
obtained on a regular basis (Stover et al., 1993).
1.9 Heterologous expression of protein please refer t0 chapter 3 
Heterologous expression is the expression of a protein in an organism different to its
origin. In many cases mammalian DNA is expressed in E.coli and kits are now commercially
available to allow the expression and rapid affinity purification of the protein of interest.
Many of these kits involve the expression of the protein as a fusion with another protein e.g.
maltose binding protein (Riggs et al., 1989) or Glutathione-S-transferase (Smith and Johnson,
1988). The fusion product can then be divided into its individual components with proteases
such as thrombin or factor X.
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The pET system (Novagen) was developed by Studier et al., (1990). With this system the 
gene of interest is placed under the control of T7 transcription and translation sequences. The 
plasmid is transformed into a strain of E.coli containing a chromosomal copy of the T7 RNA 
polymerase gene under the control of the lacUV5 promoter. Induction of T7 RNA 
polymerase production is by addition of IPTG to exponentially growing cells. T7 RNA 
polymerase then transcribes the gene of interest. This method of indirect expression prevents 
the build up of the gene product too early in the growth of the culture which is especially 
important if the product is toxic to the cell. Before addition of EPTG there is a small amount 
of T7 RNA polymerase produced. This can be counteracted by the presence of a second 
plasmid in the expression strain. pLysS contains the gene for T7 lysozyme which is 
expressed at a low level and inhibits any T7 RNA polymerase which may be produced before 
induction. There is not enough lysozyme to significantly effect the T7 RNA polymerase after 
induction. T7 lysozyme also weakens the E.coli cell wall, easing lysis of the bacteria after 
expression.
The vector pET14b also incorporates a sequence coding for a run of 6 histidine residues 
(histidine tag) and a thrombin cleavage site before the point where the gene of interest is 
inserted. As a result the gene is expressed to form protein with these sequences at the N- 
terminus. The expressed protein can then be purified form the cell lysate by passing the 
lysate through a resin containing either nickel ions (Novagen) or cobalt ions (Clontech). The 
histidine tag binds to the resin and can then be eluted by addition of imidazole which has a 
higher affinity for the metal ions than histidine. Thrombin can then be used to cleave off the 
histidine residues and leave just glycine, serine and histidine on the amino terminus of the 
protein.
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The advantage of cobalt over nickel is that cobalt ions have 4 sites of attachment to the 
resin as opposed to 3 sites for the nickel ions, leading to less metal ion loss from the column 
and an increased capacity for histidine binding. In addition to this E.coli proteins are less 
likely to bind to the column (for example, a 21KD E.coli protein which has 20 histidine 
residues in 196 amino acids has been shown to bind to nickel ion columns, but binds less 
tightly to cobalt ion columns (Wulfing et al., 1994)). Cobalt columns also bind the histidine 
tag slightly less strongly than nickel ones. As a result less washing of the column is required 
and the protein can be eluted using less stringent conditions.
. .. . . * . Please refer to chapter 41.10 Site directed mutagenesis .
Site directed mutagenesis is a method of changing specific amino acid residues by 
replacing them with another amino acid. This is achieved by changing the desired codon 
within the gene for the protein. Coupled with a system for expressing the mutant protein, 
this method is a powerful tool for investigating the role of particular amino acids within the 
protein. This method can complement the data obtained from X-ray crystal structures by 
modifying the specific residues implicated in activity to determine the accuracy of the 
predictions. In the absence of X-ray crystal data site directed mutagenesis can be used to 
determine whether educated guesses of important residues warrant further investigation. Site 
directed mutagenesis also differs from chemical modification in that the latter is generally 
used to modify classes of amino acids e.g. iodoacetate reacts with exposed cysteine residues, 
DEPC targets histidine residues. However, modification by chemical agents lacks specificity 
in targeting a precise residue. In addition chemical modification adds a chemical group to the 
residues concerned and, therefore, the enzyme can be inhibited by steric hindrance preventing 
substrates binding rather than through a critical catalytic residue being modified. Site 
directed mutagenesis overcomes the specificity and steric hindrance problems and another
49
advantage of site directed mutagenesis is that the residue of interest can be changed to retain 
the charge (e.g. change glutamic acid to aspartic acid), reverse the charge (e.g. change 
glutamic acid to lysine) or remove the side group by changing to alanine to determine whether 
the charge of the amino acid side chain is necessary for catalysis.
There are several different ways of performing site directed mutagenesis. These include, 
PCR based methods (e.g. Stratagene ExCite) and methods using ssDNA as a template such as 
the Promega Altered Sites kit. Using the Promega kit, the gene of interest is placed into the 
supplied vector (pALTER-1) and selected using blue/white selection. pALTER-1 contains 
two antibiotic resistance genes, ampicillin and tetracycline. The ampicillin gene has been 
inactivated by a small deletion. Mutagenesis is performed by annealing the mutagenic oligo 
(containing the desired codon change), an oligonucleotide to repair the ampicillin gene and a 
third to knock out the tetracycline gene to the single stranded pALTER-1 containing the gene 
to be modified. A second strand is the synthesised with T4 DNA polymerase and the three 
pieces of synthesised DNA ligated with T4 DNA ligase to form a complete second strand. 
The double stranded plasmid is then transformed into a DNA repair deficient strain to ensure 
the mismatched bases are not recognized and replaced. After a few replications there should 
be plasmid where both strands have been mutated. The plasmid is then transformed into a 
standard E.coli strain (e.g. JM109, DH5a) to prevent creation of spontaneous mutations in the 
mismatch repair deficient strain. Colonies are selected on L-agar containing ampicillin and 
tested for tetracycline sensitivity. Sequencing is then performed to confirm the mutation. 
Further site directed mutagenesis can be performed on the mutated DNA by annealing another 
mutagenic oligonucleotide along with ampicillin knockout and tetracycline repair 
oligonucleotides.
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1.11 Mapping of restriction endonuclease sites in bacteriophage lambda
Restriction sites present in DNA inserted into bacteriophage lambda clones can be rapidly
mapped by a method involving partial endonuclease digestion (Rackwitz et al 1984).
Radioactively labeled probes complementary to the left and
right cohesive (cos) ends are then added, each one to half of the digested DNA. The
fragments are separated by agarose gel electrophoresis and fragments hybridising to the
probes are detected using X-ray film. This method has been adapted to use of Digoxygenin
(DIG) (Boehringer Mannheim) labeled probes to be used with each batch of digested DNA
being split into two, separated by agarose gel electrophoresis and transferred to a nylon
membrane. DIG labeled cos probes are then hybridised to the blotted DNA.
The lengths of the DNA fragments hybridising to the probes can be determined by
comparison to size standards and each length represents the distance of the restriction site
form the left or right cos end of the lambda clone, i please re e^r t0 c^aPter $
1.12 Structure of eukaryotic genes encoding proteins please refer t0 chapter 6 
Many eukaryotic genes consist of regions coding for protein (exons) interspersed with non
coding sequence (introns). At the junctions between intron and exon there are highly
conserved motifs. The 5’ intron splice junction (donor site) consensus is C/A AGIGTRAGT
where R is a purine and I represents the exon-intron boundary. AT the 3’ end the intron splice
junction (acceptor site) is YnNYAGIR where Y is a pyrimidine and N is any base (Ohshima
and Gotoh, 1987). Introns also have a branch site near the 3’ end which has the consensus
YNYYRAY. When RNA polymerase II transcribes a gene all of the exons and introns are
transcribed to form the primary transcript. The 5’ end of the mRNA precursor is modified by
the addition of a deoxyguanine molecule in a 5’-5’ linkage to form a “cap”. The added
guanine is then methylated and adjacent nucleotides may also be methylated. Most
eukaryotic mRNA molecules contain a polyA tail at their 3’ end. The cap at the 5’ end is
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important for the stability of the molecule and for subsequent intron splicing and translation 
of the mRNA into protein.
To form mRNA the introns need to be spliced out of the sequence. Intron splicing is 
catalysed by small nuclear ribonucleoprotein particles (snRNPs). The snRNP U1 binds to the 
intron donor site and protects a 15 nucleotide region at the 3’ end of the upstream exon. 
Another snRNP (U2) binds to the pyrimidine tract at the 3’ end of the intron and the splice 
acceptor site is recognised by snRNP U5. U4 and U6 are also required in the process. The 
assembly of all these snRNPs is called the splicosome. The mechanism of splicing is thus.
The phosphodiester bond between the upstream exon (exon 1) and the intron is broken by an 
attack by the 2 ’-hydroxy group of the invariant adendine residue in the branch site forming a 
2’,5’-phosphodiester bond between this adenine and the phosphate at the 5’ terminal of the 
intron. The branch generated at this site is called a lariat. The 3’ hydroxy terminus of exon 1 
attacks the phosphodiester bond between the intron and exon 2. Exons 1 and 2 are joined and
the intron is released. | For reviews on intron splicing see Legrand and Chanfreau, 1994; Sharp, 1987
i_ . _. . ...........   . . .  - • ■ ■
1.13 Amplification of human genomic DNA by the polymerase chain reaction
The polymerase chain reaction (PCR) is used to amplify DNA where the 5’ and 3’ ends of the
sequence to be amplified are known. Isolation of the cDNA for a particular gene provides the
mRNA but will not contain the sequence of the introns or any 5’ or 3’ sequence outside of the
transcribed region. Therefore, if isolation of genomic DNA from the known cDNA sequence
into the genome is required then the cDNA can only provide the sequence for one of the
primers. In order to enable the PCR amplification of specific genes from human genomic
DNA, systems have been designed to overcome the absence of the second PCR primer. The
PromoterFinder kit (Clontech) is a commercial form of 5 libraries of human genomic DNA,
each digested with a different blunt ended restriction enzyme and with an adaptor ligated to
each end of the fragments. Two rounds of amplification are performed on each library, using
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for the first round one gene specific primer and one primer within the adaptor. The products 
from the first round of PCR are diluted and used as templates for a second round using 
primers located within the product from the first round of amplification (nested PCR). This 
method reportedly yields a single PCR product in at least four out of the five libraries 
(Clontech). A mixture of proof reading and non-proof reading thermostable DNA 
polymerases can be in order to allow amplification of large templates (Barnes, 1994). The 
use of five libraries ensures that the length of DNA between the gene specific primers and the 
end of the DNA fragments is not too long to enable amplification or too short to amplify only 
known sequence in at least one library.
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 Reagents
Agarose gel sample buffer: 0.25% (w/v) bromophenol blue, 15% (w/v) ficol in water
Luria Broth (LB): lOg tryptone, 5g yeast extract, lOg NaCl in 1 litre water pH7.0 
L-Agar/Agarose: LB containing 15g agar or agarose per litre of broth (7g for top 
agar/agarose)
SM: 5.8g NaCl, 2g M gS04.7H20 , 50ml 1M Tris/HCl pH 7.5, 5ml 2% (w/v) gelatin, water to 1 litre 
SOB: 20g tryptone, 5g yeast extract, 0.5g NaCl, water to 950ml, 10ml 250mM KC1, pH to 7.0 
and make up to 1 litre. After autoclaving add 5ml 2M MgCl2.
SOC: SOB + 20mM glucose
50 x TAE: 242g Tris base, 57.1ml glacial acetic acid, 100ml EDTA pH8.0 
TE: lOmM Tris/HCl pH8.0, ImM EDTA pH8.0
Xgal: 20mg/ml in dimethylformamide, stored in dark in glass container at -20°C
IPTG: lOOmM stock in H20 for blue white selection, 1M stock for induction of expression
stored at -20°C
Buffers for nucleic acid hybridisation
denaturing buffer: 0.5M NaOH, 1.5M NaCl (+ o.l% (w/v) SDS for colony hybridisation) 
neutralisation buffer: 0.5M Tris/HCl pH7.2, 3M NaCl (1M Tris/HCl pH7.5, 1.5M NaCl for 
colony hybridisation)
prehybridisation buffer: 5xSSC, l .0 % (w/v) blocking solution, 0.1 % (w/v) N-lauroylsarcosine, i 
0.02% (w/v) SDS
hybridisation buffer: prehybridisation solution + 5-25ng/ml Digoxygenin labeled probe 
20 xSSC: 3M NaCl, 300mM tri-sodium citrate pH7.2
10% (w /v) blocking solution: powdered blocking reagent was obtained from Boehringer 
Mannheim
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Preparation of plasmid DNA
solution 1: 50mM glucose, 25mM tris/HCl pH8.0, lOmM EDTA 
solution 2: 0.2M NaOH, 1% (w/v) SDS
solution 3: 60ml 5M potassium acetate, 1.5ml glacial acetic acid, 28.5ml water
Buffers for SDS-PAGE 
4x (w/v) resolving gel buffer: 1.5M Tris/HCl pH 8.8, 0.4% (w/v) SDS
4x (w/v) stacking gel buffer: 0.5M Tris/HCl pH 6.8, 0.4% (w/v) SDS
12% (w/v) resolving gel: 3.45ml water, 2.5ml 4x resolving gel buffer, 4.0ml 30% (w/v)
acrylamide, 50pl 10% (w/v) ammonium persulphate, 5pl TEMED
4% (w/v) stacking gel: 6.2ml water, 2.5ml 4x resolving gel buffer, 1.3ml 30% (w/v)
acrylamide, 50pl 10% (w/v) ammonium persulphate, lOpl TEMED
lOx running buffer: 0.5M Tris, 1% (w/v) SDS, 0.55M glycine
10% (w/v) SDS, 1ml glycerol, 7ml water, 5mM
2x sample buffer: 1ml Tris/HCl pH6.8,1ml 10% (w/v) SDS, 1ml glycerol, 7ml water,
5mM DTT, trace bromophenol blue
Coomassie stain: 45% (v/v) methanol, 5% (v/v) acetic acid, 0.1% (w/v) Coomassie blue
Destain: 7.5% (v/v) acetic acid, 5% (v/v) methanol 
Antibiotics
Ampicillin: 50mg/ml in H2O. Filter sterilised stored at -20°C 
Tetracycline: 12.5mg/ml in i 80% (v/v) ethanol stored at -20°C 
Chloramphenicol: 34mg/ml in ethanol stored at -20°C 
Buffers for cSHMT protein purification
8x Binding buffer: 160mM Tris/HCl pH 7.9, 4M NaCl, 40mM imidazole. Dilute to lx  
buffer for use.
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Wash buffer: 160mM Tris/HCl pH 7.9, 4M NaCl, 480mM imidazole 
Sonication buffer: 20mM Tris/HCl pH 7.9, lOOmM NaCl
2.2 Bacterial strains
Strain Phenotvne
DH5oc supE44, AlacU169, (<))80 lacZAMl5), hsdR ll, recAl, endA 1, 
gyrA96, thi-1, relAl (Hanahan 1983)
JM109 endA 1, recAl, gyrA96, thi, hsdR ll (rK-,mK+), relAl, supE44, X- 
Ailac-proAB), [F,’ traD36, proA+B+, lacPZAMIS] (Yanisch- 
Perron et al., 1985) (Promega)
ES1301 mutS lacZ53, mutS201’.:Tn5, thyA36, rha-S, metBl, deoC. IN(rmD- 
rmE) (Siegel etal., 1982) (Promega)
BL21(DE3) F', ompT rs-mB-, (DE3) (Studier and Moffatt, 1986)(Novagen)
BL21 (DE3)pLy sS F , ompT Tb-hie-, (DE3), pLysS Cmr (Studier, 1990)(Novagen)
C600 thi-1, thr-1, leu$36, lacY  1, ton A l l ,  supE44 (Jendrisak et al.,
v
1987)
INVaF’ F’, endAl recAl, hsdR 17 (rK-,mK+), supE44, thi-1, gyrA96, 
relAl c|)80/flcZAM15, A(lacZYA-argF)\J 169 (Invitrogen)
2.3 Vectors used
pUC18: general purpose cloning vector (Yanisch-Perron et al., 1985)
pCRTMfi: PCR product cloning vector (Invitrogen)
pT7blue(R): PCR product cloning vector (Novagen)
pET14b: E.coli expression vector (Studier et al., 1990) (Novagen)
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pALTER-1®: site directed mutagenesis vector (Promega) 
pUS 1203: rabbit cSHMT cDNA containing full orf in pUC18 (Byrne, 1992) 
pUS 1206: human cSHMT in pUC18 containing cSHMT from nt 697 (appendix 1) 
and 850bp of upstream intron sequence (Byrne, 1992) 
pUS1213: human cSHMT cDNA (appendix 1 nt 265-3016) lacking first 29 amino acids in 
orf. subcloned into pUC18 (Byme, personal communication) 
pUS 1217: human cSHMT cDNA (appendix 1 nt 1-1867) containing the whole orf 
in pUC18 (Byme, personal communication)
EMBL3A: lambda replacement vector (Frischauf et al., 1983)
2.4 Oligonucleotides used
All oligonucleotide sequences are in a 5’ to 3’ orientation 
Human and rabbit orf PCR
kjc5 AACCAGTCATATGACGAT
kjc6 CC AGGTGGGTCC AT ATGGGG
C CAACCAGCCATATGGCGAC
A ACTCATATGCCGGCCCCTCTA
Human cSHMT cDNA sequencing primers 
kjc8 TGTGCCTTTGGAACGGAGAT
kjc9 GGCCTATAAGCTGGACCCAC
kjclO TGGTGGCGGCTGGCGTGGTG
kjcl 1 GGCCAGGGAACACAGCAGAA
kjcl2 GCCAGGGAACACAGCAGAA
kjcl 3 ATCTCCGTTCCAAAGGCACA
kjcl 6 GGCGTGCGTTCTCCTCCAGC
kjc20 TTTGAATCTATGCCCTACA
Site directed mutagenesis
ampr GTTGCCATTGCTGCAGGCATCGTGGTG
ampko GTTGCCATTGCGGCATCGTGGTGTCAC
tetr GCCGGGCCTCTTGCGGGATATCGTCCA
tetko GCCGGGCCTCTTGCGGGCGTCCATTCC
kjc7 AGCTCGAATTCG
D182N TGGCTAC ATC AACT ATGACC
W15A GCTGACCTGGCGTCCTCACA
W15F GCTGACCTGTTTTCCTCACA
W15Y GCTGACCTGTATTCCTCACA
C68A TAGGCTCTGCCTTAAATAAC
W 11 IF CCCACAGTGCTTCGGCGTCAACG
W 111A CCCACAGTGCGCGGGCGTCAACG
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C204A GAACCATGCGCCTACTCCCGA
K257A CCACTCACGCAACCCTGCGA
C380stop AAGCCTGATCTATTGCCTG
F424stop GCCCACTAGATTCACAGAGG
K446stop AGAGCCACCCTGTAAGAGTT
Pseudogene sequencing
kjcl CTGAGCCCACCTAGTCATTG
kjc2 ACATCCTTACACTCTCAG
kjc3 GGATGCTATATTATTTGTCCCA
kjc4 CGACCATTTTTAATAAGCACAAT
ON-L AGGTCGCCGCCC
ON-R GGGCGGCGACCT
Human genomic PCR
apl GTAATACGACTCACTATAGGGC
ap2 ACTATAGGGCACGCGTGGT
gspl GGTGACATTTGGCTTCCTGATTACGG
gsp2 TGGATAACAAGCTTGTGAGGGGGCAGTG
kjc21 AGGATCAAATGGTTGTCAG
kjc22 CAAAACTGCTCGGCTGGCGAAAT
kjc23 GCAATCAGCTCCAATCCAAC
pfkl TCTTTGAGGGGTTGTGCCAGCATCT
pfk2 GTGACCAGCGGATCCAACCCCAAACC
pfk3 CTGCCTAGCGCAGGATCCGTCCTA
22/234B6P ACCTCCAAGAAGGTCAGAAGC
309INT- GTCTCTATTTCTCAGCCG
INT1 CAGGCACAAATGTCAGAATG
INT2 TTCCAAAAAGTAGCCCACT
INT3 GGGCACTCAGGTCTACACACA
8/21 24N CCTAACAGACCACAAACCAG
8/2124P GGGGCTGTTGGGTGCAATG
2.5 Basic molecular biology techniques
Most molecular biology techniques were performed according to Sambrook et al (1989).
lxTAE was used for agarose gel electrophoresis. Restriction endonucleases were purchased 
from Boehringer Mannheim Mannheim except cloned Ndel (New England Biolabs). Calf 
intestinal alkaline phosphatase was supplied by Boehringer Mannheim and New England 
Biolabs. Shrimp alkaline phosphatase was purchased from Boehringer Mannheim and T4 
DNA ligase from Life Technologies.
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2.5.1 Small scale preparation of Plasmid DNA
Plasmid DNA was routinely purified using the method of Bimboim and Doly (1979),
although Wizard (Promega) or Wizard Plus DNA (Promega) purification systems were 
occasionally used.
The alkaline lysis method was adjusted slightly to produce DNA suitable for use in the 
automated DNA sequencer. All vortexing steps were replaced with rapid inversion to prevent 
the shearing of genomic and plasmid DNA.
Alternatively plasmids to be sequenced were purified by a method recommended by 
Applied Biosystems. The solutions were the same as for standard alkaline lysis but a PEG 
precipitation step was incorporated. Up to 4.5ml of culture was pelleted, the cells 
resuspended in 200|il solution 1 by pipetting up and down. 300 j j l 1 freshly prepared solution 2 
was added, the contents mixed by inversion and placed on ice for 5 minutes. 300jil of 
solution 3 was added, mixed by inversion and again incubated on ice for 5 minutes. 
Precipitate was removed by centrifuging at 13000g for 10 minutes and the supernatant was, 
transferred to a clean tube. RNaseA was added to a final concentration of 20|ig/ml and the 
tube was incubated at 37°C for 20 minutes. Following 2 extractions with chloroform an equal 
volume of isopropanol was added and immediately centrifuged at 13000g for 10 minutes. 
The pellet was washed with 70% ethanol and dried. The pellet was resuspended in 32(il of 
water and the DNA was precipitated by adding 8j l l 1 4M NaCl and 40 j l i 1 13% PEGgooo- The 
sample was incubated on ice for 20 minutes, centrifuged (13000g) at 4°C for 15 minutes and 
the pellet was washed in 70% ethanol, dried and resuspended in water. The DNA was stored 
at -20°C
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2.5.2 Large scale preparation of Plasmid DNA
Plasmid DNA from 50-100ml of bacterial culture was purified using commercially
available columns (Qiagen, Promega). The alkaline lysis method was also scaled up to use 5 
times the amounts of solutions for the purification of plasmid DNA from 50ml of bacterial 
culture.
2.5.3 Purification of DNA fragments from an agarose gel
The band of interest was excised from the agarose gel and purified in one of several ways;
Geneclean (BIO 101, Amersham), Crystal Gelex (Stratatech) or PCR pure (Clontech) using 
the manufacturer’s protocols. These methods are based on that of Vogelstein and Gillespie, 
(1979). Alternatively the DNA was spun out of the gel through 3mM filter paper (Whatman) 
using the method of Weichenhan, (1991).
2.5.4 Rapid lysis of bacterial colonies to ascertain plasmid size
Part of a bacterial colony from an agar plate was added to 30pl of 50mM NaOH, 0.5%
SDS, 5mM EDTA pH8.0 followed by incubation at 6 8 °C for 45 minutes in a heated water 
bath. I O j l i I  of sample buffer was added and the DNA was separated by agarose gel 
electrophoresis.
2.5.5 Oligonucleotide synthesis and deprotection
Ologonucleotides were synthesised on an Applied Biosystems 381A synthesiser. Before
use, oligonucleotides needed to be deprotected and removed from the synthesis column.
1 .5 ml of 3 5 % ammonia was passed through the column at a rate of 0 .2 ml every 2 0  minutes 
and the eluted ammonia was incubated overnight at 55°C. DNA was precipitated overnight 
by the addition of 1/10 volume of 3M sodium acetate pH5.2 and 3 volumes of ethanol. DNA 
was harvested by centrifuging (13000g) for 20 minutes at 4°C. The pellet was washed twice 
with 80% ethanol and resuspended in water.
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2.5.6 Insertion of PCR products into vectors
Two vectors were used to clone polymerase chain reaction (PCR) products (Invitrogen
pCRU™ and Novagen pT7blue(R)). Both vectors contain single overhanging thymidine 
residues which can be ligated to the adenine residues added to the 3’ end of the PCR product 
by non proof reading enzymes such as Taq (Marchuk et al., 1991). PCR products were 
ligated into these vectors according to the manufacturers protocols and transformed into 
INVaF’ (Invitrogen) or DH5a competent cells.
2.5.7 Automated sequencing
DNA sequencing was performed on an Applied Biosystems 373A automated sequencer by
Stephen Dyer.
2.5.8 Preparation of competent cells
DHa competent cells were already available in the laboratory. Competent INVaF’ and
ES1301 mutS were purchased from Invitrogen and Promega respectively.
Competent bacterial cells of strains JM109, BL21(DE3), BL21(DE3)pLysS and ES1301 
mutS were prepared as follows. A 10ml overnight culture was prepared from a single colony 
of the bacterial strain. 1ml was used to inoculate 50ml of SOB. This culture was incubated at 
37°C, 250rpm until the ODeoonm was 0.6. The cells were harvested by centrifuging at lOOOg 
for 15 minutes at 4°C, and were resuspended in 25ml 50mM CaCl2 and left on ice for 30 
minutes. The cells were again harvested by centrifuging as before and resuspended in 2ml 
ice cold 50mM CaCl2 . If not used immediately, ice cold 50% glycerol was added to 15% and 
the cells were frozen in dry ice or liquid nitrogen.
2.5.9 Transformation of competent cells
Routinely, 20jil of competent cells were defrosted on ice. lOng of DNA was added and
the cells incubated on ice for 30 minutes, heat shocked at 42°C for 45 seconds, and returned
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to ice for 2 minutes. 80pl of SOC was added and the cells were incubated at 37°C for 60 
minutes before plating on L-agar containing the appropriate antibiotics.
A different protocol was used for transformation of competent ES1301 mutS cells. lOOjil 
competent cells were placed in pre-chilled Falcon 2059 tubes on ice. 1.5pl of mutagenesis 
reaction was added, and the tubes incubated on ice for 10 minutes. After heat shocking the 
cells as before and incubating on ice for 2 minutes, 900 j l l 1 of LB was added and the cells were 
incubated at 37°C for 30 minutes. 0.5ml of this culture was added to 4.5ml LB containing 
relevant antibiotics and the culture was incubated overnight.
2.5.10 Southern Blotting
Agarose gels containing DNA bands greater than lOkb were depurinated in 250mM HC1
for 5 minutes at room temperature prior to blotting. After rinsing in water the gel was placed 
in denaturing buffer for 2 x 15 minutes and neutralising buffer for 2 x 15 minutes. The 
agarose gel was then placed face down on a piece of 3mM (Whatmann) filter paper soaked in 
20xSSC and trailing into a reservoir of 20xSSC. A positively charged nylon membrane 
(Boehringer Mannheim) was then placed on the agarose gel, followed by 3 pieces of 3mM 
(Whatmann) filter paper soaked in 20xSSC, and dry paper towels. A weight was than placed 
on top and this apparatus was left overnight. The membrane was removed and baked in an 
oven for 30 minutes at 120°C or 2 hours at 80°C to fix the DNA.
2.5.11 Colony lifts
Transformed bacterial colonies were replated onto a second plate, incubated overnight and 
then placed in at 4°C for 1 hour. Positively charged nylon membrane was laid onto the 
colonies for 1 minute for a primary filter and 3 minutes for a secondary filter. The 
membranes were specifically cut allowing subsequent orientation with the agar plate. 
Membranes were placed colony side up on filter paper soaked with denaturing solution for 15
63
minutes, neutralistion solution for 5 minutes and finally 2xSSC for 15 minutes. DNA was 
fixed to the membrane by heating for 2 hours at 80°C or for 30 minutes at 120°C. Prior to 
hybridisation the membrane was incubated in 3xSSC, 0.1% SDS in the hybridisation tubes at 
6 8 °C and then wiped with a damp tissue to remove cellular debris.
2.5.12 Digoxygenin labeling of DNA
This was performed according to the manufacturers protocol (Boehringer Mannheim).
Two different methods were employed depending on the DNA to be labeled.
Oligonucleotides were 3’-end labeled by 1 molecule of DIG-ll-dUTP being added to the end
of each oligonucleotide. DNA 500bp-2.5kb in length was labeled by random priming, single
stranded DNA was created by boiling and rapid cooling and random hexanucleotides were
annealed to prime the second strand synthesis using Klenow enzyme supplied with dNTP’s
and DIG-ll-dUTP. The yield of labeled nucleotides was estimated by diluting the labeled
DNA, spotting l |il of each dilution onto positively charged nylon membrane along with
labeled control DNA, and baking of the membrane to fix the DNA. This membrane was then
placed through the detection procedure and X-ray film was exposed. The intensity of the
exposed film for the test samples could then be compared to the test samples.
Labeled probes were boiled for 10 minutes and snap-frozen before use.
2.5.13 Hybridisation and detection of DNA
Membranes were placed into hybridisation bottles (Hybaid) and incubated in hybridising
ovens (Hybaid). The membranes were incubated in prehybridisation solution for 1 hour (2 
hours for colony hybridisations) at 6 8 °C. Southern blots and colony hybridisations were then 
incubated in hybridisation solution overnight at 6 8 °C. The membrane was then washed twice 
in 2xSSC, 0.1% SDS for 5 minutes at room temperature and then twice in O.lxSSC, 0.1% 
SDS for 15 minutes at 6 8 °C. Labeled DNA still attached to the membrane after the washes 
was detected according to the manufactures protocol (Boehringer Mannheim). This
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procedure involved the blocking of the membrane to remove any extra binding sites, the 
incubation of the membrane with Anti-Digoxygenin Fab fragments coupled to alkaline 
phosphatase and the addition of Lumigen PPD and latterly CSPD. These are substrates for 
alkaline phosphatase and when cleaved emit light which can be detected on X-ray film.
2.5.14 5’ Phosphorylation of oligonucleotides
lOOpmol of oligonucleotide was phosphorylated using T4 polynucleotide kinase (Gibco).
ATP was added to the reaction buffer to a final concentration of ImM. The reaction was 
incubated at 37°C for 30 minutes and then the enzyme was inactivated by incubating at 70°C 
for 1 0  minutes.
2.6 Amplification of rabbit and human cSHMT cDNA by PCR
PCR reactions were performed using 20ng of template, lOOpmol of each primer, IOOjiM
each dNTP and 5 units of Taq polymerase (Boehringer Mannheim) in lOmM Tris/HCl pH 
8.3, 1.5mM MgCl2 , 50mM KC1, O.lmg/ml gelatin. The PCR reactions were performed at 
95°C for 3 minutes followed by 25 cycles of 95°C for 1 minute, 42°C for 1 minute and 72°C 
for 2 minutes. A final extension time of 72°C for 5 minutes was performed. PCR products 
were analysed by electrophoresis through a 1 % agarose gel, bands were excised and purified 
(section 2.5.3) before ligation into pCRU™ (section 2.5.6).
2.7 Modification of pUC18 to remove multiple cloning site
An oligonucleotide was synthesised (kjc7) to replace the multiple cloning site between the
HindiII and EcoRl sites of pUC18. lpg of pUC18 was digested with HindSE, phosphatased 
and ligated with lOOpmoles phosphorylated kjc7. After transformation into competent 
DH5a, one plasmid (pUS1248) was digested with EcoRl, the digested plasmid was purified, 
phosphatased and ligated with the EcoRl fragment from pCRH™ containing the human 
cSHMT cDNA.
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2.8 Site Directed mutagenesis of human cytosolic SHMT
Site directed mutagenesis was performed using the Promega Altered Sites II kit and
protocol.
2.8.1 Production of single stranded DNA
Single stranded DNA was created using the Altered Sites kit II protocol (Promega).
2.8.2 Mutagenesis of human cSHMT cDNA
Mutagenesis was performed according to the manufacturers protocol except that lOpmol
of mutagenic oligonucleotide was added to the reaction instead of 1.25pmol (Piechocki and 
Hines, 1994) and the annealing reactions were heated to 95°C instead of 75°C. After addition 
of the T4 DNA polymerase and DNA ligase, the reaction was incubated at room temperature 
for 5 minutes before incubating at 37°C (Piechocki and Hines, 1994). The cotransformation 
of ES1301 mutS and JM109 cells yielded no colonies. Therefore, the resynthesised plasmid 
was transformed directly into ESI031 mutS cells, according to the manufacturers alternative 
protocol (Promega) (section 2.5.9). The plasmid DNA from these cells was the extracted and 
used to transform JM109 or DH5a.
2.9 Expression of cSHMT in E.coli
To assess whether cSHMT protein was soluble when expressed at various temperatures
the following protocol was followed. 50 ml of LB was inoculated with 0.4ml of an overnight 
culture of BL21(DE3)pLysS containing pET14b with the gene of interest. The culture was 
grown at the required temperature until the ODeoonm was 0.4-0.6. 50jnl of culture was 
removed, pelleted and resuspended in 20 j l l 1 SDS-PAGE sample buffer. IPTG was added to a 
final concentration of 0.4mM and the culture was grown for either a further 2 hours or 
overnight. 20pl of cells were removed, pelleted and resuspended in 20jxl SDS-PAGE sample 
buffer. The remaining culture was harvested by centrifuging at 4000g for 10 minutes. The
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pellet was resuspended in 5ml 50mMTris/HCl pH8.0. 2mM EDTA. Lysozyme was added to 
lOOjig/ml and 0.5ml of 1% Triton X-100 were added. The mixture was incubated at 30°C for 
15 minutes and then microfuged at 4°C for 15 minutes. The supernatant (soluble fraction) 
was removed and an equal volume of SDS-PAGE sample buffer was added. The pellet 
(insoluble fraction) was resuspended in 0.5ml SDS-PAGE sample buffer. The protocol was 
modified by the addition of DNAsel and RNaseA were added to final concentrations of 
20jLig/ml and 40jLig/ml at the same stage as lysozyme to reduce the viscosity of the solution by 
removing the DNA and RNA.
C380stop and K446stop mutants were grown as above but were also tested for production 
of soluble protein by incubation of the culture at 20°C in LB containing 2.5mM betaine and 
660mM sorbitol (Blackwell and Horgan, 1991).
Protein production was monitored by SDS-PAGE electrophoresis to ascertain whether 
SHMT had been expressed and whether any SHMT protein was present in the supernatant. 
20jil of sample was analysed except for the insoluble protein in 0.5ml sample buffer where 5- 
IOjliI was analysed.
Large scale cultures (4x250ml of culture in four 1 litre flasks) were inoculated with 4ml of 
overnight culture per flask. The culture was grown at the temperature at which each SHMT 
was soluble (usually 25°C). Expression of SHMT protein was induced as above and cells 
harvested 2 hours later. The culture was harvested by centrifugation at 4000g for 15 minutes 
at 4°C and the pellets were stored at -80°C.
2.10 Purification of SHMT protein
SHMT was purified using 2 different manufacturer’s protocols from Novagen and
Clontech. Cell pellets from 1 litre of induced culture were thawed and resuspended in 20ml 
binding buffer (Novagen) or sonication buffer (Clontech). DNasel and RNaseA were added
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Amount of protein loaded on SDS-PAGE gels 
Overnight culture: 0.04% of culture volume
Before induction with IPTG: 0.1 % of culture volume 
Post induction with IPTG: 0.04% of culture volume
(uninduced culture has 1/3 of protein of induced culture (Novagen, personal communication)
Pellet post lysis: 0.1 % of culture volume
Supernatant post lysis: 0.4% of culture volume
Pellet post sonication: 0.1 % of culture volume
Supernatant post sonication: 0.025% of culture volume
Flowthrough from column: 0.025% of culture volume
Other lanes cannot be expressed as percentage of culture volume, expressed instead as 
percentage of sample
Flowthrough of wash buffer: 0.05% of sample 
Eluate: 0.013% of sample
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to final concentrations of 20jng/ml and the samples incubated for 30-60 minutes at 4°C. The 
cell slurry was then sonicated for 6  periods of 10 seconds and centrifuged at 20000g for 30 
minutes at 4°C. The supernatant was passed through a 0.45jiM filter to remove any 
remaining viscous material before being applied to the affinity purification column.
Wild type human cSHMT, the C204A mutant and the rabbit cSHMT were purified on the 
Novagen His Bind resin according to the manufacturer’s protocol except that the wash buffer 
step was replaced with a further wash with binding buffer, and the protein was eluted from 
the purification column with binding buffer containing 200mM imidazole instead of 1M.
All other cSHMT mutants were purified using Talon resin (Clontech) using the 
manufacturer’s batch/gravity flow column protocol for purification of native protein except, 
the sonication buffer was pH7.9. Protein was eluted from the affinity column using 
sonication buffer containing lOOmM imidazole.
10|il of SDS sample buffer was added to IOjllI of the column flowthrough after application 
of the cell lysate and after washing. 15j l i 1 of SDS sample buffer was added to 5jnl of fractions 
containing protein eluted from the column with imidazole. Samples were analysed by 
SDS-PAGE using 20(xl of sample except for the protein eluted from the column where 2-5 j l i 1 
was analysed.
After SHMT elution, protein was concentrated and desalted using Centriplus columns 
(Amicon). The buffer was changed to 50mM Tris/HCl pH7.5, 2mM Pyridoxal 5’-phosphate, 
2mM serine, lOmM Dithiothreitol.
2.10.1 Biorad Assay of protein concentration
This is a commercially available protein concentration assay based on the method of
Bradford, (1976). 0.8ml of water and up to 50p,l of sample was placed in a cuvette and 0.2ml 
of Biorad dye reagent (Biorad) was added and the solution mixed thoroughly by inversion.
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Two enzyme assays were performed on wild-type and mutant cSHMT proteins to assess ; 
whether the mutations had any affect on cSHMT activity. The radioactive assay was used as
I
i
serine and THF are the physiological substrates of SHMT. The dl-allothreonine assay does 
not use THF as a substrate so any mutation affecting THF binding can be determined by 
differing enzyme activities exhibited in the two assays.
The OD5 95nm was measured and compared to a standard curve created using known 
concentrations of BSA.
2.11 Assay of SHMT activity using serine and THF
This assay was based on the method of Taylor and Weissbach (1965). SHMT was diluted
to various concentrations in 80 j l l 1 of 310mM Hepes pH 7.4, 2mM THF, 12mM 
2-mercaptoethanol, 0.2mM PLP. The reaction mixture was incubated for 5 minutes at 37°C 
before the addition of 20|il 1.25mM L-[3-14C]-serine. After 10 minutes incubation at 37°C the 
reaction was stopped by the sequential addition of 60|xl 1M sodium acetate pH 4.5, 40)il 0.1M 
formaldehyde and 60jil 0.4M dimedone. The samples were boiled for 5 minutes and then 
placed on ice for 5 minutes. 1ml of toluene was added and the samples were shaken for 60 
minutes at room temperature. After vortexing and centrifuging at 13000g for 10 minutes, 
800fxl of the supernatant was added to 3ml scintillant and counts per minute recorded. The 
results were expressed as nmoles formaldehyde formed/min/nmol SHMT and the percentage 
activity compared to wild type SHMT was calculated. A graph of SHMT concentration 
verses percentage activity of the wildtype was drawn and the amount of enzyme equating to 
half of the maximum activity of the wild type SHMT (EC50) was calculated.
2.12 dl-allothreonine assay
This assay was based on the method of Schirch and Gross ( 1968). 950 j l l 1 50mM potassium
phosphate buffer, ImM EDTA pH 7.4, 90units alcohol dehydrogenase, 128nM NADH and 
0.5mM to 50mM dl-allothreonine was placed in a 1ml cuvette and incubated at 30°C for 10 
minutes. SHMT was added in 50jil to a final concentration of 1.06xl0'8M and the OD3401U11 
was measured for 10 minutes. The rate of absorbance change per minute was calculated and 
plotted according to (Hanes, 1932) to obtain a Km for dl-allothreonine.
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2.13 Bacteriophage lambda techniques
2.13.1 Preparation of plating bacteria
50ml of LB containing 0.2% maltose was inoculated with a single colony of E.coli strain
C600 and grown overnight at 37°C with shaking at 250rpm. The cells were harvested by 
centrifuging at 4000g for 10 minutes at room temperature and the pellet was resuspended in 
20ml 0.01M MgSCU. The ODeoonm was taken and the cells diluted so that ODeoonm was 2.0. 
Cells were stored at 4°C.
2.13.2 Plating Bacteriophage lambda
10 fold dilution’s of stock phage were made in SM. 0.1ml of each dilution was added to
0.1ml of plating bacteria and incubated at 37°C for 20 minutes. 3ml of molten (47°C) top L- 
agar or agarose was added to each tube, mixed and poured onto a petri dish containing 30ml 
hardened L-agar/agarose. Plates were allowed to stand for 5 minutes to allow the top layer to 
set before inverting and incubating at 37°C overnight.
2.13.3 Plaque purification
Plaques were sucked into a pasteur pipette along with the underlying L-agar/agarose and
pushed out into 1ml SM containing 1ml chloroform. Phage were titrated using serial 
dilutions and following the protocol in section 2.13.2.
2.13.4 Rapid small scale isolation of Lambda DNA
50- 100j l i 1 of 105pfu/ml phage suspension was added to 0.1ml plating bacteria. The
procedure for plating lambda (section 2.13.2) was followed using L-agarose. After overnight 
incubation, 5ml SM was added to the plates which were then gently shaken at room 
temperature for 1-2 hours. The SM was poured into a centrifuge tube together with the top 
L-agarose. The tubes were centrifuged at 7500g for 10 minutes at 4°C and the supernatant 
was decanted. DNase and RNase were added to the supernatant to a final concentration of
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ljig/ml. and incubated at 37°C for 30 minutes. An equal volume of SM containing 20% PEG 
and 2M NaCl was added followed by incubation at 0°C (ice water) for 1 hour. Precipitated 
phage were pelleted by centrifuging for 20 minutes at lOOOOg, 4°C. The supernatant was 
removed and excess supernatant drained off. The pellet was resuspended in 0.5ml SM by 
vortexing and centrifuged (13000g) for 2 minutes at 4°C to remove debris. SDS was added to 
0.1%, EDTA to 5mM and the solution incubated at 6 8 °C for 15 minutes. The solution was 
phenol extracted, phenol/chloroform extracted, chloroform extracted and isopropanol 
precipitated. Following incubation at -70°C for 20 minutes and centrifuging (13000g) for 15 
minutes at 4°C, the pellet was washed with 70% ethanol, dried and resuspended in 50|xl TE 
(pH8.0).
2.14 Mapping of Pseudogene clones
Two primers ON-L and ON-R complementary to the left and right cos end sequences
respectively were end labeled with digoxygenin (section 2.5.12). Partial digests of 
lambda clones were performed by incubating
ljug of DNA with 1-10 units of restriction enzyme at room temperature for 10 minutes. 
EDTA was added to a final concentration of lOmM, the reaction tubes were incubated at 
6 8 °C for 10 minutes to disrupt the cos ends, divided into 2 and phage DNA fragments 
separated by agarose gel electrophoresis through a 0.5 or 0.6% gel. DNA was visualised by 
staining by ethidium bromide prior to Southern blotting (section 2.5.10). Half of the samples 
were hybridised to ON-L and the other half to ON-R at 42°C for 4 hours (section 2.5.13). 
Sizes of DNA fragments hybridising to the probes were calculated by comparison to DNA 
length standards.
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2.15 Analysis of the human genomic cytosolic SHMT gene
This was performed using the Human PromoterFinder kit (Clontech) with either DNA
Advantage Tth polymerase mix (Clontech) or Expand™ Long template polymerase mix 
(Boehringer Mannheim). PCR reactions were performed according to the PromoterFinder kit 
protocol using the Clontech polymerase. When Expand™ long template polymerase 
(Boehringer Mannheim) was used 2 master solutions were made; one containing water, 
dNTP’s and oligonucleotides, the other containing water, polymerase, template and lOx 
buffer. These 2 solutions were mixed on ice prior to amplification.
The first PCR was performed as follows. 7 cycles of 94°C, 25 seconds, 72°C, 4 minutes, 
then 32 cycles of 94°C, 25 seconds and 67°C, 4 minutes and one cycle of 6 8 °C for 4 minutes. 
The second PCR conditions were 5 cycles of 94°C, 25 seconds and 72°C, 4 minutes followed 
by 22 cycles of 94°C, 25 seconds, 67°C, 4 minutes and a final cycle of 6 8 °C for 4 minutes
PCR of human genomic DNA was also performed using Expand™ long distance 
polymerase (Boehringer Mannheim). The cycles used were 94°C for 2 minutes followed by 10 
cycles o f 94°C for 1 0  seconds, 65°C for 30 seconds and 6 8 °C for 8  minutes, then a further 15 
cycles o f the above but extending the elongation element by an extra 2 0  seconds each cycle, 
r One cycle of 6 8 °C for 7 minutes completed the amplification.
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CHAPTER 3 
CONSTRUCTION OF RABBIT AND HUMAN 
CYTOSOLIC SHMT EXPRESSION VECTORS AND 
EXPRESSION AND PURIFICATION OF PROTEIN
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3.1 Summary Please refer to section 1.9
The precise tertiary and quaternary structures of SHMT are required in order to design
inhibitors of SHMT activity on a rational basis. To date no X-ray crystal structure has been 
published of SHMT protein isolated from any source (section 1.8) and, therefore, the 
structure and reaction mechanism of SHMT protein is subject to speculation. Some 
information as to critical residues for activity can be provided by modification of residues by 
chemicals and use of reaction intermediates but this method does not reveal the environment 
in which these essential residues lie. Highly pure SHMT protein is required in order for an 
X-ray crystal structure to be determined. In addition, pure SHMT protein can be used to 
assay potential inhibitory compounds designed using any potential X-ray structure or to test 
existing compounds. The orfs encoding human and rabbit cSHMT were subcloned into 
pET14b and were expressed in an E.coli in order to produce large quantities of protein for 
crystallography studies and for inhibitor screening by collaborators at the Institute of Cancer 
Research.
cDNA’s containing the full open reading frames for rabbit and human cytosolic SHMT’s 
had previously been isolated (Byrne, 1992). The cDNA’s had been subcloned into pUC18 at 
the EcoKL site and designated pUS1203 and pUS1217 respectively. To enable the rapid 
purification of expressed SHMT protein from E.coli, the expression vector pET14b 
(Novagen) was chosen (section 1.9) Modifying the translational start codons to introduce an 
Ndel site (CATATG) and incorporating a second NdeI site downstream of the stop codons 
allowed the human and rabbit cSHMT orfs to be cloned into pET14b in frame with the 
histidine tag encoding sequence. PCR amplification was chosen for the modification, with 
Ndel sites being incorporated into the oligonucleotide primers of the PCR reaction. 
Expression was followed over a three hour time course after induction with IPTG and it was
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determined that both human and rabbit cSHMT proteins are expressed in a soluble form 
enabling rapid purification of protein.
3.2 Results
3.2.1 Subcloning of rabbit cSHMT into pET14b
The cDNA coding for rabbit cSHMT (pUS1203) was amplified by PCR using primers C
and A (see section 2.6) to produce Ndel restriction sites overlapping the start codon, and 
downstream of the stop codon. The PCR product was purified from an agarose gel and 
ligated into the vector pCRU™ (Invitrogen). After transformation of the ligated plasmid into 
IN V aF’ cells, 40 white and 14 blue colonies resulted. Of 5 white colonies analysed, 4 
contained the PCR product. One of the plasmids containing the PCR product (pUS1246) was 
digested with Ndel and the 1.5kb band removed and purified. The 1.5kb fragment containing 
the rabbit cSHMT orf was then ligated into Ndel digested pET14b. DH5a cells were 
transformed to ampicillin resistance with the ligation mixture and 2 1  colonies were produced. 
Of 6  colonies analysed, 5 contained plasmids with the insert and one contained plasmid alone. 
Four plasmids contained the inserted rabbit cSHMT orf in the right orientation for expression 
(figure 3.1).
3.2.2 Expression of rabbit cytosolic SHMT
One of the clones (pUS1250) containing the rabbit cSHMT orf in the correct orientation
was used in subsequent experiments. The plasmid was extracted from DH5a cells and used 
to transform the expression strains BL21(DE3) and BL21(DE3)pLysS to ampicillin 
resistance. After checking that the ampicillin resistant colonies contained the plasmid, 1 
colony of BL21(DE3) containing the plasmid was amplified and protein expression was 
induced by the addition of IPTG to the medium. Samples were removed at 30 minute 
intervals for analysis of protein expression by SDS-PAGE. A strain containing the gene for
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Figure 3.1 Vectors used for the expression o f rabbit and human cSHMT proteins. pET 14b (Novagen) 
isthe expression vector. pUS 1250 contains the PCR amplified rabbit cSHMT in pET 14b pUS1251 
contains the amplified human cSHMT orf in pET 14b.
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Figure 3.2 Coomassie brilliant blue stained SDS-PAGE gel showing a time course of rabbit 
cSHMT protein expression in E.coli. Cells containing pUS1250 were grown and protein 
expression was induced in log phase cells by the addition of IPTG. Samples were taken every 
30 minutes after induction for 3 hours.
Lane M MW markers
Lane 1 Cells before addition of IPTG
Lanes 2 to 7 Samples taken from 30 minutes to 3 hours post induction
Please refer to p67a for protein loadings
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Figure 3.3 Comparison of soluble/insoluble fractions of rabbit cSHMT protein expressed in 
E.coli. Cells containing pUS1250 were induced with IPTG and harvested 2 hours post 
induction. Soluble and insoluble fractions of lysed cells were separated by centrifugation and 
analysed by SDS-PAGE.
Lanes M MW markers
Lane 1 Overnight culture
Lane 2 Before induction with IPTG
Lane 3 Whole cells 2 hours post induction
Lane 4 Pellet post centrifugation of lysed cells
Lane 5 Supernatant post centrifugation of lysed cells
Please refer to p67a for protein loadings
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p-galactosidase in pET14b was used as a control. The induced SHMT from pUS1250 had a 
molecular weight of 53KD, the correct weight for SHMT (figure 3.2). SHMT was seen 30 
minutes post induction and the yield of protein increased with time to approximately 15% 
total cell protein 3 hours post induction equivalent to approximately 25|Lig/ml of culture.
To determine whether rabbit cSHMT was soluble in the cytoplasm or was sequestered into 
inclusion bodies, expression was induced in BL21(DE3)pLysS cells growing at 37°C. After 2 
hours induction the cells in the culture were collected, resuspended in 50mM Tris/HCl pH 
8.0, 2mM EDTA and treated with lysozyme and Triton X-100 to lyse the cells. The soluble 
and insoluble components were separated by centrifugation. SDS-PAGE showed that the 
53KD band was present both in the pellet and supernatant showing that the protein was at 
least partly soluble (figure 3.3).
3.2.3 Subcloning of human cytosolic SHMT into pET14b
The human cSHMT was cloned into the pET14b vector in a manner identical to that used
for the rabbit. PCR was performed on pUS1217 using oligonucleotides kjc5 and kjc6 . The 
PCR product was ligated into pCRII™ and 26 colonies were produced by transforming 
INVaF’ with the ligation reaction. One plasmid containing the human orf PCR product 
(pUS 1247) was digested with Ndel to release the 1.5kb PCR product fragment which was 
purified from an agarose gel slice and ligated to Nde I digested pET14b. After transforming 
DH5a cells with the ligation reaction, 6  colonies were analysed and 2 contained plasmids 
with the human cSHMT orf in the correct orientation for expression. One of these plasmids 
was designated pUS 1251 (figure 3.1).
3.2.4 Expression of human cytosolic SHMT
pUS 1251 was used to transform BL21(DE3)pLysS to ampicillin resistance. BL21(DE3)
pLysS containing pUS1251 was grown in culture at 37°C and induction of human cytosolic
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SHMT expression was initiated by addition of IPTG to the medium. Samples were removed 
for analysis of protein expression by SDS-PAGE at 30 minute intervals (figure 3.4). SHMT 
protein was present 30 minutes post induction. The gels show appreciably easily detectable' 
expression of cSHMT by 3 hours post induction
To determine whether human cSHMT was soluble when expressed at 37°C, an 
experiment identical to that used to determine the solubility of rabbit cSHMT was performed. 
SDS-PAGE analysis identified a 53KD band in both the supernatant and the pellet fractions 
of induced and lysed cells. From the bands seen on SDS-PAGE gels it was demonstrated that-
expressed human cSHMT protein is at least partly soluble (figure 3.5).
3.2.5 Sequencing of PCR modified SHMT sequences
Amplification of DNA fragments by PCR can lead to mutations in the fragment as the
polymerase may incorporate the wrong nucleotide. This error is then carried through future 
PCR cycles. The modified SHMT orfs were to be used to generate proteins to be used to 
solve the X-ray crystal structure of SHMT and, therefore, it was vital that there are no errors 
in the coding sequence that may affect protein structure. Boehringer Mannheim Taq 
polymerase has an error rate of 2.5xl0 ‘5 (Boehringer Mannheim, personal communication), 
although PCR amplifications performed by colleagues suggested a higher error rate. The 
PCR products of the rabbit and human cSHMT orfs were, therefore, sequenced to determine 
whether any mutations had occurred.
Sequencing of the human cSHMT orf PCR product indicated three mutations. Two of 
these mutations at nucleotide (nt) 513 (C to G) and nt 1638 (G deletion) (appendix 1) did not 
affect the coding sequence as codon 1 1 2  remained coding for glycine and the second mutation 
was downstream of the stop codon. However, the third mutation was at nt 721 changing an
80
SHMT
Figure 3.4 Coomassie brilliant blue stained SDS-PAGE gel showing a time course of human 
cSHMT protein expression in E.coli. Cells containing pUS1251 were grown and protein 
expression was induced in log phase cells by the addition of IPTG. Samples were taken every 
30 minutes post induction for 3 hours.
Lane M MW markers
Lane 1 Cells before addition of IPTG
Lanes 2 to 7 Samples taken from 60 minutes to 3 hours post induction
Please refer to p67a for protein loadings
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Figure 3.5 Comparison of soluble/insoluble fractions of human cSHMT protein expressed in 
E.coli. Cells containing pUS1251 were induced with IPTG and harvested 2 hours post 
induction. Soluble and insoluble fractions of lysed cells were separated by centrifugation and 
analysed by SDS-PAGE.
Lanes M MW markers
Lane 1 Overnight culture
Lane 2 Before induction with IPTG
Lane 3 Whole cells 2 hours post induction
Lane 4 Pellet post centrifugation of lysed cells
Lane 5 Supernatant post centrifugation of lysed cells (soluble fraction)
Please refer to p67a for protein loadings
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adenine to a guanine. This mutation changed codon 182 from asparagine to aspartic acid. To 
check that the error was genuine and not a sequencing error in the original pUS1217, 
sequencing of pUS1217 was repeated in this region. The codon was confirmed as AAC 
(asparagine) in pUS1217.
The sequence of the modified rabbit SHMT orf PCR product is incomplete. However, 
two mutations have been found at nt 1484 and nt 1581 (pUS1203 sequence) changing adenine 
to cytosine and guanine to cytosine respectively. Both of these mutations were silent and did 
not affect the amino acid sequence of the rabbit cSHMT protein.
3.3 Discussion
The open reading frames encoding human and rabbit cSHMT have been subcloned into 
the prokaryotic expression vector pET14b. Both plasmids pUS1250 and pUS1251 direct the 
production of cSHMT protein when induced with IPTG. Microgram amounts of cSHMT 
protein are produced per millilitre of culture. At least 50% of protein expressed at 37°C is 
soluble and, therefore, assumed to be in a native state. The solubility of the proteins enables 
them to be rapidly purified compared to the process involving denaturation of insoluble 
protein aggregated in inclusion bodies, and refolding of the protein by removing the 
denaturant (see Fischer et al., 1993 for review). Proteins produced in a soluble state are more 
likely to have the native structure, whereas refolding denatured proteins can lead to different 
structures being formed. Consequently activity assays of proteins produced from the soluble 
fraction are more reliable than those from refolded proteins. It also follows that the X-ray 
crystal structure would be more accurate from a natively folded structure than from a refolded 
one.
From the results presented here, a method for the large scale expression of cSHMT 
protein has been devised. The strain used for expression was BL21(DE3)pLysS as this cell
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line was more easy to lyse than the strain without the pLysS plasmid. After the cells reach 
log phase and protein production induced with IPTG, cells are grown for a further 2 hours and 
then harvested (S.Renwick, personal communication). This time course gives the maximum 
amount of expression without giving the chance for excessive degradation of the expressed 
protein. There is evidence that if expressed protein reaches 30% of total cell protein, protein 
synthesis and cell growth stops, ribosomal RNA is degraded and the cell dies (Kurland and 
Dong, 1996).
PCR amplification of the human cSHMT orf generated an A to G mutation, compared to 
pUS1217, changing codon 182 to aspartic acid. Sequencing of the original pUS1217 clone 
determined that nt 721 was an adenine residue and, therefore, codon 182 encoded an 
asparagine residue. This data was also confirmed by the publication of the coding sequence 
of human cSHMT cDNA (Xu, 1992; Garrow et al., 1993). However, an alignment of SHMT 
protein sequences from different organisms using the PILEUP and PRETTY programs 
(Genetics Computer Group) (appendix 2) showed that in some other SHMT proteins there is 
an aspartic acid residue at this position instead of an asparagine so so the mutation generated 
was conservative. There could be some genetic variation within the population for the 
cSHMT gene leading to sequences different to those isolated to date. However, all of the 
human cSHMT protein primary structures translated from the cDNAs isolated so far show 
100% identity. Therefore, the mutation in the amplified human cSHMT cDNA may affect the 
activity and X-ray crystal structure of the protein.
Attempts to sequence the PCR amplified product from rabbit cSHMT template produced 
relatively poor sequence. It is possible that the primers, synthesised in 1990-92 have 
degraded and new ones need to be synthesised to allow the accurate determination of the 
rabbit cSHMT orf PCR product. Out of the good sequence obtained, two silent mutations
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were found in the space of less than lOObp. The sequence of the amplified rabbit cSHMT 
cDNA needs to be examined further to ascertain whether there are any mutations affecting the 
primary structure of the protein.
The error rate of Taq polymerase can be determined by the method in Hayes, (1965) as 
used by Saiki et al., (1988). The error rate is (m)=2(f/d) where /  is the observed error 
frequency in the PCR product and d  is the number of doublings. The error rate for the human 
cSHMT orf PCR product can be calculated as 2((3/1490)/25) which works out at 1.6xl0'4. 
However, the number of effective PCR cycles is only 60% of the number of cycles when 
amplifying a product of less than 3kb (Boehringer Mannheim, personal communication). 
Therefore, this would lead to an error rate of 2.6xl0‘4. Both error rates are at least 10 fold 
greater than those advertised by Boehringer Mannheim.
It can be concluded from the error rates shown in the PCR products discussed here that if 
it is critical for a PCR product to have no errors then an alternative DNA polymerase to Taq 
should be used. There are now several proofreading thermostable DNA polymerases 
available such as Pfu polymerase from Stratagene and Pwo polymerase from Boehringer 
Mannheim which have error rates of 1.6xl0 6 and 3xl0'6 respectively.
Once the PCR induced error had been corrected by mutagenesis (chapter 4), milligram 
quantities of wild-type human cSHMT protein were subsequently produced and purified on a 
column containing nickel ions (section 1.9) (S. Renwick, personal communication). 
Purification of cSHMT protein can be achieved in one day. Twelve milligrams of human 
cSHMT can be purified from 1 litre of culture. However, purified enzyme rapidly 
precipitates out of solution if left solely in 50mM Tris/HCl pH7.5. This problem was solved 
by adding pyridoxal phosphate, serine and dithiothreitol (DTT) to the purified enzyme 
(S.Renwick, personal communication).
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Figure 3.6 Crystals of human cSHMT. Human cSHMT cDNA was subcloned into pET14b 
and expressed in E.coli. Purified cSHMT protein was crystallised at the Institute of Cancer 
Research (Courtesy of S.Renwick)
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Since performing this work, methods for the bacterial expression and purification of sheep 
and human cSHMT have been published (Jagath-Reddy et al., 1995; Kruschwitz et al., 1995). 
Both of the cDNA’s were put under the control of the T7 promoter and produced 10mg/l and
11.25mg/l protein respectively. However, neither system had an affinity purification method 
and purification of cSHMT protein was laborious involving two purification columns and 
ammonium sulphate precipitations. The expression system described here produces a higher 
quantity of purified cSHMT more quickly.
Crystallography studies have been initiated at the Institute of Cancer Research (S. 
Renwick, personal communication) and human cSHMT crystals grown (Figure 3.6). The first 
crystals produced were sensitive to X-rays and disintegrated. Further studies are in progress 
and more stable human cSHMT crystals for X-ray diffraction have been obtained. 
Determination of an X-ray crystal structure is in progress.
Human cSHMT has also used to assay a panel of antifolate compounds synthesised at the 
Institute of Cancer Research for inhibition of SHMT activity (S. Renwick, personal 
communication). The highest inhibition exhibited by one of these compounds was an IC5 0  of 
1 ,25±0.2mM. For an inhibitor to be potentially useful an IC50 in the nM to low jiM  range is 
required. Therefore, none of the compounds tested would be regarded as useful inhibitors of 
SHMT. However, only a small range of compounds was tested. There are two potential 
routes to follow with inhibitor testing, wait until a tertiary and quaternary SHMT structure is 
available to allow the design of inhibitors based on the SHMT structure or continue testing 
banks of compounds until one with a lower IC5 0  is found and then modifying that particular 
compound to improve its inhibitory properties.
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CHAPTER 4 
SITE DIRECTED MUTAGENESIS OF HUMAN 
CYTOSOLIC SHMT
4.1 Summary Hease refer to section 1.101
Previous attempts to determine which amino acids are required for the catalytic activity of
SHMT have involved the use of chemical modification and site directed mutagenesis (section 
1.2.2). Chemical modification adds bulky groups and may inactivate the enzyme by steric 
hindrance preventing the binding of substrates or cofactors rather than altering an amino acid 
side chain critical for activity. For example, modification of a cysteine residue with 
iodoacetate (C204) produces an inactive cSHMT protein due to the fact that the added side 
chain prevents PLP binding to the critical lysine residue (K257) (Schirch et al., 1980). 
Therefore, some of the residues implicated in the catalytic reaction of SHMT may not in fact 
be involved.
The mutations chosen to produce variant human cSHMTs were based on the residues 
present in the literature which had been inactivated by chemical modification, in order to 
assess whether the modified amino acids were important for cSHMT activity. Reduction of 
the size of the cSHMT protein at the amino and carboxyl termini would aid in the 
identification of the regions essential for enzyme activity. Previous truncation studies have 
been performed using proteases (Schirch et al., 1984) but this technique is limited to 
truncation at sites recognised by the protease used. Precise truncation of the carboxyl 
terminus can be achieved by introducing early stop codons into the coding sequence by site 
directed mutagenesis. Generating a mutant cSHMT protein without the critical pyridoxal 
phosphate binding lysine (K257) would inactivate the enzyme producing a negative control 
by which activities of the mutant cSHMT proteins could be gauged. Site directed 
mutagenesis was performed to retain the charge and side chain structure or to remove the 
selected amino acid side chain by changing to alanine
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The mutations performed converted; amino acid 68 from cysteine to alanine (C68A) 
(Usha et al., 1994), C204A (Schirch et al., 1980), W15A, W15F, W15Y, W i l l  A, W111F 
(Vijayalaksmi et a l ,  1989), K257A (Schirch et al., 1993), C380stop, F424stop and K446stop.
Once pure SHMT protein had been obtained for each mutant, two assays were chosen to 
assay the enzyme activity. One assay was a spectrophotometric method involving the 
conversion of dl-allothreonine to glycine and ethanal. Ethanal production is coupled to a 
second reaction where it is converted by alcohol dehydrogenase to ethanol, with the 
concomitant conversion of NADH to NAD+. The oxidation of NADH is followed by the 
decrease in absorption at 340nm (Schirch and Gross, 1968). The second assay measures the 
rate of transfer of the one carbon group from 3-[14C]-L-serine to THF (Taylor and Weissbach, 
1965). The second assay was performed at the Institute of Cancer Research by S.Renwick.
4.2 Results 
4.2.1 Insertion of human cSHMT orf into the pALTER-1 vector
The vector pCRU™ containing the human cSHMT orf PCR product (pUS1247) was
digested with EcoRI, the 1.5kb fragment containing human cSHMT cDNA was purified from 
a 1% agarose gel and ligated into EcoRI digested and phosphatased pALTER-1®. Two clones 
containing pALTER-1® with the desired insert were obtained. Digestion with Kpnl and 
BarriHI indicated that the inserts were in opposite orientations. The orientation used for site 
directed mutagenesis was the one where the cSHMT orf ran in the same direction as the 
tetracycline gene (figure 4.1). Single stranded DNA was produced for site directed 
mutagenesis.
4.2.2 Site directed mutagenesis of human cSHMT orf to revert amino acid 182 
to asparagine
The cSHMT orf PCR product used in the generation of the site directed mutagenesis 
vector contained the N182D mutation. In order to revert the orf to wild-type, site directed
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mutagenesis was performed on the single stranded DNA produced above using the 
oligonucleotide D182N (section 2.4), the ampicillin repair and tetracycline knockout 
oligonucleotides to reverse the PCR generated mutation. ES1301 mutS cells were 
transformed to ampicillin resistance and grown in culture overnight. Plasmid DNA was 
extracted from the culture by alkaline lysis and was used to transform JM109 cells to 
ampicillin resistance. The transformation resulted in over 300 ampicillin resistant colonies. 
Fifty colonies were subcultured onto tetracycline plates and forty eight of these colonies were 
tetracycline sensitive indicating that the antibiotic knockout and repair oligonucleotides had 
been incorporated. Plasmid DNA was isolated from two colonies (1 and 10) and sequenced. 
Both plasmids were found to contain the cSHMT orf with the D182N mutation. The entire 
cSHMT orf was sequenced in the plasmid DNA isolated from colony 10 and found not to 
contain any spurious mutations. The pALTER-1® containing the modified cSHMT orf was 
renamed pUS 1252 (figure 4.1) and used in subsequent experiments.
4.2.3 Synthesis of new vectors to aid site directed mutagenesis
Every mutant orf produced should be sequenced after mutagenesis to ensure that only the
desired mutation has been incorporated. The human cSHMT PCR product inserted into 
pALTER-1® is just under 1.5kb and, therefore, if the entire sequence was used for 
mutagenesis, each mutation would require several sequencing reactions to confirm that only 
the required mutation had been incorporated. In the human cSHMT orf there are unique Kpnl 
and BatriHI sites bordering a 0.6kb fragment between nucleotides 404-1005 (appendix 1), 
containing codons Y77 to V276. This 0.6kb fragment codes for a number of potentially 
critical amino acids which could be altered by site directed mutagenesis. Subcloning and 
mutating this fragment would mean that only two sequencing reactions would be required for
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Figure 4.1 Formation of the vector for site directed mutagenesis. The human cSHMT 
orf (red) was subcloned into pALTER-1 using the EcoRl sites highlighted in red and 
then site directed mutagenesis was performed to revert the error generated by PCR to 
form pUS 1252. Highlighted are the ampicillin resistance gene in blue and the 
tetracycline resistance gene in green. Partial shading of the antibiotic resistance genes 
indicates inactivated genes.
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each mutant. This 0.6kb KpnUBamHl fragment was subcloned from pUS1252 into 
KpnUBamHl digested pALTER-1®.
pUS 1252 and pALTER-1® were digested with Kpnl and BamHl, and the linear 
pALTER-1® vector and 0.6kb bands were purified from a 1% agarose gel and ligated 
together. Three white colonies on L-agar containing X-gal and IPTG were produced when 
JM109 cells were transformed to ampicillin resistance with ligation mix. Two of these 
colonies (2 and 3) contained plasmids with a 0.6kb KpnUBamHl fragment. The recombinant 
vector isolated from colony 2 was renamed pUS1255 (figure 4.2).
Following mutagenesis of the 0.6kb KpnUBamHl fragment the whole human cSHMT orf 
needs to be reconstructed to enable expression and purification of mutant cSHMT protein. 
To achieve this, pUS1248, a modified pUC18 vector was produced to replace the Hindm  site 
of the pUC18 multiple cloning site with EcoRl (figure 4.3). To create pUS1248, pUC18 was 
digested with Hindlll and phosphatased. An oligonucleotide kjc7 (section 2.4) was 
synthesised which formed dimers to produce a linker with a site that would ligate to a Hindm  
generated site but could not be redigested. Kinased kjc7 was ligated to the digested vector. 
Transformation of DH5a cells by the ligation mixture resulted in greater than 300 colonies, 
with EcoRl, Nde I, BamHl and Hindm  were used to digest plasmid DNA, extracted from four 
cultures grown overnight. All four plasmids produced the same restriction pattern (figure 
4.4). Hindm  did not digest the plasmid DNA showing that the linker had been incorporated, 
BamHl and Nde I linearised the plasmids but EcoRl digested plasmid ran more quickly on the 
agarose gel than BamHl and Ndel digested plasmid showing that there was more than one 
copy of the linker present in each plasmid. One plasmid (1) was designated pUS1248.
To remove the multiple cloning site, pUS1248 was digested with EcoRI and purified from 
an agarose gel. The human cSHMT orf also purified from an agarose gel after EcoUl
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Figure 4.2 Construction of pUS1255 for site directed mutagenesis of the 0.6kb 
KpnUBamHl fragment of the cSHMT cDNA (red). Indicated in red are the restriction 
sites used. Indicated in blue and green are the ampicillin and tetracycline resistance 
genes respectively. Hashed shading indicates inactivated antibiotic resistance genes.
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Figure 4.3 Schematic o f pUS 1248. This vector was constructed as an intermediate in 
the removal o f the multiple cloning site (mcs) from pUC 18. The sequence o f the 
multiple cloning site o f pUS1248 is shown with the added linker DNA in bold type. 
There are potentially many copies o f the linker present at this site in the vector. 
Underlined is the H indin site removed during the process o f the linker addition.
APr Ampicillin resistance
APS Ampicillin sensitivity
p(BLA) promoter for (3-lactamase gene
pUS 1248
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Figure 4.4 Agarose gel of restriction digests of four clones obtained when kjc7 was ligated
into Hindlll digested pUC18 to replace the Hindlll site with an EcoRI site to form pUS1248.
Lanes 1-4 EcoRI digestion
Lane 5-8 Ndel digestion
Lane 9-12 Hindlll digestion
Lane 13-16 BamHl digestion
Lane M XHindlll markers
Lanes 1,5,9,13 Plasmid 1
Lanes 2,6,10,14 Plasmid 2
Lanes 3,7,11,15 Plasmid 3
Lanes 4,8,12,16 Plasmid 4
Approximately 200ng of DNA was loaded per track
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digestion of (pUS1247). The vector and SHMT were ligated and transformation of DH5a to 
ampicillin resistance resulted in more than 300 colonies. Plasmid DNA was isolated from one 
clone and digested with EcoRL, Kpnl and BamHl. EcoRl digested plasmid contained a 1.5kb 
band. Kpnl and BamHl digests linearised the plasmid. Therefore, the human cSHMT had 
been cloned into a vector which only contained Kpnl or BamHl restriction sites in the human 
cSHMT orf. This new plasmid was designated (pUS1249) (figure 4.5).
4.2.4 Mutagenesis of human cSHMT cDNA
The Altered Sites protocol was followed with the two modifications; the amount of
mutagenic oligonucleotide used was increased to lOpmol from 1.25pmol to ensure a higher 
rate of oligonucleotide binding and the oligonucleotides were annealed to the single stranded 
plasmid by heating to 95-100°C to ensure all secondary structure was removed before slowly 
cooling to 45°C and then to more rapidly 20°C. These alterations to the protocol were 
recommended by Piechocki and Hines, (1994).
Test reactions using pALTER-1® showed that the recommended cotransformation 
procedure did not work effectively. This procedure involves transforming ES1301 mutS cells 
with both DNA from the mutagenesis reaction and helper phage DNA (e.g. R408 phage 
DNA). Cotransformation causes the mutated vector to be packaged as a bacteriophage which 
is then purified and used to infect an overnight culture of JM109 cells. The probable reason 
for this method not working was that a transformation efficiency of at least lxlO7 cfu/jig of 
DNA is required and “home made” ES1301 mutS competent cells produced only 2 x l0 5 
cfu/pg DNA. It is in fact difficult to get a higher transformation efficiency in ES1301 mutS 
cells (Promega). Therefore, the alternative protocol, where ES1301 mutS cells were 
transformed with DNA produced in the mutagenesis reaction and grown overnight in broth, 
was followed. ESI301 mutS cells grew slowly and were harvested after incubating for 16-20 ,
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Figure 4.5 Diagram to show the formation of pUS1249 from pUS1248 and human 
cSHMT cDNA. pUS1249 did not contain Kpnl or BamHl sites except within the 
cSHMT orf (red) allowing the exchange of the original 0.6kb fragment with mutated 
0.6kb fragments to produce variant cSHMT orfs. Highlighted in red are the EcoRl 
sites used for subcloning and in green the Kpnl and BamHl sites lost in formation of
pUS 1249.
APr Ampicillin resistance
ORI origin of replication
p(BLA) promoter for the p-lactamase gene
p(LAC) promoter for the p-galactosidase a  peptide
PRM primer
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hours with shaking at 37°C. Plasmid DNA was then extracted by alkaline lysis and used to 
transform competent JM109. This method had the disadvantage that as ES1301 mutS is 
mismatch repair deficient, there could be some spontaneous mutations generated. However, 
these would be screened out by sequencing of the mutated cSHMT orfs after mutation. The 
cotransformation protocol was later removed from the Altered Sites protocol (Promega) and a 
revised transformation protocol was developed (Promega). Commercially produced ES1301 
mutS competent cells were also developed (Promega) and were used for subsequent 
transformations.
Using the Altered Sites kit protocol with the above modifications to the methodology on 
single stranded pUS1252 or pUS1255, mutants W15A, W15F, W15Y, W111A, W111F, 
C204A, C380stop, F424stop and K446stop were achieved (table 4.1 provides a summary of 
the mutagenesis results). Initially site directed mutagenesis with the W 111A oligonucleotide 
yielded 6 colonies, 5 of these were wild type, the sixth had the desired mutation, but a 
nucleotide 3 bases downstream had been deleted. Restriction digest of plasmids isolated from 
colonies produced by transformation with DNA from the W15A mutagenesis reaction did not 
contain mutated pUS1252. This was curious as the reaction was performed at the same time 
as W15F and W15Y mutagenic reactions using the same plasmid preparation. W15F and 
W15Y were checked and found to contain mutated pUS1252. W111A and W15A
mutagenesis reactions were repeated and resulted in mutations being obtained.
Two mutants, namely C68A and K257A had not been isolated after several mutagenesis 
attempts. In the case of K257A, the repair and knockout oligonucleotides had bound to single 
stranded pUS1255 indicated by ampicillin resistant and tetracycline sensitive colonies. 
However, sequences of the cSHMT orf in plasmids extracted from these colonies showed that 
the K257A mutagenic oligonucleotide had not bound. When using C68A as the mutagenic
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Mutation Plasmid used for 
mutagenesis
Number of colonies 
sequenced
Number of mutants 
isolated
W15A pUS 1252 2 2
W15F pUS1252 2 2
W15Y pUS1252 1 1
C68A pUS 1252 0 0f
W111A pUS 1255 10 4*
W111F pUS 1255 2 2
C204A pUS 1255 2 2
K257A pUS 1255 9 0f
C380stop pUS 1252 1 1
F424stop pUS 1252 2 1
K446stop pUS1252 2 2
* One of the mutants contained a deletion in the sequence leading to a frame shift 
t Mutants subsequently produced by L.Barratt.
Table 4.1 Mutations of human cSHMT generated. Plasmid templates pUS1252 or pUS1255 
were used as templates in site directed mutagenesis reactions. After mutagenesis and 
confirmation that the antibiotic selection of the plasmids had been reversed by the 
mutagenesis reaction, plasmids were isolated and sequenced to determine whether the 
mutagenic oligonucleotide had been incorporated into the cSHMT sequence.
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oligonucleotide ES1301 mutS cells did not grow when transformed with DNA from the 
mutagenesis reaction.
It was though that in the case of K257A the oligonucleotide was not properly 
phosphorylated. However, for the oligonucleotide C68A, it was possible there was some 
contaminant present in the oligonucleotide preparation which inhibited the synthesis of the 
second strand of the plasmid as all the other possible explanations were discounted. The 
presence of contamination in the K257A oligonucleotide may also have been a reason for the 
unsuccessful phosphorylation reaction.
Primers C68A and K257A were precipitated to remove any contaminants in the solution, 
rephosphorylated and the mutagenesis reaction undertaken by a final year undergraduate 
student. Mutations were generated at the first attempt. However, sequencing of the cSHMT 
orf mutants produced revealed extra mutations with both C68A and K257A primers. The 
C68A mutated cSHMT orf had a deletion of nt 381 and the K257A mutated cSHMT orf had a 
mutation of nt 945 from C to G changing the codon 256 from encoding histidine to 
glutamine. The experiment was repeated by the author with the same results.
The extra mutations generated in C68A and K257A cSHMT orfs were within the area 
where the mutagenic oligonucleotide annealed to the single stranded plasmid template and 
only plasmids containing the required mutation also had the additional mutations. Therefore, 
it can be assumed that the mutagenic oligonucleotides were responsible for these extra 
mutations and it follows that the sequence of these oligonucleotides was not that originally 
intended. The C68A mutation generated was not proceeded with further as the extra deletion 
introduces a frame shift and any protein produced would not have any homology to cSHMT 
downstream of amino acid 68. However, the extra mutation in the K257A cSHMT orf 
retained the correct open reading frame and as the critical lysine codon had been changed,
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protein derived from this orf would still be able to act as a negative control. The cSHMT orf 
generated with the K257A oligonucleotide was renamed H256QK257A.
4.2.5 Reformation of whole human cSHMT orf for mutants generated in 
PUS1255
The 0.6kb cSHMT sequences in pUS1255, containing mutations generating W i l l  A, 
W111F, C204A and H256QK257A had to be subcloned into the KpnUBamHl sites of 
pUS 1249 in order to regenerate the whole human cSHMT orfs. ljLXg of pUS1249 was 
digested with Kpnl and BamHl sequentially and the larger 3550bp fragment containing the 
vector and part of the cSHMT was purified from an agarose gel by either spinning the gel 
slice through filter paper or by Geneclean (BIO101). The vector was not treated with alkaline 
phosphatase as the ends were not compatible and religation to produce a functional vector in 
the absence of insert was not possible. For all the mutations, approximately l|Lig of mutated 
pUS 1255 was digested sequentially with Kpnl and BamHl and the digested DNA 
electrophoresed through 1% agarose gels. The 0.6kb band was excised and DNA was 
purified from the agarose by the following methods; C204A, spun through filter paper, 
W i l l  A, W111F by Geneclean (Bio 101) and H256QK257A using PCR Pure (Clontech) 
(section 2.5.3). The 0.6kb Kpnl/BamHl fragment was then ligated into the KpnUBamHl 
digested and purified pUS1249 vector. Controls of involving ligation of the vector alone 
were performed to assess any uncut or partially cut vector carried through. Ligation reactions 
were used to transform DH5a to ampicillin resistance. Control ligations yielded only 1 or 2 
colonies. Table 4.2 gives a summary of the transformation results. Although purification of 
the KpnUBamHl vector form an agarose gel had been performed to prevent any unmutated 
0.6kb KpnUBamHl from being carried over into the ligation, sequencing was performed to 
confirm that the cSHMT fragments ligated into pUS1249 were mutated.
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Mutant Number of colonies 
obtained
Number of 
Plasmids examined
Number of 
plasmids with 
correct inserts
W111A -150 3 3
W111F -100 2 2
C204A 3 2 2
H256QK257A 18 1 1
Table 4.2 Results of the ligations of 0.6kb KpnUBamHl mutant fragments into pUS1249. 
pUS 1255 containing the mutated 0.6kb KpnUBamHl was digested with Kpnl and BamHl to 
release the 0.6kb fragment which was subcloned into pUS1249 between the Kpnl and BamHl 
sites. After transforming E.coli cells to ampicillin resistance with the ligation reaction, 
plasmids from the colonies were extracted by alkaline lysis and sequenced to ensure that the 
fragment inserted into pUS1249 contained the mutation.
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4.2.6 Subcloning of the wild-type cSHMT orf into pET14b for expression in 
E.coli
pUS 1252 was digested with Ndel to release the 1.5kb human cSHMT orf and was ligated 
with Ndel digested and dephosphorylated pET14b. DNA from the ligation reaction was used 
to transform DH5a competent cells to ampicillin resistance, and twelve colonies were 
obtained. Of six plasmid DNAs extracted, five consisted of pET14b with the cSHMT orf 
insert, two of which were in the correct orientation with respect to the T7 promoter and 
translation initiation signals required for expression (figure 4.6). The pET14b vector 
containing the cSHMT cDNA was renamed pUS1253.
4.2.7 Subcloning of mutant human cSHMT orfs into pET14b
pET14b was prepared by digesting 3jug with Ndel, followed by heat inactivation of the
enzyme, and dephosphorylation. The digested pET14b was electrophoresed through an 
agarose gel, the linear vector DNA was cut out under UV light and the gel slice spun through 
filter paper.
The C204A mutation in pUS1249 was the first mutant cSHMT to be transferred into 
pET14b. ljug of pUS1249 containing the C204A mutation was digested with Ndel and after 
electrophoresis through an agarose gel, the 1.5kb band containing the C204A cSHMT orf was 
removed and the DNA purified by spinning the gel slice through filter paper. 31 colonies 
were obtained after ligation into pET14b and transformation of DH5a competent cells to 
ampicillin resistance. Of 10 plasmids extracted, 9 had 1.5kb inserts when digested with Ndel 
and 3 of these plasmids with inserts produced a 0.8kb band when digested with BamHl 
indicating that the cSHMT orf was in the correct orientation relative to the T7 transcription 
and translation signals. One of these plasmids was designated pUS1254.
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Figure 4.6 Diagram to show the formation of expression vector containing the mutant 
cSHMT orfs. The mutated orf (red) was subcloned into pET14b from either pUS1252 
or pUS 1249 using the Ndel sites highlighted in red. The ampicillin gene is 
highlighted in blue. The tetracycline gene is highlighted in green and shaded to 
indicate inactivity.
APr Ampicillin resistance
TCs tetracycline sensitivity
FI ORI FI origin of replication
ORI origin of replication
PMB1 origin of replication derived from PMB1
p(BLA) promoter for the p-lactamase gene
p(LAC) promoter for the p-galactosidase a  peptide
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After the insertion of the C204A cSHMT orf into pET14b problems were encountered. 
Although ligation ratios were varied, a new batch of pET14b was purchased (Novagen), 
different methods of purification of DNA from agarose gels such as Geneclean, Crystal gelex 
and PCR Pure (section 2.5.3) were tested and ligations were performed without prior gel 
purification of plasmid and insert, no plasmids were obtained that contained pET14b with a 
mutant cSHMT orf insert.
The full length cSHMT orf mutants were subcloned from pUS1252 into pUC18 using the
EcoRl sites to test all the protocols which had been used in the digestion, alkaline
 /
phosphatase treatment, gel extraction, ligation and transformation. This method indicates 
which steps were causing the problems and also produce larger amounts of mutant cSHMT 
orf DNA as pUC18 is a much higher copy number.
The first mutant tested was K446stop. The 1.5kb EcoRl fragment was purified from an 
agarose gel using Geneclean, ligated into EcoRl digested and CIP treated pUC18 and seven 
out of ten colonies resulting from the transformation of DH5a competent cells to ampicillin 
resistance contained pUC18 with a cSHMT orf inserted. The procedure was repeated for 
W15A, W15F, W15Y and C380stop mutations and the ratios of plasmids with inserts to 
plasmids isolated were 3/3, 3/3, 4/4 and 3/4 respectively. The success of this subcloning 
validated all of the methods used in the subcloning procedure.
Another attempt at cloning the mutant cSHMT cDNAs into pET14b was performed. All 
of the mutant cSHMT orf generated were now in pUC18 based plasmids (either in pUC18 or 
in pUS1249) and large amounts of all the mutant plasmids were purified using commercial 
columns (Promega, Qiagen) from 100ml cultures. Plasmids were digested with Ndel and 
1.5kb bands were purified from agarose gels and ligated to Ndel digested and 
dephosphory lated pET 14b.
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The mutation K446stop was the first mutant cSHMT orf transferred. Of 92 colonies 
obtained in the transformation, 4 contained the 1.5kb cSHMT orf inserted into the vector, one 
of which was in the correct orientation with relation to the promoter and translation initiation 
signals. The correct plasmid was designated pUS1256.
The W15Y mutation transformation yielded 11 colonies, one of these colonies was mixed 
and contained both vector alone and vector with cSHMT insert. The other colonies contained 
only vector. The mixed colony was subcultured on a L-agar plate to isolate individual 
colonies and screening yielded a pure culture of pET14b with insert. The human cSHMT 
mutant insert was in the correct orientation for expression and was designated pUS1257.
Four colonies were obtained after transforming the ligation mixture of W15A, three of 
these contained inserted cSHMT, two of which were in the right orientation for cSHMT 
expression. One of the correct plasmids was designated pUS1258.
For the mutation C380stop, 1 colony was obtained after transforming DH5a competent 
cells to ampicillin resistance. Plasmid DNA extracted from this colony contained a 1.5kb 
insert and was in the correct orientation. The plasmid was designated pUS1259.
One colony was obtained when the ligation of W111A human cSHMT orf with pET14b 
was used to transform DH5a competent cells to ampicillin resistance. Plasmid DNA was 
extracted from this colony and it was found to contain the human cSHMT orf in the correct 
orientation. The vector was renamed pUS1261.
Transformations of DH5a cells to ampicillin resistance with ligation into pET14b of 
human cSHMT orfs W111F, and W15F yielded hundreds of colonies whereas the vector 
religation control yielded 20-50 colonies. Standard plasmid preparations by alkaline lysis 
yielded only pET14b. Therefore, 100 colonies of each mutant were replated and a colony 
hybridisation was performed using the 1.8kb EcoRl fragment of pUS1217 as a probe
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(sections 2.5.11, 2.5.13). Those colonies containing DNA hybridising to the probe, as 
indicated by a corresponding signal on X-ray film, were grown overnight and the plasmids 
were extracted by alkaline lysis. For the W 11 IF cSHMT orf, 3 plasmids with inserts, all in 
the correct orientation were isolated. For the mutation W15F, one colony contained pET14b 
with the human cSHMT orf, again in the correct orientation. pET14b plasmids with inserts in 
the correct orientation were designated pUS1260 and pUS1262 for W111F and W15F 
respectively.
The mutation H256QK257A in the human cSHMT orf was the last subcloning to be 
performed out of all the mutants. Review of previous results indicated that there had 
previously been no problems ligating DNA which had been extracted from agarose gels by 
spinning through filter paper and the sudden failure of this method had led to the use of all the 
other gel purification systems and results had been patchy. The method was retried with a 
new batch of filter paper, ljxg of plasmid isolated by alkaline lysis containing the human 
cSHMT orf with the H256QK257A mutation in pUS1249 was digested with Ndel. The 
fragments of DNA were separated by electrophoresis through an agarose gel and the 1.5kb 
band was excised and spun through a new filter paper column. The eluate was used in a 
ligation with pET14b digested with Ndel and dephosphorylated. The digested pET14b had 
already been tested to ensure that dephosphorylation had been effective. Transformation of 
DH5a competent cells to ampicillin resistance yielded 14 colonies. Six colonies contained 
pET14b with a 1.5kb insert. Five of these colonies contained the inserted cSHMT orf in the 
correct orientation for expression. The designation pUS1265 was given to one of the 
plasmids with the cDNA in the correct orientation.
The F424stop mutation was not proceeded with in the light of results obtained on the 
solubility of expressed protein for the other C-terminal truncated mutants (see section 4.2.8).
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Mutant in pET14b plasmid name
wild-type (D182N) pUS 1253
W15A pUS1258
W15F pUS 1262
W15Y pUS 1257
W111A pUS 1261
W111F pUS 1260
N182D pUS 1251
C204A pUS 1254
H256QK257A pUS1264
C380stop pUS1259
K446stop pUS 1256
Table 4.3 University of Surrey plasmid assignments for mutant cSHMT orfs in pET14b. 
After site directed mutagenesis, mutant cSHMT orfs were subcloned into pET14b for 
expression in E.coli and were assigned plasmid numbers.
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4.2.8 Expression and purification of mutant human cSHMT protein
All of the pET14b plasmids containing the mutant cSHMT orf were transformed into
BL21(DE3)pLysS. Before large scale protein expression and purification was performed, the 
solubility of expressed mutant human cSHMT proteins at growth temperatures for the 
cultures of 37°C, 30°C and 25°C was assessed. For mutants C204A and W15Y, cultures were 
tested at each temperature and cSHMT protein was only found to be soluble in a reasonable 
quantity at 25°C (figure 4.7). For the other mutant human cSHMTs, solubility of expressed 
protein was tested only at 25°C. All except the C-terminal truncated mutant cSHMT proteins 
were found to be soluble at 25°C (see table 4.4).
For the expression of mutants one litre cultures were grown at 25°C in 4 batches of 250ml 
culture medium and harvested 2 hours post induction with IPTG. The plasmid pUS1251 
containing the N182D mutation generated in chapter 3 was also expressed. C204A cSHMT 
protein was purified on a nickel ion column (Novagen) using gravity flow and cSHMT 
protein was eluted from the column using 200mM imidazole (figure 4.8). Cobalt ion 
columns (Clontech) were used to purify the other mutants using a hybrid batch/gravity flow 
method and mutant cSHMT proteins were eluted from the column using lOOmM imidazole as 
recommended in the manufacturers protocol (Clontech) (figure 4.9). On passing elution 
buffer through the metal ion columns a yellow eluate was produced due to bound PLP 
(section 1.1). Once eluted from the metal ion columns, all cSHMT proteins were desalted 
and concentrated.
C380stop and K446stop cSHMT proteins had calculated molecular weights of 41.6KD 
and 48.9KD respectively. SDS-PAGE analysis of these proteins showed that the protein 
expressed by pUS1259 and pUS1256 agreed with the calculated results (figure 4.10, figure 
4.11). The truncated C-terminal cSHMT proteins were insoluble at 37°C, 30°C, 25°C and
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Figure 4.7 Expression of C204A cSHMT protein at 37°C, 30°C and 25°C in order to 
determine whether decreasing the expression temperature, raised the level of soluble cSHMT 
protein in the cytoplasm of E.coli. Culture containing pUS1254 was expressed at the above 
temperatures. Two hours after induction with IPTG, the cells were harvested, lysed and 
centrifuged to obtain the soluble (supernatant) and insoluble (pellet) fractions.
Lane M Molecular weight markers
Lane 1 25°C pellet (insoluble fraction)
Lane 2 25°C supernatant (soluble fraction)
Lane 3 30°C pellet
Lane 4 30°C supernatant
Lane 5 37°C pellet
Lane 6 37°C supernatant
Please refer to p67a for protein loadings
1 1 1
Protein Presence of cSHMT protein in the soluble fraction at the expression temperature
37°C 30°C 25°C 20°C *
Wild-type (D182N) YES nd nd nd
W15A nd nd YES nd
W15F nd nd YES nd
W15Y YES YES YES nd
W111A nd nd YES nd
W111F nd nd YES nd
N182D YES nd YES nd
C204A NO NO YES nd
H256QK257A nd nd YES nd
C380stop NO NO NO NO
K446stop nd NO NO NO
* experiment performed at 20°C included sorbitol and betaine in the growth medium 
(Blackwell and Horgan, 1991).
Table 4.4 Results of experiments to determine the extent of solubility of mutant cSHMT 
proteins when expressed in E.coli. Cultures expressing the cSHMT protein were grown at the 
temperature indicated. After expression, cells were collected, lysed and centrifuged. The 
supernatant (soluble faction) and pellet was analysed by SDS-PAGE : to determine whether 
cSHMT was present, 
nd = not determined
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Figure 4.8 Purification of C204A cSHMT using a nickel ion column. One litre of cells 
containing pUS1254 was grown at 25°C and expression of C204A cSHMT protein was 
induced by IPTG. Two hours after induction the cells were harvested, resuspended in binding 
buffer and sonicated. After centrifugation, the supernatant was passed through a nickel ion 
column. After washing the column with binding buffer and wash buffer, the cSHMT protein 
was eluted in two 4ml fractions by the addition of binding buffer containing 200mM 
imidazole.
Lane M Molecular weight markers
Lane 1 Whole culture 2 hours post expression
Lane 2 Pellet after centrifuging post sonication
Lane 3 Supernatant after centrifuging post sonication
Lane 4 Flowthrough of supernatant applied to column
Lane 5 Flowthrough after washing column with binding buffer
Lane 6 Eluate
Please refer to p67a for protein loadings
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Figure 4.9 Purification of H256QK257A cSHMT. Purification was on a cobalt ion column. 
The cSHMT protein was expressed in the same way as for C204A protein. The cells after 
expression were resuspended in sonication buffer, sonicated and centrifuged. The supernatant 
was added to cobalt ion resin in a large tube and mixed. After spinning the supernatant was 
removed and the pelleted resin was washed with sonication buffer three times. The resin was 
then place in a column and protein was eluted in two 4ml fractions using sonication buffer 
containing lOOmM imidazole.
Lane M Molecular weight marker
Lane 1 Pellet after centrifuging sonicated cells
Lane 2 Supernatant after centrifuging sonicated cells
Lane 3 Supernatant after binding to cobalt resin
Lane 4 Wash of cobalt resin
Lane 5 Eluate using 4ml sonication buffer containing lOOmM imidazole
Please refer to p67a for protein loadings
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Figure 4.10 Expression of K446stop cSHMT protein at 20°C with sorbitol and betaine added 
to the growth medium. A lower molecular weight for the truncated protein is apparent and 
match calculated values (see text). No cSHMT protein is seen in the supernatant fraction post 
lysis of E.coli indicating that the truncated mutant is insoluble.
Lane M Molecular weight marker
Lane 1 Overnight culture used to inoculate media
Lane 2 culture prior to induction of expression
Lane 3 culture 2 hours after induction of expression
Lane 4 Pellet after centrifuging lysed cells
Lane 5 Supernatant after centrifuging lysed cells
Please refer to p67a for protein loadings
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Figure 4.11 Expression of C380stop cSHMT protein at 20°C with sorbitol and betaine added 
to the growth medium. A lower molecular weight for the truncated protein is apparent and 
match calculated values (see text). No cSHMT protein is seen in the supernatant fraction post 
lysis of E.coli indicating that the truncated mutant is insoluble.
Lane M Molecular weight marker
Lane 1 Overnight culture used to inoculate media
Lane 2 culture prior to induction of expression
Lane 3 culture 2 hours after induction of expression
Lane 4 Pellet after centrifuging lysed cells
Lane 5 Supernatant after centrifuging lysed cells
Please refer to p67a for protein loadings 
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20°C with the addition of 660mM sorbitol and 2.5mM betaine to the media (Blackwell and 
Horgan, 1991) and, therefore, could not be purified in a native state.
4.2.9 Assay of mutant cSHMT protein activity
The results of the assays of cSHMT mutants performed using dl-allothreonine (section
2.12) and 3-[14C]-L-serine (section 2.11) are shown in table 4.5. The results from the assay 
using dl-allothreonine as the substrate were expressed in terms of Km and for the assay using 
3-[14C]-L-serine as EC50 (the amount of enzyme required to achieve half of the maximum 
activity).
4.3 Discussion
The orf encoding human cSHMT was subcloned into pALTER-1® enabling site directed 
mutagenesis to be performed to revert the N182D mutation in the orf generated by PCR back 
to asparagine. Once the mutation had been performed to form pUS1252 and sequence 
verified, the orf was subcloned into pET14b to form pUS1253. The wild type cSHMT orf in 
pET14b was transformed into the expression strain BL21(DE3)pLysS and expression and 
purification of wild-type human cSHMT protein for X-ray crystallography and inhibitor 
studies was subsequently performed at the Institute of Cancer Research (S.Renwick, personal 
communication) (chapter 3). A sample of purified protein was provided for determination of 
cSHMT enzyme activity by the dl-allothreonine assay.
The plasmid pUS1252 was used as a template to produce the mutations W15A, W15F, 
W15Y, C380stop, F424stop and K446stop in the human cSHMT orf. The 0.6kb KpnUBamHl 
fragment was subcloned from the wild-type cSHMT orf in pUS1252 into pALTER-1® to 
form pUS 1255. pUS 1255 was used to as a template to generate W 111 A, W 11 IF, C204A and 
H256QK257A mutants. A vector (pUS1249) was constructed to enable the reformation of 
the whole cSHMT orf once the 0.6kb KpnUBamHl fragment had been mutated.
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SHMT protein dl-allothreonine Serine and THF
Km (mM) p* Vmax 
(gmoles NADH 
oxidised/min)
p* E C 5 0  (nM) p*
Wild-type (D182N) 1.22±0.44 (n=5) - 2.31±0.55 - 25.7±14.4 (n= ll) -
Wild-type - HisTag nd - nd - 31.7±2.4 (n=3) 0.6634
W15A 3.511 (n=l) - 0.87 - 100.0±16.3 (n=3) <0.0001
W15F ncd - - - 53.3±2.4 (n=3) 0.0098
W15Y 2.37±0.93 (n=3) 0.081 0.49±0.07 0.0015 93.3±9.4 (n=3) <0.0001
W111A 4.09, 3.26 (n=2) - 0.40, 0.43 - 46.7±2.4 (n=3) 0.0383
W111F ncd - - - 73.3±4.7 (n=3) 0.0002
N182D 2.11±0.68 (n=4) 0.065 2.08±1.05 0.6828 40.0±12.2 (n=3) 0.1237
C204A 2.10±0.21 (n=5) 0.0047 0.50±0.30 0.0002 52.5±13.5 (n=4) 0.0099
H256QK257A 17.52,18.46 (n=2) - 0.34, 0.52 - nd -
t Two other assays gave inconsistent results
% Probability that the means of the mutant cSHMT activities are equal to the wild-type
Table 4.5 Results o f assays on wild type and mutant cSHMT proteins using either
dl-allothreonine or radiolabelled serine and THF as substrates. Assays were performed
using methods described in sections 2.11 and 2.12. Results are expressed as means
and standard deviations except where n=2 when the two experimental values are
shown. E C 5 0  is the amount of cSHMT protein required to produce half o f the
maximum amount of wild-type SHMT activity.
n, number of assays performed
nd, not determined
ncd, no consistent data available
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The mutated cSHMT orfs were subcloned into pET14b in order to express cSHMT 
protein. The reasons for the initial cloning problems have not been determined but nuclease 
contamination of the filter paper used to purify DNA fragments from agarose gel slices may 
have contributed as a new batch was used successfully. Recent work has shown that digested 
vector purified from an agarose gel using PCR Pure (Clontech) reduces the frequency of 
religation of digested vector molecules (L.Docherty, personal communication).
Expression of the mutant cSHMT proteins indicated that the solubility of individual 
proteins was affected, in some cases drastically, by the mutations created. This suggests that 
the amino acid residues that were mutated may be important for the correct formation of 
secondary or tertiary cSHMT protein structure. Some proteins expressed in E.coli aggregate 
in inclusion bodies in an insoluble form (Fischer et al., 1993). Mizukami et al., (1986) 
demonstrated that by reducing the temperature at which E.coli cells expressing human P- 
interferon are grown from 37°C to 20°C more protein is produced in an active state although 
the overall amount of p-interferon protein produced remained the same. Reducing the 
temperature at which culture expressing mutated cSHMT orfs was grown to 25°C increased 
the amount of cSHMT protein produced in a soluble form in all except the C-terminus 
truncated mutants. The histidine tag at the N-terminus of the mutant cSHMT added by the 
expression vector enabled the rapid purification of mutant cSHMT protein passing the cell 
lysates over an affinity column.
The C-terminus truncated mutants were insoluble when expressed at 25°C, 20°C and 20°C 
with the addition of sorbitol and betaine. The addition of sorbitol and betaine has been shown 
to increase the amount of soluble protein produced (Blackwell and Horgan, 1991; 
Brownbridge et al., 1993). However, although large amounts of truncated cSHMT were
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produced, no soluble protein was visible on a SDS-PAGE gel and no cSHMT protein bound 
to a sample of the cobalt column matrix when used in a batch purification.
Methods have been devised to purify expressed protein aggregated in inclusion bodies 
(Fischer et al., 1993). Inclusion bodies in cells expressing recombinant protein are 
predominantly composed of the recombinant protein in an aggregated form. Inclusion bodies 
can be sedimented by low speed centrifugation and can be used as a first step of purification 
(Marston, 1986). The protein in the inclusion bodies can be solubilised in denaturants such as 
urea or guanidine hydrochloride in which the protein molecules are unfolded (Fischer et al., 
1993). In the case of cSHMT mutants expressed here, the histidine tag can then be used to 
purify the cSHMT protein. Removal of the denaturant results in the refolding of the protein 
However, methods used to refold denatured proteins depends on the structure of the protein 
of interest and often only one particular method will work (Fischer et al., 1993). Success of 
refolding of denatured wild-type proteins can be assessed easily as activity of the refolded 
protein should be the same as the native protein. E.coli SHMT can be denatured in 8M urea 
and refolded by performing a 10 fold dilution (Cai et al., 1995). However, refolding of 
denatured mutant proteins is not desirable. If mutant proteins purified in this way show no 
activity, it is possible that this is due to incorrect refolding rather than the mutation having 
affected enzyme activity. With the inherent uncertainty about the validity of any refolded 
protein no further work was performed with the C-terminal truncated mutants.
The inability of truncated cSHMT proteins to fold correctly in E.coli suggest that the last 
37 amino acids are important in the folding pathway of human cSHMT. Recent publications 
(Cai and Schirch, 1996a; 1996b) on eSHMT folding adds credence to this theory. They found 
that eSHMT has two domains which fold within seconds. The second of these domains spans 
from amino acids 276 to 417, the last amino acid in eSHMT. Although eSHMT protein is
smaller than human cSHMT, alignment of SHMT protein sequences from different organisms 
shows that most of this difference in sequence length occurs internally rather than at the 
protein termini (appendix 2). Therefore, if the results from eSHMT are extrapolated to 
human cSHMT the truncations described here would occur well within the second domain. 
In the light of this information it is questionable whether the C-terminus truncations created 
here would fold into a native protein structure if refolding was attempted on protein purified 
under denaturing conditions.
E.coli SHMT contains three tryptophan residues. Refolding studies on eSHMT were 
obtained using site directed mutants of eSHMT protein to generate three mutants, each 
containing only one tryptophan residue so that the quenching of fluorescence of each 
tryptophan residue could be followed (Cai and Schirch, 1996a). Human cSHMT contains 
only two tryptophan residues. Mutations to W15 and W il l  also yield cSHMT mutant 
proteins containing a single tryptophan. In principle, fluorescence quenching could be 
applied to the tryptophan mutants generated for the human cSHMT. However, there is no 
tryptophan residue past amino acid 111 in human cSHMT so folding of the C-terminal 
domain could not be followed using this method. Site directed mutagenesis could be used to 
generate a tryptophan in the second domain, allowing fluorescence quenching to be used.
Although the purification method with the nickel ion column was rapid, the cobalt column 
offered protein binding advantages discussed in section 1.9. The hybrid batch/gravity flow 
protocol was faster giving proteolytic enzymes less opportunity to work and gave more 
thorough washing of the resin, resulting in isolation of purer cSHMT protein. When the wild- 
type cSHMT protein was purified it was found that eluting the protein in 1M imidazole 
caused rapid aggregation of cSHMT protein. Reduction of the imidazole in the elution buffer 
to 200mM still resulted in elution of cSHMT protein, but did not cause protein aggregation
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(S.Renwick, personal communication). All of the cSHMT mutant proteins were eluted with 
lOOmM as cobalt columns bind the histidine tag less tightly. Protein purified in this way did 
not aggregate.
Enzyme assays were performed on wild-type and mutant cSHMT proteins to assess 
whether the mutations had any affect on cSHMT activity. The radioactive assay was used as 
serine and THF are the physiological substrates of SHMT. The dl-allothreonine assay does 
not use THF as a substrate so any mutation affecting THF binding can be determined by 
differing enzyme activities exhibited in the two assays. The results from the assays do not 
have enough replicates in order to determine whether the differences between the activities of 
the mutants are statistically significant. However, some preliminary observations can be 
made.
Where data is available for 3 or more assays a 2 sample t-test has been performed 
to test the null hypothesis that there is no difference between the means for the wild- 
type and mutant cSHMT proteins. More replicates need to be performed to get more 
accurate probability values.
The 6nM difference in the means for the EC50 between wild-type cSHMT with and 
without the histidine tag used for purification of the protein suggested that the addition 
of the histidine tag to the N-terminus of the protein did not significantly affect the 
activity or structure of the protein. The probability that the means o f the two proteins 
were the same was high (0.6634), also suggesting that the difference between these 
proteins was not significant. The histidine tag was, therefore, left on all the mutant 
proteins purified.
The role o f lysine 257 in the catalytic activity o f SHMT has already been 
demonstrated (Schirch et al., 1993, Iurescia et al., 1996). The K257A mutation was 
performed to produce an inactive SHMT to act as a negative control to establish
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whether any of the cSHMT mutant proteins produced were inactive. Due to an extra 
mutation generated during site directed mutagenesis, the actual mutant created was 
H256QK257A. The H256QK257A mutated cSHMT protein would also act as a 
negative control as the critical lysine was still removed from the protein. There was a 
trend towards a very small amount o f activity of H256QK257A cSHMT protein shown 
using dl-allothreonine as a substrate. Purification of site directed mutants o f eSHMT 
expressed in E.coli has shown that wild-type eSHMT produced by E.coli can 
contaminate the mutant proteins and mask any potential lack of activity (Schirch et al., 
1993; Iurescia et al., 1996). However, eSHMT and human cSHMT proteins are 
different in their sizes and quaternary structure (section 1.1) and the eSHMT mutants 
were not purified by an affinity purification method whereas the cSHMT mutants 
purified here a purified on the basis of a histidine tag present only on the N-terminus of 
the expressed protein. If contamination with wild-type protein was a problem with the 
purified cSHMT proteins then a band corresponding to eSHMT would be seen on 
SDS-PAGE gels at 46KD as well as the cSHMT band at 53KD. In all mutants 
purified there is only a band at 53KD seen suggesting that contamination with active 
eSHMT protein is not a problem. However, it cannot be ruled out that there may be 
very small amount of eSHMT present in the purified mutant proteins. This may 
account for the small amount of activity seen with the H256QK257A protein. If 
contamination was a problem then it could be identified by purifying more cSHMT 
protein and determining whether the activity between the two batches is different. 
However, to ensure that eSHMT cannot be a contaminant the expression o f mutant 
cSHMT proteins could be performed in a strain of E.coli which has the glyA  gene 
encoding eSHMT deleted. To date no such strain is available which also has the DE3
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genotype containing the gene for T7 RNA polymerase required for expression o f pET 
plasmids.
The assay using serine and THF showed that the activity o f N182D was lower than 
the wild-type enzyme but the probability that the mean was equivalent to the wild-type 
was high suggesting that the change was not significant. Comparing the Km and 
Vmax for N182D to wild-type values in the dl-allothreonine assay also suggested that 
the differences between the N182D and wild-type values were not significant at the 
95% confidence level. At amino acid 182 the only SHMT proteins containing an 
asparagine residue are human, mouse and sheep cSHMT, all the other SHMT proteins 
have an aspartic acid residue in the equivalent position (appendix 2). The side chain of 
aspartic acid is negatively charged whereas that o f asparagine has no charge. As the 
change in activity between wild-type and N182D protein was not significant, it can be 
implied that a negative charge at this position does not play an important role in 
SHMT activity.
For the C204A mutation, both assays produced results which were statistically 
significant. The Km and Vmax for allothreonine were lower than the wild-type and in 
the radiolabelled serine assay, more C204A cSHMT protein was required to obtain half 
of the maximum activity of wild-type protein. However, comparing the Km for 
C204A cSHMT to H256QK257A cSHMT suggests that the C204A protein still has a 
relatively high activity. This change in activity for the C204A mutant cSHMT protein 
is different to that gained by chemical modification using iodoacetate (Schirch et al., 
1980). Incubating rabbit cSHMT with iodoacetate abolished SHMT activity as PLP 
could not bind to the active site, establishing C204 was as being in the PLP binding 
pocket but its potential role in catalysis could not be established. Using site directed 
mutagenesis the activity o f cSHMT lacking this cysteine residue has been ascertained
and the results shown above suggest that although some activity is lost, this particular 
cysteine residue is not essential for catalytic activity o f cSHMT. An alignment o f all 
the known cSHMT protein sequences (appendix 2) shows that there is a cysteine 
residue at position 204 only in the mammalian and C.elegans cytosolic isozymes. The 
other cSHMT proteins, the mitochondrial isozymes or the prokaryotic SHMT proteins 
contain an alanine residue at this position further suggesting that the C204 is not a 
critical residue for catalysis.
W111A and W111F mutations produced significantly less active cSHMT proteins 
at the 95% confidence level and approximately 2 and 3 times more cSHMT protein 
respectively, was required to get 50% of the maximum wild-type activity in the assay 
using serine and THF compared to wild-type. In the assay using dl-allothreonine as a 
substrate, preliminary results suggested that the affinity of W111A mutated cSHMT 
protein for dl-allothreonine was reduced. A Km for dl-allothreonine for W111F 
cSHMT could not be determined, as at each concentration of dl-allothreonine 
measured, the activity was too low.
In the assay using serine and THF as substrates, the activities of W15A, W15F and 
W15Y proteins were reduced at a statistically significant level compared to wild-type 
protein activity. The activity W15F cSHMT was higher than the other W15 mutants 
suggesting that phenylalanine can partially perform the role o f tryptophan at amino 
acid position 15 in cSHMT. The assay using dl-allothreonine as the substrate 
suggested that for the mutation W15Y, the difference in Km between this mutant and 
wild-type was not significant at the 95% level but the Vmax value was significantly 
different from the wild-type. Preliminary indications were that these trends may be 
mirrored in the other W15 mutants. However, the data suggests that affinity o f the
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W15 mutants for dl-allothreonine is higher than for H256QK257A mutant cSHMT and 
activity is not completely lost in either assay.
Vijayalakshmi and Rao, (1989) showed using chemical modification with N- 
bromosuccinimide (NBS) that at least one tryptophan residue was necessary for the 
activity o f human cSHMT but the enzyme was protected against inhibition by serine 
and THF. There are only two tryptophan residues in human cSHMT and they have 
both been mutated in this study. As mentioned previously the reason that two assays 
were performed is that the dl-allothreonine assay does not use THF so if the mutant 
Km values were not affected by the mutation but the EC50 was, then this would 
indicate that THF binding was affected. The results of the assays o f the tryptophan 
mutants discussed above are inconclusive in determining which o f the tryptophan 
residues is involved in THF binding as both o f the assays showed a reduction in 
activity when either o f the tryptophan residues was mutated. The changes in activity 
seen could be due to a change in the secondary, tertiary or quaternary structures o f the 
protein caused by the change in the primary structure and, therefore, it cannot be ruled 
out that THF binding is not affected. Further work needs to be performed to 
determine whether the structures of the mutant cSHMT proteins are different to the 
wild-type. Possible methods to determine whether the structures are different are 
circular dichroism and differential scanning calorimetry. Differential scanning 
calorimetry has previously been used on SHMT to determine the enthalpy of  
denaturation (Schirch et al., 1991). Mutations in SHMT can either increase or 
decrease the enthalpy, corresponding to a more stable or less stable protein 
respectively.
If a tryptophan residue is required by human cSHMT for THF binding, there is 
conflicting evidence as to which of the two tryptophan residues is necessary.
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Alignments of eSHMT to dialkylglycine decarboxylase (DGD) and aspartate 
aminotransferase (AAT) have been performed and it has been proposed that eSHMT 
shares the same protein folds (Pascarella et al., 1993). The X-ray structures o f DGD 
and AAT are known (Toney et al., 1993, McPhalen et al., 1992). In both DGD and 
AAT the N-terminus of one subunit interacts with the other subunit o f the dimer. Cai 
and Schirch, (1996b) demonstrated that on refolding denatured E.coli SHMT, the first 
55 amino acids remain in a disordered form until dimerisation occurs and so, therefore, 
the N-terminus o f the protein may have a similar role in cSHMT. It has also been 
demonstrated that by removing the first 25 amino acids of rabbit cSHMT, the catalytic 
activity was increased when serine and THF were used as substrates but was not 
changed when dl-allothreonine was used (Schirch et al., 1984) implying that W15 is 
not essential for THF binding.
In AAT, tryptophan residues from the N-terminus interact with hydrophobic 
pockets in the second subunit (McPhalen et al., 1992). If this homology is extended to 
human cSHMT then mutation of W15 to alanine, phenylalanine or tryptophan may 
prevent interaction of the subunits disrupting the quaternary structure and distorting 
the tertiary structure.
Therefore, it could be hypothesised that the first 25 amino acids, including W15 are 
near to the THF binding site but play a structural role rather than a catalytic role and 
by removing them THF can access the site more easily. However, by changing amino 
acid W15, the tertiary structure o f the first 25 amino acids is altered, perhaps because 
they cannot associate correctly with a second subunit, and the THF binding site is 
obscured so THF has more difficulty accessing the site. This hypothesis could be tested 
by calculating the affinity o f THF for the cSHMT with the first 25 amino acids 
removed and the W15 mutants and comparing to the affinity for the wild-type. The
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same "partial blocking" effect would be seen by the addition o f a chemical group to a 
tryptophan close to the THF binding site. Therefore, it cannot be ruled out that 
inactivation o f human cSHMT by NBS is also caused by steric hindrance.
Alignments o f all the amino acid sequences for SHMT (appendix 2) show that the 
tryptophan at amino acid 15 is conserved only in mammalian cSHMTs. It is, therefore, 
unlikely that the W15 plays a major role in SHMT catalytic activity.
The data for the mutants generated does not rule out W111 as being the tryptophan 
which binds THF but alignment of the amino acid sequences of all SHMTs shows that 
W i l l  is conserved in all eukaryotic SHMTs. This residue corresponds to a gap in the 
alignment in all prokaryotic sequences. If this tryptophan residue was involved in THF 
binding it is expected that this residue would be conserved in all species. One 
difference between eSHMT and eukaryotic SHMTs is that eSHMT forms dimers 
whereas, eukaryotic SHMTs from tetramers. Therefore, W i l l  may play a role in the 
formation o f cSHMT quaternary structure and mutation of this residue affects the 
interaction o f the sub units and hence the activity of the protein.
Although the activities o f the mutant cSHMT proteins have been calculated using 
serine and THF or dl-allothreonine as substrates further work is required to establish 
the precise roles of these mutations. The Km for serine and THF can be calculated by 
coupling the SHMT reaction to that o f Cl-THF synthase which reduces NADP+, 
hence the reaction can be followed spectrophotometrically. However, Cl-THF 
synthase is not commercially available and purification from cells is expensive and 
laborious. Dissociation constants for serine and THF can also be measured (Schirch 
and Ropp, 1967). The mutants could also be incubated with glycine and serine and the 
appearance of the absorption maxima mentioned in section 1.2 determined. As each 
absorption maxima corresponds to a particular intermediate in the catalytic mechanism
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(figure 1.1), any changes affecting the mechanism will be manifested by the changes in 
these maxima.
Only elucidation of a tertiary and quaternary structure will really determine the 
accuracy of theories on SHMT structure and catalytic mechanism derived from all the 
chemical modification and site directed mutagenesis studies performed here and by 
other researchers.
CHAPTER 5
CHARACTERISATION OF A HUMAN CYTOSOLIC
SHMT PSEUDOGENE
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5.1 Summary Pleasereferto se c tio n l.il
A number of cDNA’s encoding human and rabbit cytosolic and mitochondrial SHMT
isozymes have been isolated (Byme, 1992; Xu, 1992; Garrow et al., 1993; Whitehouse, 
1996). It has been demonstrated (chapters 3 and 4) that the isolation of cDNAs allows human 
SHMT isozymes to be expressed in large quantities. The sequencing of cDNAs may also 
provide evidence of translational regulation. For example, an orf overlapping the cSHMT orf 
in rabbit cSHMT cDNA was identified and experiments indicated a possible role for the 
overlapping orf in reducing the translation of the cSHMT orf (Byme et al., 1995). However, 
cDNA sequence gives no information on the regulation of transcription of the genomic 
sequences from which the cDNAs were derived. Sequences within introns normally lost in 
cDNA cloning may also contain sequences which affect transcription, as shown in the 
cSHMT gene in N.crassa (McClung et al., 1992). In the thymidylate synthase gene which is 
expressed in a cell cycle dependent manner, loss, of several introns leads to reduced 
transcription (Deng et al., 1989) and in constitutive expression (Takayanagi et al., 1992).
Human cells have two isozymes of SHMT which are differentially regulated (section 
1.1.1) and SHMT expression is increased in the build up to cell division. It can, therefore, be 
hypothesised that the genomic sequences encoding the cytosolic and mitochondrial isozymes 
of SHMT contain sequences involved in differential regulation.
Previous work to isolate human genomic sequences encoding SHMT isozymes and 
identify potential regulatory elements in the promoter and introns resulted in the isolation of 
putative SHMT genomic clones from a human genomic DNA library constructed in lambda 
phage EMBL3A (Byme, personal communication). Two of these clones (3 and 4) were 
digested with EcoRl and BamHl and fragments were subcloned into pUC18 (Byme, personal 
communication).
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The work presented in this section describes the further characterisation of the subcloned 
fragments and the two genomic clones. The genomic DNA hybridising to cSHMT was 
sequenced and found to encode a human cSHMT processed pseudogene.
5.2 Results
5.2.1 Sequencing of restriction digest fragments hybridising to cSHMT cDNA
Restriction mapping of 3kb fragments produced by digestion of clones 3 and 4 by EcoRI
showed that these fragments had identical restriction sites. Preliminary sequencing of 
the ends of these fragments produced identical sequence, indicating that they were identical 
fragments. The 3kb EcoRI fragment from clone 4 and a 1.7kb BamHI fragment from clone 3, 
both subcloned into pUC18, were digested with Kpnl, BamHI, Pstl, Hindi, Sad, EcoRI, 
HindHI and Xbal and the released fragments were subcloned into pUC18. After digestion 
with the above enzymes, parts of the original fragments were not liberated from pUC18 and 
were, therefore, religated to form smaller vectors. The resulting subcloned plasmids and a 
0.6kb BamHI fragment from clone 3 were sequenced using universal and reverse primers. 
After sequencing, two gaps remained in the sequence, one in the 3kb iscoRI fragment and the 
other in the 1.7kb BamHI fragment. Oligonucleotides kjcl-4 were designed and sequence 
spanning these gaps was obtained. Restriction maps and sequencing strategy for the 3kb 
EcoRI and 1.7kb BamHI fragments are shown in figures 5.1 and 5.2.
A further 0.6kb SaWEcoRI fragment from clone 4 hybridising to cSHMT cDNA 
(pUS1213) was identified by Southern blotting. This fragment was subcloned into pUC18 
and sequenced using universal and reverse primers. The Sail terminus of this 0.6kb fragment 
contained sequence homologous to one arm of the EMBL3 A vector.
Comparison of the sequenced fragments revealed that the 3kb EcoRI fragment overlapped 
the 1.7kb and 0.6kb BamHI fragments. The sequence of the 0.6kb SaWEcoRI fragment from
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clone 4 was matched to sequence in the 1.7kb BamHI fragment from clone 3. Figure 5.3 
shows the relationship of the fragments sequenced to each other. Sequences from the 
overlapping regions of the fragments from clones 3 and 4 were identical. The sequences of 
the fragments were merged to form one continuous sequence 4.3kb in length (figure 5.4).
By alignment with human cSHMT cDNAs it was demonstrated that the entire cSHMT 
coding sequence with some 5’ and 3’ non coding sequence was present in the 4.3kb sequence 
between nt 1157-3491 (figure 5.4). There were, however, many base changes, insertions and 
deletions in the genomic DNA fragment sequenced compared to the cSHMT cDNA sequence. 
These base changes include the mutation of the ATG start codon to ATA (nt 1177-9). No 
promoter sequences for RNA polymerase II were found in the sequence upstream of the 
mutated start codon. The point mutations and frame shifts had also introduced two premature 
stop codons in frame with the mutated start codon. The 0.6kb SaWEcoRI fragment ends at 
the Sau3A site at nt 3680. The sequence in figure 5.4 was submitted to the Genbank DNA 
database and was given the accession number X85980.
5.2.2 Mapping of genomic clones
As mentioned in the previous section lambda clones 3 and 4 contained related DNA
containing the same cSHMT sequence. Some differences between the two clones was, 
however, indicated by restriction mappingj whole lambda clones 3 and 4 i
Two mapping strategies were employed to further define the genomic DNA inserts in 
clones 3 and 4. A short range map was built up by hybridisation with DIG labeled probes 
from either the cSHMT cDNA or from the 5’ end of the sequenced section. Secondly, 
restriction sites were mapped using partial digests followed by hybridisation to the cos ends 
(Rackwitz etal., 1984).
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Figure 5.4 Sequence of the human genomic DNA fragments, merged to produce a 4.3kb 
fragment. Sequence in red italics indicates the direct repeats found at either end of the 
cSHMT cDNA homologous sequence. Sequence in blue is sequence with no homology to 
cSHMT cDNA within the direct repeat boundary. Sequence in green is the mutated start 
codon. Sequences in magenta are mutations compared to the cSHMT cDNA. Insertions in 
the sequence compared to cSHMT cDNA are underlined and sequences in bold border 
deletions in the human genomic DNA compared to the cDNA.
1 GAATTCACTTAATTAAGTGTCTAACATTAAATGTTGTTGAAATGATCTAACATTTATGGC 
6 1  CCCAGGACACATCCTCTCATTTCATTCTCTTGACTAATAAGTGAAATAAGGCTCAGACTT 
1 2 1  TTCCAAGATCACATAGCCTGTGAAGTGAGAAAGCTGTGAGAACTTTCAGTCTCCAAATCT 
1 8 1  TCATCTCCTTTCAATCTATCATATATTGGAATATGTCACAATAATTAGTTTTCTTCAGAA
2 4 1  ACTCTTTCCACTAAAAGAGTGTCTTATCAACATTTCCCACATCCTTACACTCTCAGTCTC 
3 0 1  TGGAGGGCAGAAATTAATTTCCACTCACAAAACCAATACCAAGTGTCTACTGTGTGCTAA
3 6 1  AGGCTCTGCTAGGTGTTGGCAGCCATGAATAGACCATGCCTCTATGTGAGAAGTCCACAG 
4 2 1  TCTCTATGGGA GAA GAAA TACCA GCCAA TA GT TA TA TACACAA TAACAAA GCTATGTGTG 
4 8 1  AGGCACTGTGGTGGTGGACAGGGTAGGGGAAAGAGTAATGGAGTGTATTTCTAGGTAAGG 
5 4 1  GAAGACTTTGCATTCCATGAGACCAAACAGATTCAAAAGACCTAACTCAAAATTTAGAGC 
6 0 1  AAAACAAGTGCTCAGTAAATCTGAGTTCCTTTGGACCTACTGCCATCCCCTCCCCATCTC 
6 6 1  TCTAATTAGAGGGAGATGTATCCAAGTGAGCAATACTCGAGGGAGGAAAGGAGGACTTCC 
7 2 1  CAGCAGAGAGTACCCAAGTGTGAGAGCAAACAGGCTGGCTTCCCAGAGAAGCAGGACTCT 
7 8 1  GGTCTGGACGGGTGGGCACATCAGCACCCCTTCCTTTACACTGCCTGCTCCTTAGTCTGC 
8 4 1  ACCTAGGGATGGGAGTCAATGACTAGGTGGGCTCAGGGAAGAGTGAAGCATAGGAAAAGA
9 0 1  g a a t g t a t g c t t c a c a c a g c a t t t g g g g a t t t t t t t t a a a a a g g t a a g a t t t a g g c c a a g
9 6 1  CCTAAGCCTGGTGCAAGGGGTGCACCTAGCAGAGCACTAGCAGTCCCGCACCAAGTTTGG 
1 0 2 1  GATTTGGGGTTGGTGCAGCCAGTCACGTTGCTGGTGCGTGGCAGTGTACAGGGCATTGGG 
1 0 8 1  TCAGCGGGTCTGGGACTCTGGTGGCACTGGTGGCGGCGTGGGACTGAGGCTAGGCACATG 
1 1 4 1  T GC GGGGC T GT GT TCC GGCAGCTTCGGACCCATGCAA TAGCAATGCCAGTC GACAGGGCC 
1 2 0 1  CACAAGGATGCTGACCTGTGGTCCTCACATGACAAGATGCTGGCGCAGCCCCTCAAAGAC 
1 2  6 1  AGCGATGTTGAGGTTTACAACATCATTAAGGAGAGTACCGGCAGAGGGCTGGATTGGAGC 
1 3 2 1  TGATTACCTCGGAGAATTTCGCCAGCTGGGCAGTTTTGGAGGCCCTAGGCTCTTGCTTAA 
1 3 8 1  ATAACAAATACTCTGAGGGGTACCCGGGCCAGAGATACTAAGGCAGGACTGACTTTACTC 
1 4 4 1  ATGAGCTGGAGACCCTCTGTCAGAAGCGAGCCCTGCAGGCCTATAAGCTGGACCCACAGT 
1 5 0 1  GCTGGGGGGTCAACGTCCAGCCTTGCTCAGGCTCCCCTGCAAACTTTGAGTGTAACTGCC 
1 5  6 1  CTGGTGGAAACCCATGGGTGCATCATGGGCCTGGACCTGCCAGATGGGGGTCACCTGACC 
1 6 2 1  CACGGGTTCATGACAGACAAGAAGAAAATCTCTGCCACGTCCATCTTCTTTGAATCTATG 
1 6 8 1  CCCTATAAGGTGAACCCAGACACTGGCTACATCAACTATGACCAGCTGGAGGAGAACACC 
1 7 4 1  CGCCTCTTCCACCCGAAGCTGATCAGTGCAGGAACCAGCTGCTCCTCCTAAAACCTGGAC 
1 8 0 1  TATGCCCCGCTGCAGAAAACCTGCAGATGAGAACGGGGCGTATCTCATGGTGGACATGGC 
1 8  6 1  ACATATCAGCAGGCTGGTGGCAGCTGGCGTGGTCCCCTCCCCATTTGAACACTGCCACCA 
1 9 2 1  CCACTCACAAGAACCTGAGAGGCTGCCAAGTCCGCACGATCTTCTACAGGAAAGGAGGGC 
1 9 8 1  AAAGTATGGATCCCAAGACTGGCAAAGAGATTCTGTACAACCTGGAGTCTCTCATCAACT 
2 0 4 1  CTGCTGTGTTCCCTGGCCTTCAGGGAGGTCCCCACAACCACACCATTGCTGGGGTTGCTG 
2 1 0 1  TGGCCCTGAAGCAAGCTATGACTCTGGAATTTGAAGTTTATCAGCACCATGTGGTGGCCA 
2 1 6 1  ACTGCAGAGCTCTGTCTGAGGCACTGACGGAGCTGGGCTACCAAACAGTCACAGGTTGTT 
2 2 2 1  CTGA TAAA CATTTGATCCTCGTGGATCTCCATTCAATCAAAGGCACAGATGGCA GAA GGG 
2 2 8 1  CTGAGAAGGTCCTAGAAGCCTGTTCTATTGCCTGCAACAAGAACACCTGCCCAGATGATA 
2 3 4 1  GAAACACTCTACGGCCCAGTGGACTGCGGCTGGGGAACCCAGCACTGACATCTCTTGGAC 
2 4 0 1  TTTTGGAAAAAGGCTTCCAAAAGGTAGCCCACTTTATCCACAGAGGGATAGAGCTAACCC 
2 4 6 1  TGCAGATCCAGAGCAACGCTGGCATCAGAGCCACCCTGAAAGAGTTCAAGGAGAGACTAG 
2 5 2 1  CAGGGCATAAATACCAGGGGTGTGTGCAGGCTCTCCAGGAGGAGGTTGAGAGCTTCACTC 
2 5 8 1  TCTTCCCTCTGCCTGGCCTGCCTGACTTCTAAAGGAGCCGGCCCACCCTGGATGCACCTG 
2 6 4 1  GTGCCACAGAGGAAGCTACCTGCTGGAGGATCCCCTTGAGAGATGTACAAGCTGCCCCAC 
2 7  0 1  AAGGGACCCACTGACACTTGTTTCCTTTGAGGGGTTTTCTTTTGGACTTTTTTCATGTTT 
2 7  6 1  TCTTCACAAATCAAAATTTGTTTAAGTTTCATTGTTATTAATTCTGGGACAGGTTATTAC 
2 8 2 1  AGGTTTTTAATTTGAACCTGGCTTTCTCACAGCTGGATATAATTATTCTAGAAAAATAAA 
2 8 8 1  AATACTGTGTAGCCACTTGGCCATAATCATTTAGACCATGGGGTAGGGCAGAGCTATTAG
2 9 4 1  AAAGATTCTAGTGTTTTACTCTCCCTAGGCTTTCCTTTGCCTTGCTGCAGCAGAGAGGAA 
3 0 0 1  ATGCTCCTGTCCACAGCTTGTACACACTGCCACTCTTACTATCTTGTTACCCAGCAGCAT 
3 0 6 1  GCCAAAGGGGAGCTGAATTCGCCTCTGAOGCTTCTGCTGTGTGCTGTAAATCAGAAGTGT 
3 1 2 1  ACATTAGCCAAGTGTACACAAGGTGCACTCAGTATGGTGGGAGGGTTTTGCTGTCAGTAG 
3 1 8 1  TTCAAAGTATGGTGTAGAAAGGGTCTCCTCCCTCCATCCTGGGAAATCCCAGTCCCATAC
3 2  4 1  TGGTGTGAGAATCAACCAGGCTTTCCTGCTCCACCTGAGATAACCAACTCCCTCCCATAA 
3 3 0 1  TCAGGAAACCAAATGTCACCTTCCCAAAGAAACTTTATTTTCACATAGCTGAAGTGCAAA
3 3  6 1  ACATATACGACCATTTTTAATAAGCACAATCAAATTTTTAACTACTGAATGTCTACAAGA 
3 4 2 1  ATTATAGCTTTAAAAATACAATTTTTATATTTCAAAAATATTTGAACTGAAACTAATTTC
3 4 8 1  t t a a a a a g t t a a a a a a g g t a a g a t t t a a t a g t t t t t g t g g a t c a t c t c a a a a t t a a c a c a
3 5 4 1  TCAAAAAGAGCTTTATCAAGTCCTTTTCTGTCAAAATATTGATGCTGCAGAAATCAAAAC
3 6 0 1  CTTGAATTTACTTAAGTATTTTGTGATCAAAATACCAAGAAATACTAGCTACCCATATGA 
3 6 6 1  AAAAAAAAAAAGAACCCTAGATCTCAACCTCATCCCTAACACACAAAACCAAAAATGGAT 
3 7 2 1  GAGTTAATATTTACCTATGACTACCAAATCTGTCCGCCAGAAGAAAACAAAGGATGGCAC 
3 7  8 1  CATCATCAACTACTATGTGGGTACATAAATCCCAATCCTGCTATGTAGGGCAATTTGCCA 
3 8 4 1  ATRACTCTCGRAATGTTCAAGAGGCAGAAGGAAACACAAACATAATAAGATATGAAGCAG 
3 9 0 1  AAGA TA TAA GAA GACC TAAA T GGAACC TACAGA GA GTAAA TACACA GTA T T T GACA TAA T 
3 9 6 1  AATATACATGGTGGGATTAACAAGTGATTAAATGCTACAAAAGAAGAAGCTATAAATGTG 
4 0 2 1  AAGACACAGCAATATAAACTATCCAAAATGAAGCAGA GAGA GAAA GAA GATTGTAAAACA 
4 0 8 1  CAAACCCAGAGCATCAGTGACCTGTGGGACAAATAATATAGCATCCATGTATTTGAATCC 
4 1 4 1  TGGGAAAGGAGATGAGGCAGAAAAATATTTGAGAAAATATGTAAACAAGGTCCAAATGTG 
4 2 0 1  A T TACAAA GAA TAAAACAAAACAAACAAACAA GAAAAC TA T GAACC TACA GATC T GA GGA 
4 2  6 1  GTTAAATAAACTCCAAGCCAAA TAAA TA TAAA GAAAACCACAGCCAGGCACAGTGGCTCA 
4 3 2 1  CACCTGTAATCCTAGCACTTTGGGAGACCGAGGCATGTGGATCC
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Using cSHMT cDNA (pUS1213) as a probe, fragments from EcoRI, Xbal, HindUl, and 
NdeI digests were identical in clones 3 and 4 and could be identified as spanning the coding 
region. Hybridisation of this probe to Sail, BamHI, Kpnl and Smal digests gave different 
products in the two clones which hybridised to the cDNA. Hybridisation of cDNA probe to 
Pstl digested DNA gave too many bands to be useful in mapping the fragments (figures 5.5, 
5.6). The total inserts for lambda clones 3 and 4 are approximately 12.5kb and 17.5kb 
respectively as digestion with Sail releases the DNA inserted between the lambda arms and 
there were no SalI sites inside the inserts.
A 1.4kb EcoRI/Kpnl fragment derived from the 3kb EcoRI fragment from clone 4 was 
used as a probe to detect sequences which hybridised to the 5’ end of the deduced sequence. 
The use of this probe meant that the BamHI, Kpnl and Smal restriction fragments could be 
orientated with respect to the sequenced section and additional Smal and Kpnl sites were 
located (Figure 5.7).
further evidence was provided that the same piece of human genomic DNA had been 
inserted into the two clones as many of the fragments were identical for both clones. It was 
already known that the Sau3A site at nt 3680 in the sequence was the end of the clone 4 insert 
and was, therefore, ligated to one of the arms. The restriction maps suggested that this was 
the right arm. For clone 3, a 1.2kb SaWEcoRI fragment corresponded to the 3’ end of the 
1.7kb BamHI fragment suggesting that the end of the sequence derived in 5.4 was one end of 
the insert in clone 3. The Kpnl, HindlR and Smal digests suggested that this end was ligated 
to the left arm of EMBL3 A.
To confirm information obtained from probing digested DNA with sequence from the 
inserts of the lambda clones, partial digestion of the full lambda clones and mapping with 
DIG labeled oligonucleotides complementary to the left and right cos ends of the lambda
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Lane Enzyme Clone 3 (kb) Clone 4 (kb)
1 Sail 12.5 17.5
2 Sall/EcoRl 3.0, 1.4 3.0, 0.6
3 EcoRI 3.0 3.0
4 Xbal/EcoRl 2.7 2.7
5 Xbal 3.8 3.8
6 Pstl nd 1.8, 0.4, 0.3
7 Nde I 4.8 4.8, 3.7
8 Hind\LI 4.0 4.0
Figure 5.5 Hybridisation of human cSHMT cDNA (pUS1213) to digests of lambda clones. 
The table indicates the sizes of the fragments hybridising to the probe, nd not determined 
Lane M XHindlll DNA size markers
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ClONt 3 
1 7 3 4 5  6 7 w *b
Lane Enzyme Clone 3 (kb) Clone 4 (kb)
1 Sail 12.5 17.5
2 EcoRI 3.0 3.0
3 BamHI 10.0, 1.7, 0.6 10.0, 0.6
4 Pstl nd nd
5 Kpnl 4.4 11.0
6 HindlR 22.0, 4.0 4.0
7 Smal 3.5 5.0
Figure 5.6 Hybridisation of human cSHMT cDNA (pUS1213) to digested lambda clones. 
Indicated in the table are fragments hybridising to the probe, nd not determined 
Lane M XHindlll DNA size markers
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Lane Enzyme clone 3 (kb) clone 4 (kb)
1 Sail 12.5 17.5
2 EcoRI 3.0 3.0
3 BamHI 10.0 10.0
4 Pstl 1.8 1.8
5 Kpnl 2.0 2.0
6 H indm 4.0 4.0
7 Smal 12.5 14.5
Figure 5.7 Hybridisation of a 1.4kb EcoKUKpnl fragment from clone 4 to the digested 
lambda clones. Fragments hybridising to the probe are shown in the table.
Lane M XHindlll DNA size markers
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arms was performed.(this technique is described in section 1.11). Results of the hybridisation 
of the partially digested fragments to the left and right arms of EMBL3A are shown in figures 
5.8, 5.9 and 5.10. The sizes of the partially digested fragments, derived from agarose gel 
electrophoresis, were often inaccurate due to the high sizes of most fragments meaning that a 
1mm difference on the gel was equivalent to several kilobases. However, the relationship of 
the different restriction sites to each other can be seen by comparing the locations of the 
signals detected on the X-ray film for each enzyme to each other. This method confirmed that 
in clone 4 the sequenced fragment was located adjacent to the right arm. The sequence of the 
fragment was running from 5’ to 3’ in clone 4. For clone 3, evidence from the mapping gave 
credence to the theory that the sequenced part of the insert was ligated to the left arm. In this 
case the BamHI site which occurs at the end of the sequenced region is ligated to the BamHI 
site of the left arm. Therefore, the sequence was running 3’ to 5’ in clone 3. By putting all 
the information together maps were produced for lambda clones 3 and 4 (figure 5.11).
5.3 Discussion
5.3.1 Sequencing of genomic DNA homologous to cSHMT cDNA
The sequencing of the human genomic library clones hybridising to human cSHMT
revealed a sequence similar to that of human cSHMT cDNA. Using the BESTFTT program 
(Genetics Computer Group) the genomic sequence was aligned to the human cSHMT cDNA 
with 91% identity over the region nt 1157-3491 (figure 5.4). BESTFTT alignment of the 
genomic sequence to mSHMT cDNA yielded only a 65% identity. It can, therefore, be 
assumed that the human genomic sequence presented here was derived from the cSHMT 
gene.
The sequence of the DNA hybridising to the human cDNA probe has been compared to all 
the human SHMT cDNA’s that have been isolated. The region corresponding to the coding
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Lane Enzyme Left arm oligo Right arm oligo
1 Sail 16.4,21.2 9.6, 19, 28
2 EcoKl 23 16.3, 19, 28
3 BamRl 16.3 10.6, 23
4 Kpnl 15.4, 23 13.7,16.4, 18,20.5, 25
5 HindUl 23 4.6, 13.8, 16.3, 20, 25
6 Xmnl 1 2.4
7 Clal 4.2, 15.4, 23 2.0, 4.3, 9.3
Figure 5.8 Mapping of clone 3 by partial digestion and hybridisation to oligonucleotides 
complementary to the cos ends.
Lane M XHindlll DNA size markers
Lane 8 control lambda DNA partial digest
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Lane Enzyme Left arm oligo (kb) Right arm oligo (kb)
1 Sail 16.5,23 9.4, 23
2 EcoRl 24 9.6, 12, 23
3 BamHl 17.8 9.7, 23
4 HindUl 25 23
5 Kpnl 15.4, 23 10, 23
6 Smal 17.8,23 5, 22, 23
7 Clal 4.3, 6.5 2, 5.5
Figure 5.9 Mapping of clone 4 by partial digestion and hybridisation to oligonucleotides 
complementary to the cohesive ends (cos) of the lambda arms.
Lane M XHindlll DNA size markers
Lane 8 control lambda DNA partial digest
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Lane Enzyme Left arm oligo (kb) Right arm oligo (kb)
1 BamUl (10U/pl) 20 9.6
2 BamHl ( I U / jllI) 20 9.6
3 EcoBl ( I O U / jliI) 23 9.6
4 EcoBl (lU/jil) 23 9.6, 13, 25
5 HindUl (lOU/pl) 22 4.5, 9.6
6 HindRl (lU/^tl) 23 4.5, 9.6, 13.5,25
7 Sail ( I O U / jliI) 20 9.8
Figure 5.10 Mapping of clone 4 by partial digestion and hybridisation to oligonucleotides 
complementary to the cohesive ends (cos) of the lambda arms. Two different concentrations 
of enzyme were used for BamHl, HindRl and EcoKl.
Lane M XHindlll DNA size markers
Lane H High size DNA markers
Lane 8 Lambda DNA control
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sequence for the protein spans nt 1177-2609 and the 3’ untranslated region from nt 2610- 
3491. However, as mentioned in the results the start codon has been mutated from ATG to 
ATA and there were many point mutations, deletions and insertions in the genomic sequence 
compared to the cSHMT cDNA.
Kozak, (1987a) studied 699 vertebrate sequences and deduced a consensus sequence for 
initiation of translation. The translation initiation consensus was compared to the human 
genomic sequence isolated here and to cSHMT cDNA below with the start codon underlined, 
consensus (GCC)GCC A/G CCATGG
genomic sequence (ACC)CAT G CAATAG
cSHMT cDNA (ACC)AGT G CAATGA
Although the human cSHMT cDNA sequence is not a perfect match for Kozak’s 
consensus, the most highly conserved element of a purine at -3 is conserved. The cytosine 
residues at -1, -2, -4 and -5 are less conserved than the purine at -3 and translation will occur 
when these positions are different. (Kozak, 1987b). The human genomic sequence does not 
match the Kozak consensus either, although it is interesting that there is the more favoured G 
residue at +4. However, translation would not be initiated as the start codon is mutated. If 
translation of the genomic SHMT isolated were possible, the resulting protein would be 
totally dysfunctional and would be truncated due to two in frame early stop codons produced 
by the mutations.
Introns are a common feature of human genes, they are present in the mSHMT gene 
(Stover et al., 1985) and would have been expected in the cSHMT gene as well. However, 
there are no introns present within the region homologous to cSHMT.
Upstream of the mutated start codon there are 20 nucleotides (nt 1157-1176) of sequence 
homologous to the 5’ untranslated region of previously isolated human cSHMT cDNA’s
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(Byme, personal communication) some of which may be incompletely spliced and still 
contain intron sequences. Two of these human cDNA’s contain a sequence consistent with 
an intron having been spliced from the mRNA at the point where pseudogene and cDNA 
homology ends (pUS1216 and pUS1217) and one sequence (pUS1214) contains an intron at 
this point. Nucleotides 1-1156 have no homology to SHMT cDNA’s isolated or to the intron 
in pUS 1214. The region spanning nt 1140-1158 in the genomic DNA does not correspond to 
the consensus for an intron splice acceptor site (Ohshima and Gotoh, 1987) and it is, 
therefore, unlikely that the sequence upstream of nt 1156 is an intron. There are also no 
sequences corresponding to a RNA polymerase II promoter suggesting that the cSHMT 
sequence is not transcribed by RNA polymerase n. Searching of the Genbank database 
reveals no homology to known sequences between nt 1 and 1156.
At the 3’ end of the gene, homology to cSHMT cDNAs ends at nt 3491. Directly 
following this nucleotide is a 16 base sequence AAAAAGGTAAGATTTA which is also 
present between nucleotides 938-953. A comparison of the 3’ untranslated region 
downstream of the second direct repeat to sequences within the Genbank database shows only 
homology to an Alu repeat element starting at 4313 and running to the end of the known 
sequence.
Alu repeats are the most abundant family of repeated sequence in the human genome. 
The name was derived from the fact that the repeat is digested by the restriction endonuclease 
Alul (Houck et al., 1979). The Alu repeat sequences are closely related 300nt sequences, with 
an average homology to the consensus of 87%. Each Alu repeat consists of a tandem 
duplication of a 130bp sequence with an additional 31bp inserted into the right half of the 
sequence (Deninger et al., 1981). Alu repeats also have direct repeats at each end due to 
duplication of the target site at the point of insertion into the chromosome. As the homology
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to the Alu repeat occurs at the end of the isolated human genomic sequence, it cannot be 
confirmed that this is a genuine Alu repeat sequence.
The presence of such an adenine rich direct repeat at each end of the coding sequence
combined with the sequence mutations, lack of introns and lack of promoter sequence
indicates that this sequence is a processed pseudogene (for review see Vanin, 1985). It is
proposed that processed pseudogenes arise from the insertion of either mature mRNA or
cDNA into a staggered break in a chromosome. (Vanin, 1985). Recently it has been
demonstrated that human cells have a endogenous reverse transcriptase activity which can
'(Maestre et al, 1995).
generate cDNA copies of mRNA Using reporter gene technology and following the insertion 
of processed pseudogenes into the HeLa cell genome it has been shown that processed 
pseudogene formation is still continuing and is not an evolutionary relic (Maestre et al., 
1995).
In processed pseudogenes studied by Vanin, (1985) sequence divergence between the 
original and the pseudogene between the two direct repeats was uncommon. As mentioned 
above the genomic sequence between nt 954 (the end of the 5’ direct repeat sequence) and 
1156 does not have any homology to cSHMT cDNA’s isolated so far but is within the direct 
repeats bordering the pseudogene. Vanin, (1985) proposed the formation of some processed 
pseudogenes was due to transcription by RNA polymerase HI rather than RNA polymerase n. 
It has previously been shown that the human p-globin gene can be transcribed by RNA 
polymerase IH and that this transcript is processed in the same way as transcripts generated by 
RNA polymerase II (Carlson and Ross, 1983). Sharp et al., (1981) and Geiduschek et al., 
(1988) defined the consensus sequences for boxes A and B where transcription factors 
responsible for the transcription of tRNA genes by RNA polymerase IE bind to the DNA.
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These consensus sequences were compared to the sequence between 954 and 1156 of the 
human genomic DNA isolated.
Box A TRGCNNAGY.GG T in bold is generally at +8 of transcript
sequence TAGCAGAGC.CT corresponding T is at nt 987
BoxB GGTTCGANTCC T in bold is generally at 55 of transcript
sequence GCTTCGGACCC corresponding T is at nt 1131
It can be seen from these comparisons that there is almost an exact match for box A in the 
human genomic sequence. The alignment with box B is less exact. The distance between the 
two putative boxes in the pseudogene is higher than in the consensus. However, in yeast 
tRNA genes the distance between the two boxes varies between 31 and 93 bp (Geiduschek et 
al., 1988). The distance of box A from the 5’ end also varies. tRNA genes without the 
second control region (box B) can be transcribed but with reduced efficiency (Sharp et al., 
1981). Therefore, it may be possible for RNA polymerase in  to have generated a transcript 
from the cSHMT gene which was processed in the same way as transcripts generated by RNA 
polymerase II and subsequently incorporated into the genome as a processed pseudogene.
An estimation of the time since the pseudogene was created from the cSHMT gene can be 
performed based on the number of substitutions made in the pseudogene compared to the 
cDNA. As the pseudogene has no RNA polymerase II promoter it is assumed that the gene 
was inactivated as soon as the duplication event occurred and therefore, any mutations in the 
pseudogenes are neutral. Using the figure of 0.7% per million years as the rate of fixation of 
neutral mutations in the genome (Perler et al., 1980; Ochman and Wilson, 1987), and there is 
7.2% nucleotide substitution (excluding insertions and deletions) over the region that used to 
code for cSHMT protein compared to cSHMT cDNA, the duplication event can be estimated 
as being 11.5 million years (MY) ago.
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This method of calculation assumes that the rate of fixation is the same in pseudogenes as 
in functional genes. In functional genes there are two types of mutations, ones that are silent 
and do not affect the coding sequence and those that do affect the coding sequence, known as 
replacement mutations. The rate of fixation of replacement sites in functional genes is slower 
than for silent site as those mutations changing the amino acid often lead to a dysfunctional 
protein and are eliminated. The other assumption in the calculation is that there has been no 
change in the sequence in the functional gene since the duplication event. Others authors 
have modified Perler’s assumption and attributed half the nucleotide substitution rate at the 
third codon position to evolutionary drift, i.e. the functional gene has accumulated silent site 
mutations since the time of divergence, and these mutations are likely to be at third position 
of the codon (Lee et al., 1983). Using this assumption the time since the cSHMT pseudogene 
was created is 7.7 MY, a reduction of about 4 MY from the previous calculation.
There is evidence that the mutation rate in inactivated pseudogenes is faster than in 
functional genes as there is no selective pressure on the mutation. Using the method of Perler 
et al., (1980), Proudfoot and Maniatis, (1980) estimated the time since divergence of the 
mouse a  globin and its pseudogene was 30 MY, between human a  globin and its pseudogene 
was 60 MY and between rabbit p globin and its pseudogene was 55 MY. However, Li et al.,
(1981) calculated the time since duplication for) the same samples as above as 27MY, 49MY
/■
and 44MY. This method was achieved by calculating substitutions since duplication between 
the pseudogene and two functional counterparts. The substitutions between the two 
functional genes were also calculated It was found that the rates of change in all three codon 
positions were equal in the pseudogene as opposed to biased towards the third codon in the 
functional genes and were higher in all three positions in the pseudogene than in the 
functional gene from which it was derived.
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Attempts to produce a figure for human cSHMT pseudogene divergence were made using 
the method in Li et al., (1981) similar results were obtained in that the rate of nucleotide 
substitution was equally spread over the three codon positions and was faster than for the 
human cSHMT gene. However, the final calculation using rabbit cSHMT as the second 
functional gene sequence, gave a time since divergence of 24.25MY, a result higher than 
estimated using the other methods. It is noteworthy here that the ratio of third codon 
substitutions was higher when comparisons were made between the pseudogene and the 
rabbit cSHMT than between the human cSHMT and the rabbit cSHMT whereas in the 
example given by Li et al., (1981) this ratio was lower and this change would affect the 
outcome. However, the authors used two mammalian comparisons and averaged them out. 
This could not be done for cSHMT as rabbit and human cSHMTs are the only two 
mammalian DNA sequences known which span the entire coding sequence for cSHMT. 
Once other mammalian sequences are available the calculations of age can be repeated to 
establish whether this method of estimation of pseudogene age is useful for SHMT.
Some processed pseudogenes are still functional after creation and time since inactivation 
can be calculated in using the results from the nucleotide substitutions calculated above (Li et 
al., 1981). Function may be retained if, for instance, RNA polymerase HI is responsible for 
the creation of some processed pseudogenes, the internal promoters are still present and 
mRNA transcripts can still be made. Under some circumstances where RNA polymerase IQ 
transcription was started before the RNA polymerase II promoter, the signals for transcription 
by RNA polymerase II are still present. It is possible, therefore, that if the human cSHMT 
pseudogene was generated by RNA polymerase m  it was still transcribable by RNA 
polymerase IE after its creation and remained functional. This transcription may have been at 
a low level and maybe the mutation occurred in the translation start consensus at +4 to
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increase the efficiency of translation as a result. It was only later that other mutations 
including the mutated start codon accumulated which made the cSHMT pseudogene 
unfunctional.
The cSHMT pseudogene has been mapped to chromosome lp33.2-33 by in situ 
hybridisation. (Byrne et al., 1996). cDNA encoding human cSHMT was also mapped using 
the same technique. In 12.5% of the spreads there was a signal at lp32.2-33 and in 11.5% 
there was a signal at 17pl 1-12 when cSHMT cDNA was used as a probe. The cSHMT gene 
has previously been mapped to 17pl 1.2 using cSHMT cDNA (Garrow et al., 1993). 
However, these author did not detect a signal on chromosome 1.
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CHAPTER 6
ISOLATION OF HUMAN GENOMIC SEQUENCES 
ENCODING CYTOSOLIC SHMT
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6.1 Summary Please refer to sections 1.12 and 1.13
Several cDNAs encoding cSHMT had previously been isolated (Byrne, 1992; personal
communication), several of which had cSHMT sequence adjacent to sequences with no 
homology to SHMT. At the junctions between the cSHMT and non cSHMT sequences there 
were motifs with good homology to intron splice junctions suggesting that the non cSHMT 
sequences were introns which had not yet been spliced from the mRNA used to synthesise the 
cDNA library. The locations of these potential introns are shown relative to cSHMT cDNA 
in figure 6.1. Three other potential intron splice junctions were identified by Xu, (1992) who 
isolated human cSHMT cDNAs encoding proteins shorter than the full length sequence by 39 
and 80 amino acids, due to deletions near the C terminus (figure 6.1).
A previously undetected processed pseudogene encoding human cSHMT was 
characterised in chapter 5. However, there are no introns or RNA polymerase II promoter 
sequences within the pseudogene so no information on the potential regulation of cSHMT 
expression has been generated. The work in this section describes attempts to characterise the 
cSHMT gene. Several approaches were taken to isolate DNA fragments encoding cSHMT. 
The human PromoterFinder kit (Clontech, section 1.13) was used in conjunction with primers 
complementary to the 3’ end of the human cSHMT to determine how much of the whole 
sequence could be isolated. Evidence from the isolation of the human mSHMT gene (Stover 
et al., 1995) indicated that the coding sequence spanned approximately 4.5kb of genomic 
DNA. Therefore, if the same was true for the cSHMT gene, much of the gene could be 
amplified in one PCR reaction if the reported sizes of products produced by the human 
PromoterFinder kit were accurate.
Once the products of this reaction were characterised and it was found that only sequence 
3’ of nt 1349 (appendix 1) had been obtained two other reactions were performed, one at the 
5’ end of the gene to try to isolate the promoter and one to determine the sequence of the
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introns present in the alternatively spliced region of the cSHMT gene (introns 6,7 and 8, 
figure 6.1). In order to determine the size and sequence of the intron in pUS1206 (intron 5, 
figure 6.1) identified by Byrne, (1992), this region of human genomic DNA was amplified by 
PCR using primers either side of the intron junction.
6.2 Results
6.2.1 Amplification of human cSHMT genomic DNA using sequences from the 
3’ end of cSHMT cDNA sequence
Oligonucleotides were designed which were complementary to nt 2300-2326 (gspl) and
nt 2041-2069 (gsp2) of human cSHMT cDNA (appendix 1). The oligonucleotides were used 
with the human PromoterFinder kit to amplify human genomic DNA. The results from the 
amplification of the five libraries are shown in figure 6.2.
Fragments from libraries 1,2 and 5 were subcloned into pT7blue(R) (Novagen). After 
transforming DH5a cells to ampicillin resistance, white colonies were grown overnight and 
the plasmids were extracted by alkaline lysis. The 0.8kb product from library 1, the 1.5kb 
and 3.5kb products from library 2 and the 1.4kb product from library 5 were all successfully 
subcloned into pT7blue(R).
The primers gspl and gsp2 also have homology to the cSHMT pseudogene and, therefore, 
amplification of this DNA is also possible. The subcloned PCR products were sequenced 
with gsp2 to check whether the PCR products obtained contained the cSHMT gene. All 
except the 3.5kb product contained sequence identical to human cSHMT cDNA. Alignments 
were done with the mSHMT cDNA and the cSHMT pseudogene sequence to rule out the 
amplification of these sequences. The clones containing cSHMT sequences were then 
sequenced to establish the 5’ end of the amplified products with primer ap2 from the human
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5'UTR orf 3'UTR
f t f t  t t f t
J cSHMT cD N A
1 2 3 4 5 6 7 8
Scale 250bp
Figure 6.1 Putative intron locations in the cSHMT gene derived from alternatively spliced 
and incompletely spliced cSHMT cDNAs.
1-5 were obtained from incompletely spliced cDNAs (Byme, personal communication).
6-8 were obtained from the alternatively spliced cDNAs isolated by Xu, (1992).
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Figure 6.2 Agarose gel showing results of PCR amplification of the human genomic libraries 
in the human PromoterFinder kit using nested primers gspl and gsp2 with the adaptor primers 
supplied.
Lane M /Udindlll markers
Lane 1-5 libraries 1-5
Lane 6 negative control
Lane 7 positive control (3.9kb)
A 0.8kb band is present in lane 1 but only just visible on this figure 
A 1.5kb band is present in lane 3 but only just visible on this figure
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1 8 1 C A G A G T G G C C A A A C G T G G T T G T G C C T C C T T G T G C C T T G G G T T C T A C T T T A G T T T C T G A A T
2 4 1 C A G T T G T A C T C C T T G C T A G G G A C A G C C A G T A T C C T C A G G C C A G T T C T C T T T T G C C C A C A T
3 0 1 G T C C C T T T T T A A A T G C A C C A C C A T C A C A G T G G T G A C A A T G T G A C T T A G G G  A C A G A G C C C C
3 6 1 G T T T A T C T T G T A G G T G A C A G A A G C G C T C T G C G G C C C A G T G G A C T G C G G C T G G G G A C C C C A
4 2 1 G C A C T G A C G T C C C G T G G A C T T T T G G A A A A A G A C T T C C A A A A A G T A G C C C A C T T T A T T C A C
4 8 1 A G A G G T A A G G A T A A A A G T T T G G A A G T T G C C A C A T C T T A T T G T G T G T A T T T A G T T T C T G A T
5 4 1 T G T G A T G A G T A G C T G A G A C C C T G C C A C C G A A A G A C A A T T A . T G C A C C A A G G C T G A G T G T T G
6 0 1 G G G T G G G A G A C A G C A A A A A A C A C A T G T A A A T C A C C T T G T C T G A G A G G G T T  A T A A A T T T G G
6 6 1 G C T G C C C A G G  A T A T C T G T C C A A G G G T G G G T G C A T C T C A G A G T A A T T G A G G T A A G C A T G G A
7 2 1 G A C C T T G T G C C C T G C C A C A C T C C C C A G C T G G G G G A C A T T C T G A C A T T C T G  A C A T T G T G C C
7 8 1 T C A G C C C C C A G C C A T T G T A C C C C C T T T G G T G T G T A G T G T G G G G T G A C T C A T T T G T G T C T T
8 4 1 G T G G C A C A G G G A T A G A G C T G A C C C T G C A G A T C C A G A G C G A C A C T G G T G T C A G A G C C A C C C
9 0 1 T G A A A G A G T T C A A G G A G A G A C T G G C A G G G G A T A A G T A C C A G G C G G C C G T G C A G G C T C T C C
9 6 1 G G G A G G A G G T T G A G A G C T T C G C C T C T C T C T T C C C T C T G C C T G G C C T G C C T G A C T T C T A A A
1 0 2 1 G G A G C G G G C C C A C T C T G G A C C C A C C T G G C G C C A C A G A G G A A G C T G C C T G C C G G A G G A C C C
1 0 8 1 C C A C C T G G A G A G A T G G A T G A G C T C G T C C A A A G G G G A A C T G T T G A C A C T C G G G C C C T T T G A
1 1 4 1 G G G G G T T T C T T T T G G A C T T T T T T C A T G T T T T C T T C A C A A A T C A A A A T T T G T T T A A G T C T C
1 2 0 1 A T T G T T A G T A A T T C T G G G A C A G G T T A T T A A A G G A T T T A A A T T T G A A C C T G G C T T T C T C A C
1 2  6 1 A G C T G G A C A T A A T T C T A G G A A A A T A A A A T A C T A T G T C G C C A C T T G G T C A T A A T C A T T T A G
1 3 2 1 A T G G T G G T G T A G G G C A A A G C T G T T A G A A A G A T T G T A G C G T T T T A C T C T C C C T G G G C T T T C
1 3 8 1  C T T C C G C C T T  G C T G C A A C A . G  A G A G G A A A T G  C C C A T G T C C A  C A G C T T G T A C  A C A C T G C C C C  
1 4 4 1  C T C A C T A T C T  T G T T A T C C A
Figure 6.3 Sequence o f the products obtained using primers gspl and gsp2 in conjunction 
with the human PromoterFinder kit. The whole sequence spans from the start of the genomic 
DNA from library 2 to the end o f the gsp2 primer. The products from libraries 5 and 1 start at 
nt 87 and 670 respectively, splice acceptor sites are highlighted in red, splice donor sites in 
blue and motifs matching the branch point consensus in green. Underlined are the bases 
between which the introns are removed from the exons. The sequence o f the gsp2 primer is 
italicised.
158
PromoterFinder kit, and with internal primers INTI and INT2. The consensus sequence of 
the PCR fragments is shown in figure 6.3. Two sections of the sequence (nt 1-373, and nt 
485-849, figure 6.3) had no homology to cSHMT cDNA. The sequence nt 1-373 had a splice 
acceptor site at the 3’ end and the sequence between nt 485-849 had splice donor and 
acceptor sites (Ohshima and Gotoh, 1987). It follows that these sequences are introns. The 
5’ end of the first intron was not identified but is at least 373bp in length. The second intron 
was 364bp in length. Also included in the sequence were cSHMT exons between nt 375-484 
and from nt 850 to the end of the sequence which corresponded to cSHMT cDNA sequence 
(appendix 1) from nt 1350-1459 and from nt 1460 to the end of the gsp2 primer. The 
sequence of the exons isolated was 100% homologous to the cSHMT cDNA sequence. The 
intron-exon boundaries fell between nt 1349-1350 and nt 1459-1460 of cSHMT cDNA 
sequence (appendix 1). A search of the Genbank database with the sequence obtained from 
the 3.5kb product from library 2 with gsp2 as a primer revealed no homologies and no further 
work was performed with this clone.
6.2.2 Amplification of human cSHMT genomic DNA from the 5’ end of cSHMT 
cDNA towards promoter region
Amplification of the cSHMT gene indicated that the whole genomic sequence could not 
be amplified from the 3’ end. In addition evidence from Elsea et al., (1995) indicated that the 
cSHMT gene might cover up to 25kb of DNA. Work, therefore, focused on amplifying 
specific regions of the gene. In order to amplify upstream sequences from known cSHMT 
sequence, primers complementary to human cSHMT cDNA from nt 237-260 (pfkl) and nt 
45-70 (pfk2) were used in conjunction with the human PromoterFinder kit. After the first 
round of amplification, the expected smears were seen in all libraries. However, after the 
second round of amplification, there were no discreet bands present. An additional primer 
complementary to nt 138-62 (pfk3) was synthesised and used on the first round amplification
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products of pfkl. Again no discreet bands were produced after the second round of 
amplification.
In another attempt two further primers complementary to human cSHMT cDNA were 
synthesised namely kjc22 (nt 341-363) and kjc23 (nt 313-332) (appendix 1). The primary 
amplification with kjc22 yielded smears when the products from the libraries were visualised 
on an agarose gel. Secondary amplification with kjc23 yielded two products in each of 
libraries 1,2 and 4 (figure 6.4). The largest product was approximately lkb in library 4. This 
lkb band was subcloned into pT7blue(R) and sequenced with kjc23, ap2 and internal primers 
309int- and 22/234B6P. The sequence of the lkb fragment is shown in figure 6.5.
The sequence obtained was compared to cSHMT DNA. Nucleotides 1-1091 (figure 6.5) 
showed no homology to cSHMT cDNA but had a splice acceptor site. Sequence from nt 
1092-1159 was identical to human cSHMT cDNA (appendix 1) from nt 274-332. The intron 
identified is at least 109 lbp in length and the 5’ end of the intron has not been found.
6.2.3 Amplification of human cSHMT genomic DNA to amplify across the 
intron junction boundary at nt 1231
The variant cSHMT cDNAs identified by Xu, (1992) coded for alternatively spliced
cSHMT proteins, identifying 3 putative intron splice sites between nt 991-992, nt 1108-1109 
and nt 1231-1232 in cSHMT cDNA sequence (appendix 1). The sequences of any introns 
sequences adjacent to these potential splice sites had not been determined.
One of the primers previously synthesised for sequencing cSHMT cDNA (kjc8) was 
complementary to nt 1262-1281 cSHMT cDNA (appendix 1). Another primer, namely kjc21 
complementary to nt 1238-1256 was synthesised and kjc8 and kjc21 were used with the 
human PromoterFinder kit to amplify genomic DNA upstream of these two primers
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Figure 6.4 Agarose gel of the PCR amplification of human genomic libraries 1 to 5 of the 
human PromoterFinder kit using primers kjc22 as the first primer and kjc23 as the nested
primer.
Lane M XHindlll markers
Lanes 1-5 libraries 1-5
Lane 6 negative control
Lane 7 positive control (1.8kb)
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1 A c m m c - G G C A C G C G T G G T C G A C G G C C C G G G C T G G T C T G T T T C A C T A G A C
5 1 C T C A C C T C C A A T G A C T G A C A G A A A C T G G T T C T G G T A A A A C T C A C C C A G C A
1 0 1 T A T T C T C C T G T T C C A T A T G T G C A C G T T G A C A T T A T G A G A A C T A C A A A A A A
1 5 1 G G A C C C A A A G  A C C T G G T A A G A T C C A G A T G A A A C A T A T T T G T C A T A A T T C A
2 0 1 G T A G C A G T G T G G C T G C C C C C A A G A A A A C A A T G T A T T A . T C T T T C C T T C C T G
2 5 1 T A C A G T G A G A A T T A T G T A G T A A A C C A T G T T T C T T T T T T G C T T T G A C C T C C
3 0 1 A A G A A G G T C A G A A G C A A A T T T A C A C C T T A A T C A T A T G A A A C T T T A C A G T G
3 5 1 CTTTTTTTTC C C C C C C T T C T A G T A T A A T T T  A C T C C A T T T T G T T T T T T C C T
4 0 1 G C T A C T G A T T T T A T T T A T A T G T A A C T A G T T A A G C A T T T C T C T A G C T G G G T
4 5 1 T T C C T T T A A C A C T A C T T T T A T A T A T A T G A A T A G A T C C T T T A T G A A A A A A A
5 0 1 T T C C C T T I A A A A G G T T T T A G G G A A A T A T T G C A T A A T A A C T A T A G C C C G A C
5 5 1 A T C A T C C C C A A A A . G T C A C T T T T A T T G A A T T T T A A G G G A A T C C C A A A A A T T
6 0 1 C C A G A G A A A T T T G A A C A T G G A A C A G T T T T G T C A T G A T A T A T A T T A A T A T C
6 5 1 T T A A A A T A T A G T T T G C A A A A C A C T G T G C T T T C T T G C T T T G T G T A T T ' T T C T
7 0 1 G A T A G C C A C T T T A T A T C C T T G A G G A A A T C A G G A A A G G T A T A T T G G G G G A A
7 5 1 C C C A C C C C C A A T A T T T C A A C C T A G G T T C T T T C T A T T T T C C A T A A G T G T C G
8 0 1 G C C G G C T G A G A A A T A G A G A C A G T A C A A A G A G A G G G A T T T T A C A G G T G A T C
8 5 1 C A C C A G C C T C G G C C T C C C A A A G T G C T G G G A T T A C A G T C G T G A G C C A C C G C
9 0 1 A C C T G G C T A T C A T T T T G T T T T T G T T A A T T C A T T G A T T A G T G C T T T C T C A G
9 5 1 A T A C T A A A A C C T T T G A G G A G G A T T C A T T T T  A T T C C A T A A T G T G A A A G A G T
1 0 0 1 G T C T T T T C T C T T T A G G A G G T T G T A A T T T G G A T C A G A G C A A A A T T T T A A A C
1 0 5 1 1 A A A A T T T C C A A A T A T C A A G C A T C T G T T T T C T T C T C A T A A G G T T T A C A A C
1 1 0 1 A T C A T T A A G A A G G A G A G T A A C C G G C A G A G G T T G G A T T G G A G C T G A T T G C
Figure 6.5 Sequence of the lkb product produced by amplification of library 4 o f the human 
PromoterFinder kit with primers kjc22 and kjc23. In italics is the primer ap2 (at 5 ’ end) and 
kj c23 (at 3 ’ end). The sequence o f the genomic DNA starts at nt 47. splice acceptor motif is 
shown in red. Underlined bases indicates the intron-exon boundary'.
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Figure 6.6 Agarose gel of amplification of the human genomic libraries in the human 
PromoterFinder kit libraries with primers kjc8 and kjc21.
Lane M XHindlll markers
Lanes 1-5 libraries 1-5
Lane 6 negative control
Lane 7 positive control (0.9kb)
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1  A A A A A G C A C A  T A G C A A A A G G  A T A C A T A G A A  T A T G A T G T C A  T T T A T A G A T C  
5 1  A T A A A G A T G T  A A G A C A A T A T  T A T A A A A T A T  T T A G G G A T A C  A T T C C T A T G A  
1 0 1  A G T A A A A A A T  A T G A A G A T A T  A T T C A A C T G T  A T T G C T A A T G  G T C T A T C T C T  
1 5 1  T A A G C T G A C T  T T C A T A A A C C  T T A T A T G A A G  T T G G T C A G C T  G G G C A C A G T T  
2  0 1  A A A C A A T A T C  T C A T A A G A C T  T C T T A A T T T A  A T A A G A T G G G  A T T G T A A A A A  
2 5 1  G C A T T A G G G C  T T C C T G A T A T  G A A A A T T C C A  A A C C C T A A G G  C A G T T A G A C T  
3 0 1  A T G C A G T T C T  I A A A A C A T G A  A C A A T T G C A A  A C T T A A T T G A  C T T G A A A T T T  
3 5 1  T T T A G T T A C T  T G T C C T G G A T  G A A G A G A A T A  T G A T G A C C A T  T T C T T T T T G T  
4  0 1  T C T A T A A C T A  C T C T A C A T A A  T G A A A C C A G  .  A C A C A C C T G G  T A G G T G G C A C  
4 5 1  C A G G A C T G T G  T G G T G A T G C C  T T G G A C T G T G  C C A G G G G A G T  G T C T T C T C T C  
5 0 1  A C C C C G C T G A  G C T G G G G G T G  C A G G G G C T C T  C C C C T C C C A G  T T T C C T G C A T  
5 5 1  A T T C C T G G G G  A G T T G G C T T G  C T T T A G G C A T  G T T T G C T T G G  A T C T G T A C A T  
6 0 1  T C T G G A G C T G  A T G G G C T G T G  A A T G A G A T G G  A C T T C C C A G G  T C A G G G C C C C  
6 5 1  A C T C T G G G G T  G C C A T C C A C C  T C A C A G T C A C  T G C A G C T T T C  C A C G G A G A A C  
7  0 1  G C A T T T T T T T  G G C A G G C A G C  A T A C T C A G T C  C T C C G G A G G A  A G G G C G A C T T  
7 5 1  T A T A C C T A G T  C C C A C A A G A C  T G C C G A T T G T  G C T A G C A G T G  G T G T G G T C C A  
8 0 1  G G A A T A T G G G  T C C T G C T G T G  T G T A G A C C T G  A G T G C C C A C T  C T C T G C A C C G  
8 5 1  T G T C C T T T G C  C C T T T A C A G G  G A T T A C A G G C  C C T C T G A T C T  A A G G A T T G G G  
9 0 1  G A G G G A T T A C  A G G C C T C C T G  G T T T A A G G A G  T G G G G C T C C C  A C C C A A T C C T  
9 5 1  G C A T G T G C G G  C A G T G C C T G G  G A A G G C C G G G  C C A G T G C T G T  C T C C T C A G C A  
1 0 0 1  G T A C C A G C C G  T A C C C T C T T T  T A T G T T A T A C  T T C A C T T A C T  T T C T G T T C T C  
1 0 5 1  C C T T C A T C C T  C C A T G T C T T C  A A A T A A T A A A  G C T C A A G A A G  T C C T T G T G C A  
1 1 0 1  G A C T G T G A A A  T T C A G G G T G C  T T T A G C T C A G  G A G T C C C C A A  C C T C C G G G C C  
1 1 5 1  A C  A . C T G G T T  T G T G G T C T G T  T A G G A A C C T G  G C C G C A C A G C  A G G A A G T G A G  
1 2  0 1  C T G G G C C G A G  A G C A T T G C C A  C C T G A G C T C C  G C C T C C T G T C  A G A T C A G T G G  
1 2 5 1  C A G C A T T A G A  T T C T C A G A G G  A G C T G A A C G C  T G G T T T G A A C  T G C A C A T G T G  
1 3 0 1  A G G G A T C T A G  G T T G G G C C T A  G A C A C T T T C A  A G A A A C T A T C  T T T T T T T T C C  
1 3 5 1  T T C T G A T T A T  A C C T G C A T C C  T T A T G A G A A T  C T A A T G C C C G  A T G A T C T G A G  
1 4  0 1  G T G G A A G T T T  C A T C C C A A A A  C C A T C C C C C G  A T G C C A T C C G  T G A A A A A A C T  
1 4 5 1  G T C T T C C A G A  T A A C C A G T T C  C T G G T G C C A A  A A A G G T T G G G  G A C C A C T G C T  
1 5 0 1  T T A G G T C C C T  G T T T C T T A A A  C T T C A A T G T T  G C A C A C C A C C  C C T G G G G C T G  
1 5 5 1  T T G G G T G C A A  T G C A G A T T C T  G A C C A G G C C T  T G G G T G A T G C  T G G T C T G G G A  
1 6 0 1  G C C A C C C T T G  G A G T T G T G A G  G G T T T A G G C C  A T A G T C C C T G  T C A C C A T G G G  
1 6 5 1  C A T C T C A T G G  C A T G G G C C T G  C C C T C T C C C T  G G T G A C T G T G  T C A T T G T C A C  
1 7  0 1  T C T G C C A T C T  G A G G A C C C G A  T G C A C A T G G C  T G A A A C A G A T  A A T G C T T G C A  
1 7 5 1  A A T G C C C T C T  T T G G T G C C T G  G T G C T A T G A G  A A G C A C T A T G  T C C A G T A T C T  
1 8 0 1  T A C T T A A A C T  T C A T G A C A G C  C C T G T G A A T T  A T T G G T C T T T  T T G T T A C A A A  
1 8 5 1  T G G G C A T C T G  A G G T T T C A C A  A T G T T G A G C T  G C C T G C C T A A  A G C C A C A C G G  
1 9 0 1  C A A G T G G G T G  G G C A C A G C T G  G G G G G C T G C A  A A G C C A A G C T  G G A G C C C T A G  
1 9 5 1  C T C A C C C G C A  T C T T G A A A G G  G A T C C C C G C A  A C A C A G C T C A  G A A G C A G A G G  
2  0 0 1  C C C C A G T G C T  G T C A G C A C C C  A A G G C A C T A C  C C C A G C T T A A  T G A A G G T T C A  
2 0 5 1  A A G T G G A A G G  A T C C T C C T G T  A T G A C C T C G G  G C C A G G T C C A  G A A A A C T C T G  
2 1 0 1  T T A G C C T T G C  T G T T G T C A C C  T T A C C A C T T T  G A T A A T A C C A  T C A G C C T C A C  
2 1 5 1  A G G A T C C G G G  A A A A A C C T A C  C A C A G G C T A C  A G T G T C T G G C  A C C T A A T G T G  
2 2  0 1  C T C T G T G A A C  A T G C C C C T T A  C C C C C C A A A G  T A A A T T G A A C  T G C T G C C C A A  
2 2 5 1  T A T T C A T G C T  G C C T T C A G G G  G A G C C T T T A C  C A T C A A T G T T  A G G G A A T T G C  
2 3 0 1  C C A A G C A A C T  T G T C A G A G A A  A A C A A G C C A G  G A G C A G C C T G  A G G A A G C T G T  
2 3 5 1  C C C T T C C C C A  T G G G A G T G T C  A G G C C C T C T G  C T G T A T G A T C  A G T T A C C C C T  
2 4 0 1  T T C A A A A G T G  C T C T G T C C T T  C C T T T C A C A T  T C T T A G G C A C  G G G C A T C T T T  
2 4 5 1  T G T G G G G A T T  A G A A T C C C A G  G C C A T G T G G T  G G G G G T G C T C  A C C T T C C T G A  
2 5 0 1  C C T C A T T T G C  T T T G A C T G C C  T T C A T C C T C G  C C T T C G T T T C  T C A G A G A T T C  
2 5 5 1  C T T C A C G G C A  T A G A A T T C G C  C T G C A T T T C T  A C A T G T C C A A  C G T T G T T T C C  
2  6 0 1  A G G T G G T T C y  G A C A A C C A T T  T G A T C C T ,
kjc 21
Figure 6.7 Sequence of the products isolated from the using human PromoterFinder kit with 
primers kjc8 and kjc21. The whole sequence corresponds to the 2.6kb product from library 3, 
starting from the end of the human genomic DNA fragment. The products from libraries 2 
and 4 begin at nt 1154 and 1915 respectively. The splice acceptor site is shown in red and the 
putative branch point consensus in green. represents gaps of unknown length in the 
sequence. Underlined bases indicate the intron-exon cleavage site. Sequence of primer kjc21 
(2609-2627) is indicated.
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The products from the 5 libraries were visualised by agarose gel electrophoresis and 
staining with ethidium bromide. As figure 6.6 shows, there are products present in libraries 
2, 3, 4 and 5 after the second round of amplification. The DNA in libraries 2, 3 and 4 was 
purified from the mineral oil used in the PCR reaction and ligated into pT7blue(R) 
(Novagen). After using the ligation mixed to transform DH5a cells to ampicillin resistance, 
white colonies were grown in broth and plasmids extracted by alkaline lysis. A 700bp 
product from library 4 was isolated along with a 1.5kb product from library 2 and an 
approximately 2.5kb product from library 3. The products were sequenced initially with 
kjc21 to check for homology to cSHMT cDNA and to rule out presence of the cSHMT 
pseudogene. Further sequencing was performed with primer ap2 and internal primers, INT3, 
8/2124N, and 8/2124P. Sequencing with these primers left two small gaps in the sequence 
estimated to be no more than lOObp. The sequence is shown in figure 6.7 was compared to 
cSHMT cDNA. Sequence from nt 1-2603 of the clone showed no homology to cSHMT 
DNA. Sequence from nt 2603-2627 (figure 6.7) was identical to cSHMT sequence between 
nt 1232-1256 (appendix 1). At the junction between non-homologous and homologous 
sequence there is a motif matching the consensus for a splice acceptor (Ohshima and Gotoh, 
1987). There 5’ end of the intron is unknown but the intron is at least 2062bp long.
6.2.4 Amplification of the intron present between nt 696-697 of cSHMT cDNA
A human cDNA (pUS1206) had previously been isolated containing 850bp of sequence
with no homology to cSHMT cDNA followed by sequence from nt 697 of cSHMT(appendix 
1) (Byrne, 1992). At the junction between the two sequences was a consensus sequence for a 
splice acceptor site. Amplification of human genomic DNA (Promega) was performed using 
Expand Long Template DNA polymerase (Boehringer Mannheim) using primer pairs kjc9 
and kjcl6 or kjc20 and kjcl6 which had previously been synthesised for sequencing cSHMT
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cDNA. These primer pairs were situated in the cDNA either side of the site where the intron 
was inserted between nt 696-697 (appendix 1). Using PCR reaction buffer 2 several bands 
were produced for each PCR reaction (figure 6.8). Amplification with kjc9 and kjcl6 yielded 
a strong band at 267bp corresponding to amplification of the pseudogene. Other discreet 
bands ranged from 1.8kb to approximately 9kb. Amplification of human genomic DNA with 
kjc20 and kjcl6 yielded bands between 2kb and approximately 9kb (figure 6.8). A fragment 
corresponding to the pseudogene was not observed which was not unexpected as this product 
would have only been 75bp. DNA from the amplification reactions was transferred to a nylon 
membrane by Southern blotting and hybridised with the DIG labeled intron sequence from 
pUS 1206. It was found that the DNA hybridising to the intron probe corresponded to 8.0kb 
for kjc9/kjcl6 and 6.8kb for kjc20/kjcl6 primer pairs respectively (figure 6.8). Further PCR 
amplification of human genomic DNA using primers kjc9 and kjcl6 and reaction buffer 3 
yielded a single 8kb band. Initial attempts to subclone the 8kb band into pT7blue(R) failed 
and no sequence data is available.
6.3 Discussion
All of the intron location data obtained in these experiments was added to figure 6.1 to 
form figure 6.9.
Sequences which had homology to human cSHMT cDNA were amplified by PCR using 
the human PromoterFinder kit. The two introns isolated by amplification with gspl and gsp2 
(introns 9 and 10, figure 6.9) had not been previously identified by isolation of alternatively 
or incompletely spliced cDNAs. However, a PCR reaction performed using primers derived 
from the cSHMT cDNA sequence yielded a 660bp product instead of the expected 270bp 
(Elsea et al., 1995). Analysis of the PCR primers used by these researchers indicates that the 
primers were located either side of the second of the introns identified (intron 10).
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Figure 6.8 Agarose gel of PCR products from human genomic DNA amplified using 
kjc9/kjcl6 and kjc20/kjcl6 primer pairs. A second gel was run with these samples and DIG 
labelled DNA size markers, blotted and hybridised with a DIG labeled probe containing human 
cSHMT intron sequence from pUS1206.
Lane M XHindlll markers
Lane L (j)X 114Haelll markers
Lane 1 amplification with primers kjc9 and kjcl6
Lane 2 amplification with primers kjc20 and kjcl6
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Figure 6.9 Illustration of the sequences isolated in this chapter in relation to human cSFIMT 
cDNA and the putative intron boundaries illustrated in figure 6.1 Highlighted in red are the 
intron sites confirmed in this study.
Intron 2a was isolated using primers kj c22 and kj c23 with the human PromotrFinder kit 
Intron 8 was isolated using primers lg c8 and lg c 2 1 with the human PromoterFinder kit 
Introns 9 and 10 were isolated using primers gsp 1 and gsp2 with the human PromoterFinder 
kit
Intron 5 was identified by amplification of human genomic DNA with lg c20 and lg c 16
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human cSHMT cDNA
Figure 6.10 Illustration of the human genomic DNA sequences isolated compared to human 
cSHMT cDNA. Indicated in black are the introns identified and sequenced. Marked on the 
cDNA sequence are the positions of the intron boundaries confirmed in this study.
1
kjc22/kjc23 gsp1/gsp2
kjc8/kjc21
Scale 250bp
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Approximately 170bp of cDNA sequence at the 3’ end of the cSHMT cDNA downstream of 
gsp2 remains uncloned.
The amplification of the libraries in the human PromoterFinder kit using primers kjc22 
and kjc23 did not result in the isolation of a promoter sequence. Another intron was 
identified (intron 2a, figure 6.9) which was not predicted by the cSHMT cDNAs isolated to 
date. In order to isolate the promoter, further PCR reactions need to be performed, perhaps 
using sequence from the 5’ end of the intron identified here as a template.
Other attempts to isolate the promoter region using primers pfkl to pfk3 indicated the 
limitations of the nested PCR method used. From the estimation of the length of the human 
cSHMT gene spanning 25kb (Elsea et al., 1995) and evidence from the introns isolated here, 
it is possible that some of the introns within the human cSHMT gene are several kilobases 
long. It is also possible, therefore that there are restriction sites in these introns that match 
those used to generate the libraries provided in the human PromoterFinder kit. If there is a 
long intron between the sites of the nested gene specific primers then the first PCR reaction 
product may not be of sufficient length to include the binding site for the primer used in the 
second round of amplification and no products will be seen. It is proposed that this is the 
reason that the reactions using primers pfkl to pfk3 failed.
Using primers kjc8 and kjc21 yielded products in the libraries of the human 
PromoterFinder kit. Sequencing of these products showed that the intron site (intron 8) 
predicted by the alternatively spliced cSHMT cDNAs isolated by Xu, (1992) was genuine. 
The length of the intron meant analysis of further splice sites predicted from the alternatively 
spliced cSHMT cDNAs was not possible in this particular experiment. Only one strand of 
DNA has been sequenced in all the human PromoterFinder kit isolates. In order to confirm 
the sequence is genuine, the other strand should be sequenced.
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PCR amplification using primers kjc20 and kjcl6 followed by Southern blotting produced 
a band of 6.8kb which hybridised to the intron sequence isolated by Byrne, (1992). If this 
primer pair was used on the cSHMT cDNA, a product of 75bp would be produced. It follows 
that the intron previously identified is approximately 6.7kb in length. The primer kjc9 is a 
further 193bp upstream of kjc20 but the differences in size between the products produced in 
PCR reactions using kjc9/kjcl6 and kjc20/kjcl6 is nearer to 1.2kb in size. Therefore, it is 
likely there is at least one more intron present relative to the cSHMT cDNA sequence 
between nt 483 (the start of primer kjc9) and nt 675 (appendix 1). The potential location of 
one intron (intron 4) were identified from incompletely spliced cSHMT cDNAs (Byrne, 
personal communication) in this region of cDNA (figure 6.9). Further work needs to be 
performed to characterise the PCR products obtained and to determine whether intron 4 has 
also been isolated.
The subcloning of PCR products into the pT7blue(R) vector relies on the fact that a single 
overhanging adenine nucleotide is added to each end of the PCR product by the DNA 
polymerase. In fact the overhanging nucleotide is not always an adenine and the nucleotide 
added depends on the preceding nucleotide (Hu, 1993). Sanchez et al., (1996) demonstrated 
with primers beginning with one of the four nucleotides that the success of cloning into 
vectors with T overhangs depended on the base at the 5’ end of the PCR primers. The 
descending order of efficiency was A,T,G,C. Primer kjc9 starts with a G and kjc20 starts 
with a T. Therefore, the overhanging nucleotides added to this PCR product may not be 
adenine and pT7blue(R) may not be suitable for the insertion of this particular PCR product. 
An alternative strategy for cloning the PCR product would be to remove the overhanging 
nucleotides and ligate into Smal digested pUC18.
All sequences determined here were used to search the Genbank and EMBL databases 
against other human DNA sequences. No significant homologies were found other than to
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human cSHMT. The sequences were also searched for direct and inverted repeats. A direct 
repeat where 29 out of 34 basepairs matched was found in the product isolated using kjc8 and 
kjc21 (figure 6.7) between nt 868-901 and 902-935. This direct repeat is present in the intron 
'intron 8) which is present 3’ to two exons which may be alternatively spliced. An intron at the same 
site has been identified in the human mSHMT gene (Stover et al., 1995). The intron in the 
mSHMT gene is only 87bp and there is no evidence to date for alternative splicing in 
mSHMT at this point. Therefore, it is possible that the length of this intron in the cSHMT 
gene and repeat sequences within it may play a role in the selection of alternatively spliced 
exons. No repeat sequences were found in the other introns isolated.
Holland and Blake, (1987) proposed that introns are ancient pieces of DNA which enabled 
the shuffling of exons to form functional proteins. The introns were then lost in prokaryotes 
and in eukaryotes can be retained, lost, or the splice sites may drift, due to mutation. Craik et 
al., (1982) postulated that the drifting of intron boundaries may have evolutionary advantages 
in that it may generate functional differences in the same protein family. The gene encoding 
human mSHMT has been published (Stover et al., 1995). Comparing the mSHMT gene to 
the known and potential intron splice sites in the cSHMT gene, many of the splice sites either 
match exactly or are within 25bp of each other. As yet some of the mSHMT splice sites have 
no known equivalents in the cSHMT gene as some areas of the latter have still to be 
characterised. By comparing the introns found in this study with the mSHMT gene it is found 
that the introns at nt 1231-2 of cSHMT cDNA (intron 8) is matched in the mSHMT gene but 
the intron found at nt 273-4, 1348-1349 and 1459-60 (appendix 1) (introns 2a, 9 and 10) do 
not have equivalents in the mSHMT gene. Conversely, there is an intron boundary in the 3’ 
end of the coding sequence of the mSHMT gene which is not present in the cSHMT gene. 
The intron boundaries in the N.crassa gene (McClung et al., 1992) are not conserved in the 
human mSHMT gene. There is not enough information to say whether this is also the case
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for the cSHMT gene. The drifting of some intron junctions when comparing cSHMT and 
mSHMT genes may account for the functional differences between the two proteins which 
lead to the mSHMT protein having a higher affinity for glycine than the cSHMT isozyme 
(Schirch and Peterson, 1980). Only determination of the tertiary and quaternary protein 
structures of the SHMT isozymes and the full characterisation of the cSHMT gene will 
determine whether this hypothesis is correct.
In conclusion, the work described here has gone someway to determining the structure of 
the SHMT gene. Some intron boundaries suggested by incompletely spliced and alternatively 
spliced cSHMT cDNAs have been confirmed as genuine. The complete sequence of the 
cSHMT gene still has to be determined.
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CHAPTER 7
CONCLUDING REMARKS AND FURTHER STUDIES
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7.1 Concluding remarks and further study
The expression of human and rabbit cSHMT in E.coli described here has made it possible
to rapidly generate large quantities of highly pure cSHMT. Work is in progress at the 
Institute of Cancer Research to determine the structure of human cSHMT by X-ray 
crystallography and to screen folate analogues for cSHMT inhibition. An alternative to using 
protein crystals to generate a tertiary and quaternary structure is to use NMR. The addition of 
label to the protein for NMR analysis is much simpler and cheaper when the protein is 
expressed in E.coli as only one labeled nutrient has to be added to the medium instead of 
many labeled amino acids that need to be added to animal cell cultures. Therefore, the 
expression system described here could be used for NMR studies as well.
There are two potential phosphorylation sites (at amino acids 38-41 and 158-161, 
appendix 1). Now that large quantities of pure human cSHMT are available, studies can be 
performed to see whether these sites can be phosphorylated and the role that any 
phosphorylation may play on the SHMT activity. Site directed mutagenesis of the potential 
phosphorylation sites may also aid these studies.
Some residues have been identified by chemical modification as being important for 
SHMT activity, although in some cases a more likely cause of inhibition was steric hindrance 
preventing substrates binding. Work performed here using site directed mutagenesis shows 
that this is the case for iodoacetate inactivation of cSHMT activity as performing the mutation 
C204A did not significantly alter SHMT activity.
Now that site directed mutagenesis has been shown to be a valuable tool for determining 
whether amino acids implicated in SHMT activity by chemical modification really are 
important, other potential sites for site directed mutagenesis would be other amino acids 
implicated in SHMT activity by chemical modification. For example, R270 is implicated in
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THF binding (Usha et al., 1992). Another potential area of research would be the site 
directed mutagenesis of amino acids conserved in all SHMT protein sequences (appendix 2). 
The structures of mutants created by site directed mutagenesis could also be ascertained to 
help determine the residues required for substrate binding and catalysis.
A pseudogene, previously undetected by in situ hybridisation (Garrow et al., 1993) has 
been characterised and found to be located on chromosome lp32-33. Several other genes 
have been identified within this region of chromosome 1 which may contribute to breast 
cancer (J. Shipley, personal communication). Further study of this region of chromosome 1 is 
required to isolate the genes within this area of the genome.
The lowest estimated age of the cSHMT pseudogene is 7.7MY so it would be interesting 
to see whether the pseudogene is also present in monkeys as the divergence of monkeys and 
humans occurred after this date.
Human genomic DNA has been isolated which encodes cSHMT gene. Further work 
needs to be performed to further characterise the gene and its promoter region. Probing of a 
human genomic DNA library with human cSHMT cDNA led to the isolation of only the 
pseudogene. As the pseudogene does not contain any introns, then a combination of cSHMT 
intron and exon sequences could be used to isolate the cSHMT gene from a genomic library 
in bacteriophage lambda or in cosmids. As the cSHMT gene fragments isolated here contain 
both intron and exon sequence, these sequences could be used as the probes.
Alternatively, as the cSHMT gene is predicted to be 25kb (Elsea et al., 1995), the 
promoter alone could be isolated using the human PromoterFinder kit and used in conjunction 
with reporter genes such as Green Fluorescent Protein, which allows the real time study of 
expression in cells, to determine how the cSHMT gene is regulated. It has recently been 
suggested that cSHMT may be regulated by retinoic acid (Nakshatri et al., 1996). It would be
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interesting to determine whether there are any potential binding sites for retinoic acid 
dependent transcription factors present in the cSHMT gene promoter.
Isolation of the complete SHMT sequence would also allow the construction of a SHMT 
minigene. This minigene would consist of all the exons and the 5’ and 3’ sequences. Introns 
can then be added to determine whether any particular introns affect transcription. This 
technique was used on the human thymidylate synthase gene by Deng et a l ,  (1989) and 
several introns were found to affect transcription. It was also found that intron 1 of the 
thymidylate synthase gene was required for cell cycle dependent expression (Takayanagi et 
a l,  1992).
Mitochondrial SHMT genomic and cDNA sequences have been identified (Garrow et al., 
1993; Stover et al., 1995, Whitehouse, 1996). These sequences could be used in conjunction 
with cSHMT sequences to probe for SHMT RNA in tissues by in situ hybridisation. This 
would be of particular use in brain tissue to determine the potential role of SHMT in
schizophrenia. Further information will arise from the development and characterisation of
mice genetically engineered for transgenic expression or null expression of different SHMT
isozymes (Thomas and Capecchi, 1987, Gu et al., 1994).
It is critical for understanding the diseases in which SHMT has been implicated to
determine the contribution to human physiology of the individual SHMT isozymes and their
regulation. The work presented in this thesis has increased knowledge of the gene and
protein structures of cSHMT and the foundations have been laid to enable characterisation of
the precise role that SHMT plays in mammalian metabolism.
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APPENDICES
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Appendix 1 DNA and Protein sequence of human cytosolic SHMT cDNA. Highlighted in 
red is the asparagine residue changed to aspartic acid by the mutation generated in the PCR of 
the cSHMT orf. Highlighted in green are the amino acids changed by site directed 
mutagenesis. Underlined are the nucleotides between which introns have been isolated in the 
human cSHMT gene.
1
61
121
1 8 1
2 4 1
3 0 1
3 6 1
4 2 1
4 8 1
5 4 1
6 0 1
6 6 1
7 2 1
7 8 1
8 4 1
9 0 1
9 6 1
1021
1 0 8 1
1 1 4 1
1201
1 2 6 1
1 3 3 1
1 3 8 1
1 4 4 1
1 5 0 1
1 5 6 1
1 6 2 1
1 6 8 1
1 7 4 1
1 8 0 1
1 8 6 1
1 9 2 1
1 9 8 1
2 0 4 1
2101
2 1 6 1
2221
2 2 8 1
2 3 4 1
2 4 0 1
2 4 6 1
TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTAGGTTTG GGGTTGGAGC
GGCTGGTCAC GTGGCTGGCC CGCGGCGGTG CGCGGCGTTG GGTCAGCGGG TCTGGGACTG
GTGGCACCGG CGGCGGCGTA GGACGGAGGC GTCGCTAGGC AGCTTCGAAC CAGTGCAATGrjr 1
ACGATGCCAG TCAACGGGGC CCACAAGGAT GCTGACCTGT GGTCCTCACA
ri
TGACAAGATG
1
T M P V N G A H K D A  D L W S S H D K M 2 1
CTGGCACAAC CCCTCAAAGA CAGTGATGTT GAGGTTTACA ACATCATTAA GAAGGAGAGT
L A  Q P L K D S D V E V  Y N I  I  K K E S 4 1
AACCGGGAGA GGGTTGGATT GGAGCTGATT GCCTCGGAGA ATTTCGCCAG CCGAGCAGTT
N R Q R V  G L E L I A  S  E N F A S R A  V 61
TTGGAGGCCC TAGGCTCTTG CTTAAATAAC AAATACTCTG AGGGGTACCC GGGCCAGAGA
L E A L G S C L N N K Y S E G Y P G Q R 8 1
TACTATGGCG GGACTGAGTT TATTGATGAA CTGGAGACCC TCTGTCAGAA GCGAGCCCTG
Y Y G G T E F I D E L E T L C Q K R A  L 1 0 1
CAGGCCTATA AGCTGGACCC ACAGTGCTGG GGCGTCAACG TCCAGCCCTA CTCAGGCTCC
Q A  Y K L D P Q C W G V N V Q P Y S G S 1 2 1
CCTGCAAACT TTGCTGTG3A CACTGCCCTG GTGGAACCCC ATGGGCGCAT CATGGGCCTG
P A  N F A  V  Y T A  L V E P H G R I M G L 1 4 1
GACCTTCCGG ATGGGGGCCA CCTGACCCAT GGGTTCATGA CAGACAAGAA GAAAATCTCT
D L P D G G H L T H G F M T D K K K I  S 1 6 1
GCCACGTCCA TCTTCTTTGA ATCTATGCCC TACAAGGTGA ACCCAGATAC TGGCTACATC
A  T S I F  F  E S M P Y K V  N P D T G Y I 1 8 1
AACTATGACC AGCTGGAGGA GAACGCACGC CTCTTCCACC CGAAGCTGAT CATCGCAGGA
N Y D Q L E E N A  R L F H P K L I I  A  G 2 0 1
ACCAGCTGCT ACTCCCGAAA CCTGGAATAT GCCCGGCTAC GGAAGATTGC AGATGAGAAC
T S C Y S R N L E Y A  R L R K I  A D E N 2 2 1
GGGGCGTATC TCATGGCGGA CATGGCTCAC ATCAGCGGGC TGGTGGCGGC TGGCGTGGTG
G A  Y L M A D M A H I  S G L V  A  A G V  V 2 4 1
CCCTCCCCAT TTGAACACTG CCATGTGGTG ACCACCACCA CTCACAAGAC CCTGCGAGGC
P S  P F E H C H V  V T T T T H K T L R G 2 6 1
TGCCGAGCTG GCATGATCTT CTACAGGAAA GGAGTGAAAA GTGTGGATCC CAAGACTGGC
C R A G M I  F Y R K G V K S V  D P K T G 2 8 1
AAAGAGATTC TGIACAACCT GGAGTCTCTT ATCAATTCTG CTGTGTTCCC TGGCCTGCAG
K E I  L Y N L E S L I  N S A V F P G L Q 3 0 1
GGAGGTCCCC ACAACCACGC CATTGCTGGG GTTGCTGTGG CACTGAAGCA AGCTATGACT
G G P H N H A I  A  G V  A  V A L K Q A  M T 3 2 1
CTGGAATTTA AAGTTTATCA ACACCAGGTG GTGGCCAACT GCAGGGCTCT GTCTGAGGCC
L E F K V  Y Q H Q V V  A  N C R A  L S E A 3 4 1
CTGACGGAGC TGGGCTACAA AATAGTCACA GGTGGTTCTG ACAACCATTT GATCCTTGTG
L T E L G Y K I  V T G G S  D N H L I  L V 3 6 1
GATCTCCGTT CCAAAGGCAC AGATGGTGGA AGGGCTGAGA AGGTGCTAGA AGCCTGTTCT
D L R S K G T D G G R A  E K V  L E A C S 3 8 1
ATTGCCTGCA ACAAGAACAC CTGTCCAGGT GACAGAAGCG CTCTGCGGCC CAGTGGACTG
I  A  C N K N T C P G D R S A L R P S G L 4 0 1
CGGCTGGGGA CCCCAGCACT GACGTCCCGT GGACTTTTGG AAAAAGACTT CCAAAAAGTA
R L G T P A L T S R G L L E K D F Q K V 4 2 1
GCCCACTTTA TTCACAGAGG GATAGAGCTG ACCCTGCAGA TCCAGAGCGA CACTGGTGTC
A  H F I H R G I  E L T L Q I Q S D T G V 4 4 1
AGAGCCACCC TGAAAGAGTT CAAGGAGAGA CTGGCAGGGG ATAAGTACCA GGCGGCCGTG
R A  T L K E F K E R L A  G D K Y Q A A V 4 6 1
CAGGCTCTCC GGGAGGAGGT TGAGAGCTTC GCCTCTCTCT TCCCTCTGCC TGGCCTGCCT
Q A  L R E E V E S  F A  S L F P L P G L P 4 8 1
GACTTCTAAA GGAGCGGGCC CACTCTGGAC CCACCTGGCG CCACAGAGGA AGCTGCCTGC
D F * 4 8 3
CGGAGGACCC CCACCTGGAG AGATGGATGA GCTCGTCCAA AGGGGAACTG TTGACACTCG
GGCCCTTTGA GGGGGTTTCT TTTGGACTTT TTTCATGTTT TCTTCACAAA TCAAAATTTG
TTTAAGTCTC ATTGTTAGTA ATTCTGGGAC AGGT1ATTAA AGGATTTAAA TTTGAACCTG
GCTTTCTCAC AGCTGGACAT AATTCTAGGA AAATAAAATA CmTGTCGCC ACTTGGTCAT
AATCATTTAG ATGGTGGTGT AGGGCAAAGC TGTTAGAAAG ATTGTAGCGT TTTACTCTCC
CTGGGCTTTC CTTCCGCCTT GCTGCAACAG AGAGGAAATG CCCATGTCCA CAGCTTGTAC
ACACTGCCCC CTCACTATCT TGTmTCCAG TGGCATGCCA AAGGAGAACT GAATIAGCTT
CTGAGGCTTC TGCTGTAAAT CAGAAGTGTA TGTTAGTCAA GAGTAAACAA GATGCACCAG
1ATGGTGGGA GGGTTGCTGT CAGTAGCTCA AAGTATGGTG TAGAAATGGC CTCCTCCCTC
CATCCTGGGA AGTCCCAGTC CCATCCTGGT GTGAGAATCA ACCAGGCTTT CCTGCTCCAC
CTGAGATAAC CAACTCCCTC CCG3AATCAG GAAGCCAAAT GTCACCTTCC CAAAGAAATT
TTATTTTCAC GTAGCTGAAG TGCAAAACAT AGATGACCAT TTTTAATAAG CACAATCAAA 
TTTTTAACCA CAGAATGTCT ACAAGAATTA TAGCTTTAAA AAATACAACC AATTTTTATA 
TTTCAAAAAT ATTTGAACTC AAATAAATTA ATTTCTTAAA AAGTAAAAAA AAAAAA
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Organism SwissProt
accession
number
Reference
Neurosporra crassa cytosolic P34898 McClung et al.,( 1992)
Saccharomyces cerevisae 
cytosolic
P37291 McNeil etal., (1994)
Schizzosaccharomyces pombe 
cytosolic
Q10104 Connor et al., (1995)
Flaveria pringlei mitochondrial P49357 Kopriva and Bauwe, (1993)
Flaveria pringlei mitochondrial P49358 Kopriva and Bauwe, (1993)
Pisum sativum mitochondrial P34899 Turner et a l, (1992)
Solanum tuberosum 
mitochondrial
P50433 Kopriva and Bauwe, (1995)
Homo sapiens mitochondrial P34897 Garrow etal., (1993)
Oryctolagus cuniculus 
mitochondrial
P14519 Martini etal., (1989)
Homo sapiens cytosolic P34896 Garrow etal., (1993)
Mus muris cytosolic P50431 Nackshatri et al., (1996)
Orytolagus cuniculus cytosolic P07511 Martini et al., (1987)
Ovis aries cytosolic P35623 Usha etal., (1994)
Caenorhabditis elegans cytosolic P50432 Du, (1994)
Saccharomyces cerevisiae 
mitochondrial
P37292 McNeil etal., (1994)
Escherichia coli P00477 Plamannetal., (1983)
Salmonella typhimurium P06192 Steiertetal., (1990b)
Actinobacillus
actinomycetemcomitans
P34894 Brogan and Demuth, (1993)
Haemophilus influenzae P43844 Fleischmann et al., (1995)
Bradyrhizobium japonicum P24060 Rossbach and Hennecke, 
(1991)
Methylbacterium extorquens P50435 Chistoserdova and Lidstrom, 
(1994)
Hyphomicrobium methylovorum P34895 Miyataetal., (1993)
Bacillus subtilis P39148 Glaser and Danchin, (1994)
Campylobacter jejuni P24531 Chan and Bingham, (1988)
Mycoplasma genitalium P47634 Fraser etal., (1995)
Corynebacterium sp P50434 Chlumsky etal., (1995)
Methanobacterium
thermoautotrophicum
P50436 Vaupel et a l, (1996)
Appendix 2 Protein sequences for SHMT proteins in the SWISSPROT database. These 
protein sequences were used to produce the alignment overleaf using PELEUP and PRETTY 
from the GCG suite of programs (Genetics Computer Group). In the alignment residues 
marked with a * are conserved in all SHMT protein sequences, f  a re W1 5 , W l l l , N 1 8 2  and 
C204 residues mentioned in the text.
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VLDAAGSVLT
VMEAQGSVLT
VMEVMGSILT
ILAVTGSVLT
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01
NKYSEGLPGA
NKYSEGYPGA
NKYSEGYPGA
NKYSEGYPGA
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NKYSEGYPGA
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NKYSEGYPGK
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NKYSEGYPGQ
NKYSEGYPGQ
NKYSEGYPGQ
NKYSEGYPGQ
NKYSEGYPGA
NKYSEGYPGE
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NKYAEGYPGK
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LELYGLDPAK 
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KELFGADYA. 
KELFGADYV. 
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KKLFGAGFA. 
KRLFGCGFA. 
KKLFNCEFA. 
KEIFGAEHV. 
KKLFNCKFA. 
KTLFGAQWA.
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WGVNVQCLSG 
WGVNVQTLSG 
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shmt.msf{GLYC_NEUCR} SPANLQVYQA IMPVHGRLMG LDLPHGGHLS HGY.QTPQRK ISAVSTY.FE
shmt.msf{GLYC_YEAST} SPANLQVYQA IMKPHERLMG LYLPDGGHLS HGY.ATENRK ISAVSTY.FE
shmt.msf{GLYC_SCHPO} SPANLQAYQA VMKPHDRLMG LDLPHGGHLS HGF.STPQKA ISAVSTY.FS
shmt.msf{GLYM_FLAPR> SPANFHVYTA LLKAHDRIMA LDLPHGGHLS HGY.QTDTKK ISAVSIF.FE
Shmt.msf{GLYN_FLAPR} SPANFHVYTA LLKAHDRIMA LDLPHGGHLS HGY.QTDTKK ISAVSIF.FE
shmt.msf{GLYM_PEA} SPSNFQVYTA LLKPHDRIMA LDLPHGGHLS HGY.QTDTKK ISAVSIF.FE
shmt.msf{GLYM_SOLTU} SPANFQVYTA LLKPHERIMA LDLPHGGHLS HGY.QTDTKK ISAVSIF.FE
Shmt.msf{GLYM_HUMAN} SPANLAVYTA LLQPHDRIMG LDLPDGGHLT HGY.MSDVKR ISATSIF.FE
shmt.msf{GLYM_RABIT} SPANLAAYTA LLQPHDRIMG LDLPDGGHLT HGY.MSDVKR VSATSIF.FE
Shmt.msf{GLYC_HUMAN} SPANFAVYTA LVEPHGRIMG LDLPDGGHLT HGF.MTDKKK ISATSIF.FE
Shmt.msf{GLYC_MOUSE} SPANFAVYTA LVEPHGRIMG LDLPDGGHLT HGF.MTDKKK ISATSIF.FE
shmt.msf{GLYC_RABIT} SPANFAVYTA LVEPHGRIMG LDLPDGGHLT HGF.MTDKKK ISATSIF.FE
shmt.msf{GLYC_SHEEP} SPANFAVYTA LVEPHGRIMG LDLPDGGHLT HGF.MTDKKK ISATSIF.FE
shmt.msf{GLYC_CAEEL} SPANFAVYTA IVGSNGRIMG LDLPDGGHLT HGF.FTPARK VSATSEF.FQ
Shmt.msf{GLYM_YEAST} APANLYVYSA IMNVGERLMG LDLPDGGHLS HGYQLKSGTP ISFISKY.FQ
shmt.msf{GLYA_ECOLI} SQANFAVYTA LLEPGDTVLG MNLAHGGHLT HG.............SP VNFSGKL.YN
Shmt.msf{GLYA_SALTY} SQANFAVYTA LLQPGDTVLG MNLAQGGHLT HG.............SP VNFSGKL.YN
shmt.msf{GLYA_ACTAC} SQANAAVYMG LLNPGDTILG MSLAHGGHLT HG AS VSFSGKI.YH
Shmt.msf{GLYA_HAEIN} SQANAAVYGA LINAGDTILG MDLAHGGHLT HG............AK VSFSGKI.YN
shmt.msf{GLYA_BRAJA} SQMNQAVFLA LLQPGDTFMG LDLAAGGHLT HG SP VNMSGKW.FK
shmt.msf{GLYA_METEX} SQANQGVFMA LMQPGDTFLG LDLAAGGHLT HG............AP PNVSGKW.FK
Shmt.msf{GLYA_HYPME} SQANQGVFNA LAQPGDTILG LSLAAGGHLT HG............AP VNQSGKW.FK
shmt.msf{GLYA_BACSU} AQANMAVYFT ILEQGDTVLG MNLSHGGHLT HG.............SP VNFSGVQ.YN
shmt.msf{GLYA_CAMJE} SQANQGVYAA LINPGDKILG MDLSHGGHLT HG............AK VSSSGKM.YE
shmt.msf{GLYA_MYCGE} SSANYAVYLA LLKPGDTILG LDLNCGGHLT HG SP VNFSGKQ.YQ
shmt.ms f{GLYA_CORSP} ...............................................................................................................................
shmt.msf{GLYA_METTH} WANLACFFA TADVGDPMMA MEVPYGGHIS HA...............K VSAAGVRGFK
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ICGFSNYSRT
VAGWSAYPRQ
LFGGSLFLFP
IDYERMRKIA 
IDYKRMREIA 
VDYKRMRKIT 
YDYARIRKVC 
YDYARIRKVC 
YDYARIRKVC 
YDYDRIRKVC 
IDYARMREVC 
IDYARMREVC 
LEYARLRKIA  
LDYARLRKIA 
LDYGRLRKIA 
LDYARLRKIA 
LDYERFRKIA  
IDYARFKEIS  
VDWAKMREIA 
VDWAKMREIA 
VDWKKMREIA 
VDWAKMREIA 
WDFKRFREIA 
WDFAKFREIA 
IDFAAFRAIA  
IDFKKFREIA  
IDFAKFREIA  
VDFKKFSAIA  
LDFVRFREIA  
HPVEEAVEAA
2 5 1 ^300
shmt.ms f{GLYC_NEUCR} 
shmt.ms f{GLYC_YEAST} 
shmt.ms f{GLYC_SCHPO} 
shmt.ms f{GLYM_FLAPR} 
shmt.ms f{GLYN_FLAPR} 
shmt. ms f { GLYM_PEA} 
shmt.ms f{GLYM_SOLTU} 
shmt.ms f{GLYM_HUMAN} 
shmt.ms f{GLYM_RABIT} 
shmt. ms f { GLYC_HUMAN } 
shmt.ms f{GLYC_MOUSE} 
shmt.ms f{GLYC_RABIT > 
shmt.ms f{GLYC_SHEEP} 
shmt.ms f{GLYC_CAEEL} 
shmt.ms f{GLYM_YEAST} 
shmt.ms f{GLYA_ECOLI} 
shmt.ms f{GLYA_SALTY} 
shmt.ms f{GLYA_ACTAC} 
shmt.ms f{GLYA_HAEIN} 
shmt.ms f{GLYA_BRAJA} 
shmt.ms f{GLYA_METEX} 
shmt.ms f{GLYA_HYPME} 
shmt.ms f{GLYA_BACSU} 
shmt.ms f{GLYA_CAMJE} 
shmt.ms f{GLYA_MYCGE} 
shmt.ms f{GLYA_CORSP} 
shmt.ms f{GLYA_METTH}
DSVGAYLWD
DKCGAYLMVD
EMCNAYLLCD
DKQKAIMLAD
DKQKAILLAD
DKQKAVLLAD
NKQKAILLAD
DEVKAHLLAD
DEVKAHLLAD
DENGAYLMAD
DDNGAYLMAD
DENGAYLMAD
DDNGAYLMAD
TKAGAYLMSD
QGCGAYLMSD
DSIGAYLFVD
DSIGAYLFVD
DEVGAYLFVD
DEVGAYLFVD
DSVGAYLLVD
DSVGAYFFVD
DEVGAIFLVD
DEVGAYFMVD
DEVGAYLFAD
KQVNAYLLAD
DKVGAYLFVD
EEVGARIMYD
MAHISGLIAS
MAHISGLIAA
MAHISGLVAA
MAHISGLVAA
MAHISGLVAA
MAHISGLVAA
MAHISGLVAA
MAHISGLVAA
MAHISGLVAA
MAHISGLVAA
MAHISGLVAA
MAHISGLWA
MAHISGLVAA
MAHISGLVAA
MAHISGLVAA
MAHVAGLVAA
MAHVAGLIAA
MAHVAGLVAA
MAHVAGLIAA
MAHFAGLVAG
MAHFAGLVAA
MAHFAGLVAA
MAHIAGLVAA
IAH IAG LW A
IAH IAGFIAA
MAHFAGLVAT
GAHVLGLIAG
E V IP S P F . LY 
G V IP S P F . EY 
G V IP S P F .E Y  
G V IP S P F . DY 
G V IP S P F . DY 
G V IP S P F . DY 
G V IP SP F .D Y  
K V IP S P F . KH 
K V IPSP F.K H  
G W P S P F . EH 
G W P S P F . EH 
G W P S P F . EH 
G W P S P F . EH 
G L IP S P F . EY 
N W P S P F . EH 
GVYPNPV. PH 
GVYPNPV. PH 
G IY PN PL .PY  
GLYPNPL. PH 
GVHASPV.PY  
G LH PSPF. PH 
G L IP S P F .P H  
GLHPNPV.PY  
G EH PSPF. PH 
GLHQNPL. PF 
GLHPSPV.PH  
GYFQDPLREG
ADWTTTTHK
ADIVTTTTHK
ADIVTTTTHK
ADWTTTTHK
ADWTTTTHK
ADWTTTTHK
ADWTTTTHK
ADIVTTTTHK
ADWTTTTHK
CHWTTTTHK
CHWTTTTHK
CHWTTTTHK
CHWSTTTHK
SDWTTTTHK
SDIVTTTTHK
AHWTTTTHK
AHWTTTTHK
AHWTTTTHK
AHWTTTTHK
AHVTTTTTHK
AHVATTTTHK
AHWTTTTHK
ADFVTTTTHK
AHW SSTTHK
VDWTSTTHK
AHWTSTTHK
ADMLVGSTHK
SLRGPRGAMI
SLRGPRGAMI
SLRGPRGAMI
SLRGPRGAMI
SLRGPRGAMI
SLRGPRGAMI
SLRGPRGAMI
TLRGARSGLI
TLRGARSGLI
TLRGCRAGMI
TLRGCRAGMI
TLRGCRAGMI
TLRGCRAGMI
SLRGPRGALI
SLRGPRGAMI
TLAGPRGGLI
TLAGPRGGLI
TLGGPRGGLI
TLGGPRGGLI
SLRGPRGGLI
TLRGPRGGMI
TLRGPRGGMI
TLRGPRGGMI
TLRGPRGGII
TLRGPRGGII
TLAGPRGGII
TFPGPQGGII
196
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shmt.msf{GLYC_NEUCR} F F . RGVRSVD AKTGKETLYD LEDKINFSVF PGHQGGPHNH TITALAVALK
shmt.msf{GLYC_YEAST} FFRRGVRSIN PKTGKEVLYD LENPINFSVF PGHQGGPHNH TIAALATALK
Shmt.msf{GLYC_SCHPO} FYRKGTRSHD . KRGNPILYE LEDKINFSVF PGHQGGPHNH TITALAVALG
shmt.msf{GLYM_FLAPR} FFRKGLKEVN . KQGKEVFYD YEDKINQAVF PGLQGGPHNH TITGLAVALK
shmt.msf{GLYN_FLAPR} FFRKGVKEVN . KQGKEVLYD YEDKINQAVF PGLQGGPHNH TITGLAVALK
shmt.msf{GLYM_PEA} FFRKGLKEVN .KQGKEVFYD YEDKINQAVF PGLQGGPHNH TITGLAVALK
shmt.msf{GLYM_SOLTU} FYRKGVKEVN .KQGKEVFYD YEDKINQAVF PGLQGGPHNH TITGLAVALK
shmt.msf{GLYM_HUMAN} FYRKGVKAVD PKTGREIPYT FEDRINFAVF PSLQGGPHNH AIAAVAVALK
shmt.msf{GLYM_RABIT} FYRKGVRTVD PKTGQEIPYT FEDRINFAVF PSLQGGPHNH AIAAVAVALK
shmt.msf{GLYC_HUMAN} FYRKGVKSVD PKTGKEILYN LESLINSAVF PGLQGGPHNH AIAGVAVALK
shmt.msf{GLYC_MOUSE} FYRKGVRSVD PKTGKETYYE LESLINSAVF PGLQGGPHNH AIRGVAVALK
Shmt.msf{G LYC_RABIT} FYRRGVRSVD PKTGKEILYN LESLINSAVF PGLQGGPHNH AIAGVAVALK
shmt.msf{GLYC_SHEEP} FYRKGVRSVD PKTGKETRYN LESLINSAVF PGLQGGPHNH AIAGVAVALK
shmt.msf{GLYC_CAEEL} FYRKGVRSTN AK . GVDTLYD LEEKINSAVF PGLQGGPHNH TIAGIAVALR
shmt.msf{GLYM_YEAST} FFRKGIKSV. TKKGKEIPYE LEKKINFSVF PGHQGGPHNH TIGAMAVALK
shmt.msf{GLYA_ECOLI} LAKGGSEELY KK......................................LNSAVF PGGQGGPLMH VIAGKAVALK
Shmt.msf{GLYA_SALTY} LAKGGDEELY KK......................................LNSAVF PSAQGGPLMH VIAGKAVGLK
shmt.msf{GLYA_ACTAC} LSSCGDEEIY KK......................................LNSAVF PAGQGGPLVH IIAAKAVCFK
shmt.msf{GLYA_HAEIN} LSSCGDEEIY KK...................................... LQSSVF PANQGGPLVH IIAAKAVCFK
shmt.msf {GLYA_BRAJA} L S N . . DETLA KK....................................... L N SA IF PGLQGGPLMH VIAAKAVAFG
Shmt. ms f { GLYA_METEX } LTN . . DEALA KK....................................... F N SA IF PGLQGGPLMH VIAAKAAAFG
shmt.msf {GLYA_HYPME} LTN. .DA D IA  KK........................................IN S A IF  PGIQGGPLMH VIAGKAVAFG
shmt.msf {GLYA_BACSU} LCR. .E E .F G  KK........................................ID K S IF  PGIQGGPLMH VIAAKAVSFG
shmt. ms f { GLYA_CAMJE} MTN. . DEELA KK........................................IN S A IF  PGIQGGPLMH VIAAKAVGFK
shmt.msf { GLYA_MYCGE} MSN. .N Q A II  KK...............................LDSGVF PGCQGGPLQH VIAAKYVCFK
shmt.msf {GLYA_CORSP} L SN . .D A E IA  KK....................................... LNSAVF PGQQGGPLEH VIAGKAVAFK
Shmt.msf{GLYA_METTH} LCRE.............................................. E LADDIDEAVF PGLVSNHHLH HVAGLGIATA
Shmt.rns f{GLYC_NEUCR} 
shmt.ms f{GLYC_YEAST} 
shmt.ms f{GLYC_SCHPO} 
shmt.ms f{GLYM_FLAPR} 
shmt.msf{GLYN_FLAPR} 
shmt.msf{GLYM_PEA} 
shmt.ms f{GLYM_SOLTU} 
shmt.msf{GLYM_HUMAN} 
shmt.ms f{GLYM_RABIT} 
shmt.msf{GLYC_HUMAN} 
shmt.ms f{GLYC_MOUSE} 
shmt.ms f{GLYC_RABIT} 
shmt.ms f{GLYC_SHEEP} 
shmt.ms f{GLYC_CAEEL} 
shmt.ms f{GLYM_YEAST} 
shmt.ms f{GLYA_ECOLI} 
shmt.ms f{GLYA_SALTY} 
shmt.ms f{GLYA_ACTAC} 
shmt.msf{GLYA_HAEIN} 
shmt.ms f{GLYA_BRAJA} 
shmt.ms f{GLYA_METEX} 
shmt.ms f{GLYA_HYPME} 
shmt.ms f{GLYA_BACSU} 
shmt.ms f{GLYA_CAMJE} 
shmt.ms f{GLYA_MYCGE} 
shmt.ms f{GLYA_CORSP} 
shmt.ms f{GLYA_METTH}
3 5 1
QAASPEFKEY
QAATPEFKEY
QAKTPEFYQY
QATTAEYKAY
QATTAEYKAY
QATTPEYRAY
QATTPEYRAY
QACTPMFREY
QACTPMFREY
QAMTLEFKVY
QAMTT............
QAMTPEFKEY
QAMTPEFRAY
QCLSEDFVQY
QAMSPEFKEY
EAMEPEFKTY
EAMEPEFKVY
EALEPEYKVY
GALEPQYKEY
EALRPDFKVY
EALKPEFKIY
EALRPDFKVY
EVLQDDFKTY
FNLSDEWKVY
EALNPKFKQY
IAASAEFKER
EMLEFG.SEY
4 0 0
QQKWANAKA
QTQVLKNAKA
QKDVLSNAKA
QEQVMSNSAK
QEQVMSNCAK
QEQVLSNSSK
QEQVLSNSSK
SLQVLKNARA
SLQVLKNARA
QHQWANCRA
LEK KLKE.. .  
L E S E F K N .. .  
M ANAFIT. . .  
FA E T LV K .. .  
FA E T LV K .. .  
FAKALSE. . .  
FAQALGE. . .  
M ADALLE.. .  
MADALLE. . .  
LSEALTE. . .
. LGYKLVSD G .
. LGYRLVSN G .
. RGYKLVSG G.
. SGYELVSG G .
. SGYELVSG G .
. KGYDLVSG G.
. KGYELVSG G .
. RGYSLVSG G .
. RGYSLVSG G .,  
. LGYKIVTG G . .
.TDSHMV 
.TDSHMV 
. TDTHLV 
.TENHLV  
.TENHLV  
.TENHLV  
. TDNHLV 
. TDNHLV 
. TDNHLV 
. SDNHLI
QRQWANCRA
QRQWANCRA
GEQVLKNAKT
QQKIVDNSKW
QQQVAKNAKA
QQQVAKNAKA
QQNVLKNAKA
QANVIKNAKA
AKNWENAKA
AKQVIDNARA
IKQVMDNARA
AQNVISNAKR
AKQVRTNAQV
MQQVKDNALA
QQRTLAGSRI
AAQTIRNAKK
LSAALVE. . .  
LAEALMG. . .  
LAERMKK.. .  
FA Q EL TK .. .  
MVEVFLE. . .  
M VEVFLN.. .  
MVEVFKQ. . .  
MVEVFKQ. . .  
LAEAMKS. . .  
L A D T I IS . . .  
LGEVLVQ. . .  
L A EA L TK .. .  
LANVLMD.. .  
MANWFLK.. .  
LAQRLTQADV 
L A E N L N E.. .
. . LGYKIVTG 
. . LGYRWTG 
. . HGYALATG 
. . MGYKLVSG 
. . RGYKWSG 
. .RGYKW SG  
. . RCYKWSN  
. . RGYDWSN  
. . HGFDIVSG 
. . GGYDITSG 
. . NGFALVSG 
. . EGIQLVSG 
. .RKFKLVSD 
. . QGYRWSK 
AAKGISVLTG 
. . LGFNVLCE
G .
G .
G .
G .
G .
G .
G .
G .
G .
. SDNHLI 
. SDNHLI 
. TDNHLL 
. TDNHLI 
. TDNHLF 
.TENHLF 
.TENHLF 
.TENHLF 
. TDNHLM 
G . . .TDNHLM 
G . . .TDTHLV  
G . . .TDNHLI 
G . . .TDNHLV 
G . . . TETHLF 
G . . . TDVHLV
HLDFTESHQV
4 0 1 4 5 0
shmt.ms f{GLYC_NEUCR} 
shmt.ms f{GLYC_YEAST} 
shmt.ms f{GLYC_SCHPO} 
shmt.ms f{GLYM_FLAPR} 
shmt.ms f{GLYN_FLAPR} 
shmt.msf{GLYM_PEA} 
shmt.ms f{GLYM_SOLTU} 
shmt. ms f { GLYM_HUMAN } 
shmt.ms f{GLYM_RABIT} 
Shmt.ms f{GLYC_HUMAN} 
shmt.ms f{GLYC_MOUSE} 
shmt.ms f{GLYC_RABIT} 
shmt.ms f{GLYC_SHEEP} 
shmt.ms f{GLYC_CAEEL} 
shmt.ms f{GLYM_YEAST} 
shmt.ms f{GLYA_ECOLI} 
shmt.msf{GLYA_SALTY} 
shmt.ms f{GLYA_ACTAC} 
shmt.msf{GLYA_HAEIN} 
shmt.ms f{GLYA_BRAJA} 
shmt.ms f{GLYA_METEX} 
shmt.ms f{GLYA_HYPME} 
shmt.ms f{GLYA_BACSU} 
shmt.ms f{GLYA_CAMJE} 
shmt.ms f{GLYA_MYCGE} 
shmt.ms f{GLYA_CORSP} 
shmt.ms f{GLYA_METTH}
LVDLRPIGVD
LVSLREKGVD
LVDLTDKGVD
LVNLKNKGID
LVNLKNKGID
LVNLKNKGID
LVNMKNKGID
LVDLRPKGLD
LVDLRPKGLD
LVDLRSKGTD
GARVEFLLEQ
GARVEYICEK
GARVERILEL
GSKVEKVLEA
GSRVEKVLEA
GSRVEKVLEL
GSRVEKVLEA
GARAERVLEL
GARAERVLEL
GGRAEKVLEA
INITCNKNAV
IN IA LN K N SI
VNISANKNTV
VHIAANKNTV
VHIAANKNTV
VHIAANKNTV
VHIAANKNTV
VSITANKNTC
VSITANKNTC
CSIACNKNTC
P .G D
P .G D
P .G D
P .G D
P .G D
P .G D
P .G D
P .G D
P .G D
P .G D
. KSALT 
•KSALV 
.K SA L I  
. VSAMV 
. VSAMV 
.VSAMV 
.VSAMV 
. R SA IT  
. R SA IT  
.RSALR
PGGLRIGTPA
PGGVRIGAPA
PRGLRLGTPA
PGGIRMGTPA
PGGIRMGTPA
PGGIRMGTPA
PGGIRMGTPA
PGGLRLGAPA
PGGLRLGAPA
PSGLRLGTPA
LVDLRSKGTD
LVDLRSKGTD
LVDLRPIGVE
VIDLSGTQVD
LVDLVDKNLT
LLDLVDKNLT
LVDLVSHGLT
LVSFIKQGLT
LVDLRPKGLK
LVDLQKKGLT
LVDLRPKKLT
LVDLRSLGLT
LMSFLDREFS
S L W G N ____
LVDLRHSELD 
VMDVSDIG. R
GGRAEKVLEA
GGRAEKVLEA
GARAEHVLDL
GARVETILSA
GKEADAALGR
GKEADAALGR
GKAADAALGK
GKAADAALGK
GNVSEKALVR
GKAAEAALSR
GTKAEKALGR
GKVAEHVLDE
GKDADLALGN
GKDVALWLQK
GQQAEDLLAK
AAEISKKLEA
CSIACNKNTC
CSIACNKNTC
AHIACNKNTC
LNIAANKNTI
ANITVNKNSV
ANITVNKNSV
ANITVNKNSV
ANITVNKNAV
AAITCNKNGI
ADITCNKNGV
ANITCNKNGI
IG ITSNK NAI
AGITANKNTV
ANIVLNMNTI
VEITVNRNSV
NNIILNKNLL
P.G D .K SA L R  
P.G D .K SA LR  
P.G D .V SA L R  
P .G D .K SA L F  
P.N D PK SPFV  
P.N D PK SPFV  
P.N D PQ K PFI  
P . NDPQKPFV 
P . FDPEKPFV  
P . FDPQKPTI 
P . FDPEKPMV 
P . YDPEKPFV 
P . G E IR S P F I  
P . FETKSAFS 
P . FDPRPPMT 
PWDDVNRSDD
PSGLRLGTPA
PSGLRLGTPA
PGGIRLGTPA
PSGLRIGTPA
TSGIRVGTPA
T SG IR IG SPA
TSGIRVGTPS
TSGIRVGTPS
TSGLRLGTPA
TSGIRLGTPA
TSGIRLGSPA
TSGIRLGTAA
TSGLRLGTPA
PSGIRLGTPA
TSGLRIGTPA
PSGIRIGTQE
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451 500
shmt.ms f{GLYC_NEUCR 
shmt.ms f{GLYC_YEAST 
shmt.ms f{GLYC_SCHPO 
shmt.ms f{GLYM_FLAPR 
shmt.ms f{GLYN_FLAPR 
shmt.ms f{GLYM_PEA 
shmt.ms f{GLYM_SOLTU 
shmt.ms f{GLYM_HUMAN 
shmt.msf{GLYM_RABIT 
shmt.ms f{GLYC_HUMAN 
shmt.ms f{GLYC_MOUSE 
shmt.ms f{GLYC_RABIT 
shmt.ms f{GLYC_SHEEP 
shmt.ms f{GLYC_CAEEL 
shmt.ms f{GLYM_YEAST 
shmt.ms f{GLYA_ECOLI 
shmt.ms f{GLYA_SALTY 
shmt.ms f{GLYA_ACTAC 
shmt.ms f{GLYA_HAEIN 
shmt.ms f{GLYA_BRAJA 
shmt.ms f{GLYA_METEX 
shmt.ms f{GLYA_HYPME 
shmt.ms f{GLYA_BACSU 
shmt.ms f{GLYA_CAMJE 
shmt.ms f{GLYA_MYCGE 
shmt.ms f{GLYA_CORSP 
shmt.ms f{GLYA_METTH
shmt.ms f{GLYC_NEUCR 
shmt.ms f{GLYC_YEAST 
shmt.msf{GLYC_SCHPO 
shmt.ms f{GLYM_FLAPR 
shmt.ms f{GLYN_FLAPR 
shmt.ms f{GLYM_PEA 
shmt.ms f{GLYM_SOLTU 
shmt.ms f{GLYM_HUMAN 
shmt.ms f{GLYM_RABIT 
shmt.ms f{GLYC_HUMAN 
shmt.ms f{GLYC_MOUSE 
shmt.ms f{GLYC_RABIT 
shmt.ms f{GLYC_SHEEP 
shmt.ms f{GLYC_CAEEL 
shmt.ms f{GLYM_YEAST 
shmt.ms f{GLYA_ECOLI 
shmt.ms f{GLYA_SALTY 
shmt.ms f{GLYA_ACTAC 
shmt .msf{GLYA_HAEIN 
shmt.ms f{GLYA_BRAJA 
shmt.ms f{GLYA_METEX 
shmt.ms f{GLYA_HYPME 
shmt.ms f{GLYAJ3ACSU 
shmt.ms f{GLYA_CAMJE 
shmt.ms f{GLYA_MYCGE 
shmt.ms f{GLYA_CORSP 
shmt.ms f{GLYA_METTH
MTSRGFGEAD
MTTRGMGEED
CTTRGFDEKD
LTSRGFVEED
LTSRGFVEED
LTSRGFVEED
LTSRGFLEED
LTSRQFREDD
LTSRQFREDD
LTSRGLLEKD
FEKVAVFVDE
FHRIVQYINK
FERWELIDE
FAKVAYFFDL
FAKVAYLFDL
FVKVAEYFDA
FVKVADFFDA
FRRWDFIDE
FRRWDFIDE
FQKVAHFIHR
AVKLCKEI.. 
AVEFAQQV.. 
WSLTKKIN. 
AVKLAVKIK. 
AVKLAVKIK. 
AVSLALKVK. 
AVKIAVKVK. 
GVNIGLEVK. 
GVNIGLEVK. 
GIELTLQIQ.
.QASLPKEA 
.QQSLPKDA 
.EAALKEGK 
.GEA..KG. 
.GEA..QG. 
.AES..KG. 
.AET..QG.
. SKT..........
.RKT..........
.SDT..GVR
NKQKDFKAKI
CRLKDFKAKV
SKFRDFKAYV
TKLKDFVTAM
TKLKDFVAAM
TKLKDFVEAL
TKLKDFVATL
AKLQDFKSFL
AKLQDFKSFL
ATLKEFKERL
LTSRGLLEKD
LTSRGLLEED
LTSRGFQEQD
MTTRGFGREE
ITRRGFKEAE
VTRRGFKEAE
VTRRGFNEAD
VTRRGFNEND
ATTRGFGVAE
STTRGFGVAE
GTTRGFGVAE
VTSRGFDGDA
LTARGFKEKE
MTTRGFKTND
LATRGFSEEA
ITRRGMKESE
01
.ATSDI.PRI 
DEGSDV.. .L 
GDGSKF.SEI 
ESSA.IQSEI 
QSSA.FQSEI 
QTSSYVQSEI 
ESSAPIKSEI 
LKDSETSQRL 
LKDPETSQRL 
AGD.KYQAAV
FQKVAHFIHR 
FRKVAHFIHR 
FEKVGDFIHE 
FSQVAKYIDS 
AKELAGWMCD 
VKELAGWMCD 
VKELAGWMCD 
VRELAGWMCD 
FQQVGGMIAE 
FKQVGSLIVQ 
FQEIGRLISE 
LEEVGAII.. 
MEIVSNYIAD 
FIFVASLIDK 
FAEVAEIIAQ 
MSEVAEYIKK
NELKQEIAAW
NTWKKEIYDW
AKLKKEVITW
SKLRHDVEEY
SKLRHDVEEY
SKLKHDVEEF
AKLRHDVEEY
ANLRQRVEQF
ADLRRRVQQF
QALREEVESF
GIELTVQIQ. . .DDT..GPR ATLKEFKEKL 
GIELTLQIQ. . .DAV..GVK ATLKEFMEKL 
GVQIAKKYN. ..AEA..G.. KTLKDFKSFT 
AVKLAENLKT LEPTTKLDAR SRLNEFKKLC
VLDSI..............................................................
VLDNI..............................................................
VLDAIGK..........................................................
VLDALGK..........................................................
VLNAIAQ..........................................................
VLDGIAE..........................................................
VLDGVAK..........................................................
. . .ALAL..........................................................
ILDDINN..........................................................
VIKS.................................................................
TLIA.................................................................
WIDGRNVKE EVSEFMSSYT RSTTPLRSQG
SNTFPLPVEG 
AGEYPLAV.. 
AGKFDFPV.. 
AKQFPTIGFE 
AKQFPTIGFE 
AKQFPTIGFE 
AKQFPTIGFE 
ARAFPMPGFD 
ARAFPMPGFP 
ASLFPLPGLP
5 3 8
WRYDAGL.
KETMKYKN
KETMKYKN
KATMKYNK
KETMKYKN
EH............
EH............
DF............
AGDEKHQRAV
AGAEEHQRAV
ETNEPFKKDV
NESS EV
.NDEA.. .VI 
.NDEA...TI 
DNEAE. . .VI 
ENEEQ. . .VI 
SDDGKAPLVE 
KGDGGDAAVE 
NGEDGNGAVE 
KNHEDEGKLE
EK.............LQ
.. .NGNQKVI 
.GAEGNTGVL 
PTSTWRSCR.
RALRQEVESF 
TALRAEVESF 
ADLAKRVEEF 
AALSGEISKW 
ERIKGKVLDI 
ERVKAKVLDI 
ADTKDKVLAI 
AETKEKVLAI 
AAIKERVKAL 
AAVKEKVHAL 
AAVKAKAIAL 
EA.RQRVAAL 
ENIKQELKKL 
SQTKTAVLNL 
PELKARILEL
AALFPLPGLP GF___
ATLFPLPGLP GF___
STKFEIPGNE TF___
VGQYPVPGDI ............
CARYPVYA...................
CARFPVYA...................
CKRLPVYA...................
CKRLPVYPK.................
TDRFPIYQ...................
TDRFPIYA...................
CDRFPIYA...................
TDKFPLYKEL DY___
ASNFIIYERA MF___
LKRFPLYKGL AY___
AAAHPLYPNL KKIGE.
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